Analysis of data on spontaneous reports of adverse events associated with drugs by Baah, Emmanuel Mensah
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Baah, Emmanuel Mensah (2014) Analysis of data on spontaneous reports 
of adverse events associated with drugs. PhD thesis. 
 
 
http://theses.gla.ac.uk/4990/ 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 
Analysis of Data on Spontaneous
Reports of Adverse Events
Associated with Drugs
by
Emmanuel Mensah Baah
A thesis submitted to the
College of Science and Engineering
at the University of Glasgow
for the degree of
Doctor of Philosophy
February 2014
iAbstract
Some adverse drug reactions (ADRs) are not detected before marketing approval is given
because clinical trials are not suited for their detection, for various reasons [5, 23]. Drug
regulatory bodies therefore weigh the potential benefits of a drug against the harms and
allow drugs to be marketed if felt that the potential benefits far outweigh the harms [26,48].
Associated adverse events are subsequently monitored through various means including
reports submitted by health professionals and the general public in what is commonly
referred to as spontaneous reporting system (SRS) [19, 23, 69]. The resulting database
contains thousands of adverse event reports which must be assessed by expert panels to
see if they are bona fide adverse drug reactions, but which are not easy to manage by virtue
of the volume [6].
This thesis documents work aimed at developing a statistical model for assisting in the
identification of bona fide drug side-effects using data from the United States of America’s
Food and Drugs Administration’s (FDA) Spontaneous Reporting System (otherwise known
as the Adverse Event Reporting System (AERS)) [28].
Four hierarchical models based on the Conway-Maxwell-Poisson (CMP) distribution
[43,78] were explored and one of them was identified as the most suitable for modeling the
data. It compares favourably with the Gamma Poisson Shrinker (GPS) of DuMouchel [19]
but takes a dimmer view of drug and adverse event pairs with very small observed and
expected count than the GPS.
Two results are presented in this thesis; the first one, from a preliminary analysis,
presented in Chapter 2, shows that problems such as missing values for age and sex that
militate against the optimal use of SRS data, enumerated in the literature, remain. The
second results, presented in Chapter 5, concern the main focus of the research mentioned
in the previous paragraph.
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Chapter 1
Introduction
1.1 Drug Safety and Related Issues
Many issues are involved in the difficult and often uncertain undertaking of drug develop-
ment, amongst them finance, ethics, efficacy of product and safety of users. The process
requires meticulous care right from the conception stage to well beyond the stage where
approval has been given for marketing, primarily because of safety concerns.
Even though the foremost motivation in drug development is finding a treatment for
an illness, safety is of utmost concern because drugs are basically chemicals [77]; they hold
the potential to cause harm given the right (or rather wrong) circumstances. This places
a huge responsibility on drug producing entities (sponsors) to not only ensure that their
products are well formulated and safe, but also provide enough information on the best way
to use them. Indeed safety issues are not and should not be the preserve of only sponsors
but all, including regulatory bodies and consumers.
Regulatory bodies are there to ensure that only medicines that meet the necessary
safety requirements are allowed to enter the market or effect the withdrawal of medicines
that have been found unsafe from the market. Otherwise an unscrupulous sponsor could
market an unsafe product [77], under the lure of pecuniary or commercial considerations;
every facet of drug development is capital intensive and the sponsor is expected not only to
have the wherewithal to carry through the venture, but be able to recoup the investment,
keep body and soul of its facilitators, meet shareholder expectations and as a commercial
entity expand by exploring other remedies. Additionally, it is not difficult to perceive the
existence of the huge market for drugs given the proliferation of diseases, in spite of the
impressive advances in the science of medicine.
1
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1.1.1 Adverse Drug Reactions
The harm(s) a drug can cause are discussed in terms of the adverse reaction(s) associated
with it. Put simply, an adverse drug reaction (ADR), otherwise known as side-effect, is
any unwanted effect of a drug [18, 51]. Factors that impinge on the severity and nature of
an ADR include the overall health status of the individual taking the drug, dose level of
drug, gender, genetic make up, age, chemical composition of the drug, weight and disease
condition [18, 51]. Attention usually focuses on undesirable or harmful effects of drugs at
the required dose level when side-effects come up for discussion.
1.1.2 Nature and Types of ADRs
A number of factors influence the way an ADR is viewed, which include how it is caused,
how serious it is and the way it manifests itself. Based on these influencing factors, Edwards
and Aronson [22], drawing from the works of other authors [39, 42, 71, 73], present six
classes of ADRs: “dose-related (Augmented), non-dose-related (Bizarre), dose-related and
time-related (Chronic), time-related (Delayed), withdrawal (End of use), and failure of
therapy (Failure)” [22] in their article “Adverse Drug Reactions: Definitions, Diagnosis, and
Management”. Another classification in the literature on ADRs puts them into two classes,
namely Type A and Type B reactions. Type A reactions (also known as pharmacological
reactions) are predictable because they relate to dose, and the chemical process by which
they result are understood while Type B reactions (also known as idiosyncratic reactions)
are unpredictable from knowledge of the composition of the drug; the process through
which they result are not yet understood and are not dose-related. They occur in some
people because they are allergic to, or their immune system does not respond favourably
to, the medication as a result of their genetic makeup [51, 67, 71, 77].
Some adverse reactions are relatively common, often less serious and easy to manage
than others [51]. Examples of common ADRs are “weakness, sweating, nausea and palpi-
tations” [51]. At the risk of belabouring the point, some adverse reactions are rare; they
tend to occur in a minority of people and are often more serious [51, 77]. “Skin rashes,
jaundice, anaemia, a decrease in the white cells count, kidney damage, and nerve injury
that may impair vision or hearing” [51].
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1.1.3 Prevalence of ADRs
Over 80 percent of side-effects are Type A reactions [63, 67]. In the United States of
America (US), the proportion of hospital admissions attributable to side effects is about 3
to 7 percent. Of those admitted to hospitals for reasons other than side-effects, between 10
to 20 percent manifest side effects during their stay “and about 10 to 20 percent of these are
severe” [51]. The corresponding values for the United Kingdom (UK) are 5 percent and 10
to 20 percent respectively, with about 0.11 percent of side effects resulting in deaths [64].
The respective values of 5.2%, 14.7% and 0.15%, obtained in some fairly recent studies of
three major hospitals in the UK are consistent with the above values [16,65]. These values
are expected to be higher in countries where the literacy rate is low, prescription-only-
medications are more or less treated like over-the-counter drugs because of weak regulatory
systems and virtually non-existent systems of reporting ADRs.
The sixty-fifth edition of the British National Formulary [74] presents a classification
of ADR on the basis of prevalence as shown in Table 1.1.
Table 1.1: A classification of ADRs based on prevalence.
Prevalence Description
1 in 10 Very Common
1 in 100 to 1 in 10 Common
1 in 1000 to 1 in 100 Less common
1 in 10000 to 1 in 1000 Rare
Less than 1 in 10000 Very Rare
Source: British National Formulary, March 2013 [74].
1.1.4 Detecting ADRs
As mentioned above some adverse reactions are rare in occurrence because they occur in
a small minority of people, for a given medication. They are therefore often not detected
at the development stage where the number of subjects on whom the drug is tested is, for
various reasons, considerably smaller than the number of patients that take the medication
when it is marketed [23,64,77]. The number of patients that may have undergone trials with
a drug by the time it is marketed is on average less than 3000 [77]. While this number may
be enough to identify frequently occurring side-effects, it may not be enough to pinpoint
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the attributes of all of them [64], let alone detect rare side-effects which occur at a rate
of about one in 10000 or less [5, 74]. This is all the more palpable when one considers the
fact that some ADRs result from drug-drug and drug-disease (other than the one being
treated) interactions [51,64] which are often not the focus of clinical trials. Thus one needs
many more subjects than studied in a clinical trial to fully capture and understand the
attributes of a medication with respect to side-effects. This is only possible when a drug
has been marketed, as apart from numbers the population of patients is more diverse than
in pre-approval studies [5, 23, 70].
Some ADRs take time to manifest (referred to as long-latency) [23, 70] or result from
continuous use of the drug over a long period [23,70] and the limited time of clinical trials,
given the interplay of factors, might not permit their detection.
Indeed there are various reasons for an ADR escaping detection before approval is given
for marketing, which could include failure of the sponsor to do due diligence in respect of
all precautionary measures that must be taken before approval is sought; the onus lies
on the sponsor to ensure that all the necessary safety measures are met as it is not the
primary responsibility of regulatory bodies to conduct safety tests [26, 48, 77]. Also what
might eventually happen with the use of a drug, as far as dealing with nature is concerned,
might simply be beyond the recognition of man [77].
1.2 Pharmacovigilance
Drug regulatory bodies such as the Medicines and Healthcare Products Regulatory Agency
(MHRA) and Commission on Human Medicines (CHM) of the UK and the Food and Drugs
Administration (FDA) of the US therefore weigh the potential benefits of a drug against
the harms, on the basis of the documentation submitted by the sponsor, and allow drugs
to be marketed if it is felt that the potential benefits far outweigh the harms [26, 48], and
then monitor the associated adverse events that arise in order to fully characterize the
side effects of the drug and to take remedial action where necessary, including advising
health care practitioners and the general public on what to do [27, 50]. The World Health
Organization (WHO) also has a monitoring centre in Uppsala, Sweden, known as the WHO
Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre) that,
among other things, serves as the unifying point for the drug monitoring activities of various
drug regulatory agencies of member countries [86].
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There is an ethical implication in approaching drug administration this way in the sense
that one could be unwittingly toying with people’s lives if the drug is a potential health
hazard to, for instance, a minority sub-population who do not react favourably to the drug.
However, regulatory bodies and sponsors can for the present hardly do otherwise; the com-
plex process of pharmaceuticals development involves seeking a trade-off between a number
of factors which present as ‘obstacles’ in the process. These impediments, paradoxically,
include ethics; one needs, and rightly so, the educated consent of subjects who undergo
trials and this could also limit the number of people who volunteer.
The system of tracking the use of drugs throughout their marketed life in order to find
unknown harms or changes in adverse reactions associated with it, with the view to take
remedial action if necessary, is known as Pharmacovigilance [23, 50].
It involves the detection of hitherto unknown adverse drug reactions including those
resulting from drug-drug interactions, through uninterrupted safety surveillance of drugs
that are in use, particularly newly approved ones and additional indications (diseases or
circumstances of use of drug) [23, 70]; keying out sub-populations of users who are at risk
along the lines of “dose, age, gender, underlying disease” [70], drug class, genetic make
up and any other relevant variable; superintending proper administration of medications
by health professionals and the general public in respect of prescription-only-medicines
(POMs) and over-the-counter (OTC) drugs including off-label use [23, 70]; studying the
adverse reaction characteristics of a medication relative to those of the same therapeutic
class [70] and “providing information to healthcare professionals and patients to optimize
safe and effective use of medicines” [50].
The action a regulatory body, in collaboration with a sponsor, may effect takes several
forms depending on the enormity and urgency of the problems associated with a medical
product, once the problems have been identified. They range from improving precautionary
and warning messages on packages and information leaflets, labeling modification; limiting
indications, mandatory monitoring of patients, dose modification; and limiting distribution
and prescription of product, seeking informed consent of patients; to suspension of distri-
bution and marketing, drug withdrawal from market, banning of product and revoking of
licenses [17, 23, 50, 89].
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1.2.1 Spontaneous Reporting System (SRS)
One of the main approaches used by regulatory bodies and sponsors to conduct drug
safety surveillance is what is generally known as the Spontaneous Reporting System (SRS)
[19, 23]. This is known as the Yellow Card Scheme (YCS) and Adverse Event Reporting
System (AERS/MedWatch) in the UK and the US respectively. Under this system, health
professionals and the general public report adverse events associated with a medication
either directly to the regulatory bodies or to drug firms, who must by regulation pass on
the information to the regulatory bodies [28, 49].
1.2.2 Problems of the Spontaneous Reporting System
Undoubtedly this system plays a leading role in drug surveillance and is very important
in facilitating the identification of rare but bona fide harms associated with medications,
especially those that have just been approved [17, 81], as in the case of the link between
aplastic anaemia and remoxipride [64]. However it suffers from a number of problems:
Adverse events are generally under-reported [4, 70] but the problem appears to be more
serious with regard to some adverse events and drugs than with others. For instance in a
study of the problem by Alvarez-Requejo et al. [4] in Spain, they found out that serious
events tended to be reported more than non-serious events. They found reporting to be
higher for newly marketed medications and unclassified events. They also pointed out that
under-reporting in the case of psychiatric and gastrointestinal disorders were relatively
more pronounced than others. Further, medications belonging to the anti-infective and
cardiovascular class were more likely to be cited as being the causative agents of adverse
events. They thus concluded that the problem of under-reporting is significant but not uni-
form across events and medications; it is more likely to involve common and non-serious
events, and underscored that this phenomenon, in some way, augurs well for pharmacovig-
ilance as rare or novel but serious adverse reactions are likely to show up in spontaneous
reporting system as events with ‘unusually’ high frequencies, warranting further investiga-
tion [4]. However, it must be pointed out that the downside of this phenomenon is that
new adverse reactions whose attributes are reminiscent of commonly occurring adverse re-
actions or diseases could be missed if care is not taken [23, 70], so are adverse reactions
whose attributes bear close semblance to the disease under treatment [54]. For instance
Moore et al [54] report on the inability of the spontaneous reporting system to either dis-
cover mortality increases due to use of flosequinan in congestive heart failure or detect that
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cardiac arrest could arise from the use of flecainide and encainide.
There seems to be no clear trend in the reporting rate of adverse events. Promotional
activities of pharmaceutical companies, it is thought, influence reporting at times. Me-
dia attention resulting from episodes of adverse events could also make the public extra
sensitive psychologically, and thereby result in irregular periods of increased reports of
adverse events some of which are not real. Additionally, regulatory policy could also tilt
the reporting rate in a given direction; regulatory bodies request reporting institutions to
be particular about serious and uncommon events, which could bias reporting in favour of
these events [4, 6, 70, 81].
Reporting partial and erroneous information on adverse events are also problems that
plague the spontaneous reporting system. Variables that are affected include suspect drug,
dose, cotherapy, indication, age and gender. Others are the duration of treatment and
medical and disease profile of patients [6, 81]. Non-uniformity of reporting practices and
conventions from company to company and from country to country or even between
regions of the same country and amongst health personnel also make the system less useful
than it might be [6, 70, 81].
Multiple reports of adverse event episodes arising from use of multiple channels or
inappropriate tracking of events leading to misrepresentation of old cases as new is reported
to be common [6, 29, 30]. The number of people actually using a given medication at any
point in time is unknown and the current information situation does not permit accurate
estimation of it.
1.2.3 Effects of the Problems of Spontaneous Reporting System
The above inadequacies make it impossible to accurately determine incidence rate and
prevalence of adverse reactions [4, 70, 81]. It is not easy to establish whether or not the
relationship between a drug and an adverse event which occurred during the administration
of the drug is causal on the basis of spontaneous reporting system data alone; as the event
may have occurred accidentally or have been associated with the disease under treatment.
Other factors that may be responsible for the adverse event include an unrecognized disease,
other medications being used at the same time [23,29], or drug-drug interaction [23,29,64],
such as happen when isoniazid is administered concurrently with rifampicin [64].
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1.2.4 Contribution of Spontaneous Reporting System to Pharmacovigi-
lance
The spontaneous reporting system, nonetheless, has played and continues to play an im-
portant role in the identification of adverse drug reactions which otherwise would have
taken more time or been difficult to identify [6, 17, 54]. The link between troglitazone,
tramadol, felbamate, temafloxacin and the respective side-effects of liver damage, seizures
and addiction, aplastic anaemia and blood disorders were all established with the aid of
the spontaneous reporting system in the 1990s [54]. Other instances where side-effects
have been identified through the spontaneous reporting system and have led to regulatory
action of one form or the other include the occurrence of tendinitis and tendon rupture in
the use of quinolone antibiotics; renal failure induced by the use of aristolochia; “serious
cardiovascular reactions” in the use of cisapride (prepulsid, alimix); and “hyperglycaemia,
diabetes and exacerbation of diabetes” [17] occasioned by the use of olanzapine (zyprexa).
Indeed, as alluded to above, the spontaneous reporting system is not the only means by
which pharmacovigilance is conducted. Any means that has the capability of assisting in
establishing that the relationship between a suspect drug and an adverse drug event (ADE)
is causal or otherwise can be used. These include laboratory and tolerability data from
trials, case-control and cohort studies using data from case registries, general practitioners
and hospitals, and vital statistics and information from the coroner or pathologist [17, 23,
70,77]. However the spontaneous reporting system is, arguably, the most valuable because
of the vanguard role it plays in the detection of unknown adverse drug reactions, especially
rare ones [81]; which is in line with the primary aim for which the system was set up. It
is often the case that the other means are called upon to complement the spontaneous
reporting system in causality assessments when the SRS has identified a plausible causal
relationship between a drug and an adverse event [89].
1.3 Motivation for this Work
Good health plays a pivotal role in the development of individuals and larger society. This
is the justification for governments and local authorities doing all they can to provide
health services. These services could be broadly classified as curative or preventive [85].
Curative services involve the treatment of diseases and the preventive include public health
administration, which among other things, involves pest control, maintenance of hygiene,
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periodic immunization and ensuring that quarantine requirements are adhered to. It also
calls for the education of the public on health issues, all with the view to getting the public
to act in such a way as to inhibit the growth of health problems if not avert and eliminate
them [85].
For a health delivery regime to be total and effective, stakeholders must also address
themselves to the possibility of dealing with iatrogenic problems as part of the preventive
approach to health delivery. The preventive approach to health delivery holds a number
of benefits, viz:
◦ eliminates unnecessary deaths, pain and discomfort associated with diseases and
iatrogenic problems,
◦ obviates the huge cost in terms of time and funds involved in dealing with diseases
and iatrogenic problems, and
◦ savings in time and funds could be channeled into supporting other areas of the
economy needing attention.
The recognition of this situation has spawned such health fields as epidemiology and
pharmacovigilance. Pharmacovigilance in particular, and indeed the drug industry in gen-
eral (including the development process) faces a challenge which when overcome will benefit
all. The challenge, as alluded to above, has to do with the detection of unknown adverse
drug reactions associated with marketed drugs as soon as practicable. Some adverse drug
reactions are not easy to detect after marketing approval because of inaccurate reporting
of adverse events and lack of information regarding the population of users of drugs.
Timely detection of new and unknown serious adverse drug reactions would ensure the
aforementioned benefits via:
◦ “reduced morbidity, sick leave days and impaired days
◦ reduced potential disabilities
◦ reduced mortality
◦ less need for hospital capacities
◦ reduced number of hospital stays and outpatient care" [35].
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To place the discussion in perspective and bring to the fore the burden presented by
ADRs as a whole and unknown ADRs in particular, we look at some studies that have
been conducted on ADRs in general and then concentrate on unknown ADRs:
Using a meta-analysis of 39 studies on adverse drug reactions in the US, spanning three
decades, it was estimated that over 1.5 million people were hospitalized in the US in 1994
due to serious adverse drug reactions, over 700 000 experienced a serious adverse drug
reaction while on admission for reasons other than ADRs and over 100 000 cases of adverse
drug reactions resulted in death in the same year, "making [ADRs one of the] leading cause
of death in the United States" [45, 54]. The overall prevalence of ADRs amongst hospital
patients was said to be 6.7% (95% CI: 5.2% – 8.2%). Most of these adverse reactions
occurred at the required doses or doses considered to be normal in human use [45].
A study involving two general hospitals and a population of 18820 inpatients over a six-
month period in the UK, published in 2004, found out that 5.2 percent of the admissions
resulted directly from ADRs, with the overall prevalence of ADRs for the study standing
at 6.5%. Length of stay was found to have a median of 8 days (Q1 − Q3: 4 – 18 days),
taking up 4% of bed capacity. The study estimated that ADRs could cost the National
Health Service an estimated £466 million annually [65]. In a recent publication (2009)
of another study with the same duration as above but focusing on ADRs occurring after
hospitalization, involving one hospital and two of the authors of the above report (including
others), the prevalence rate of ADRs and the associated direct annual cost to the National
Health Service was estimated to be 14.7% and £637 million respectively; and 26.8% of the
patients stayed longer than expected as a result of experiencing ADRs. They pointed out
that the latest estimate of the direct cost, which was arrived at after careful consideration
of the circumstances of the study, is consistent with figures from mainland Europe and the
US [16].
Muehlberger et al. [55] and Goettler et al. [35] published a twin investigation that
focused on frequency, cost and preventability of adverse drug reactions that lead to hospital
admissions. The first investigation looked at 25 studies that took place over the previous
25 years and published in English or German. The study concluded, inter alia, that the
proportion of hospital admissions attributable to ADRs has a median of 5.8% (Q1 − Q3:
4.2 – 6%) [55]. The second investigation was a meta-analysis of 13 studies involving several
countries of similar health delivery sophistication and published between 1975 and 1996 in
English, French or German [35]. This investigation estimated the median length of hospital
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stay due to ADRs to be 8.7 days (Q1−Q3: 8 – 12.3 days). Based on the information from
the two investigations and an average inpatient cost per hospital day of 465 DM in 1995,
the researchers estimated that Germany incurred a direct cost of 1.05 billion DM per year
from hospitalization occasioned by ADRs around 1995 [35].
The two studies used the WHO definition of an ADR, namely "an adverse drug reaction
is a reaction that is noxious and unintended, and occurs at doses used for prophylaxis,
diagnosis, or therapy of disease, or for modification of physiological function" [88]. However
as acknowledged by the second study [35], total adherence to the above definition, as
expected of a review of several studies whose foci were not exactly the same, proved difficult.
Thus the above cost most likely includes cost arising from improper use of drugs or some
anomaly in their use. Indeed 30.7% of hospitalizations due to ADRs were considered to be
preventable [35]. Another meta-analysis by Beijer and de Blaey [9] involving 12 studies put
the figure at 28.9% (±0.02%). The scenario above, nonetheless, illustrates the enormity
of the problem of serious but unknown ADRs, as it is not inconceivable that a reasonable
portion of the cost of the remaining seventy or so percent of the hospitalizations due to
ADRs could be attributable to ADRs of this category.
The last two decades have seen a number of studies that estimated frequency of hospital
admissions due to ADRs and the associated length of hospital stay and direct cost, and
frequency of ADRs amongst inpatients admitted for reasons other than ADRs and the
associated extra length of stay and direct cost. The figures from these studies demonstrate
that ADRs have been a constant cause of economic loss over the years [8,15,16,38,65]. Table
1.2 gives the estimated annual cost attributable to ADR hospitalizations or experience of
ADR while on admission for some selected studies.
Table 1.2: Cost of ADR hospitalization estimated in selected ADR studies.
Setting Cost per Reference Country to Reference
annum year which
(millions) for cost cost applies
Meta-analysis of 13 studies DM 1050 1995 Germany Goettler et al. [35]
Meta-analysis of 69 studies £380 1994-1995 England Wiffen et al. [84]
Meta-analysis of 68 studies £110 - £256 2000 Netherlands Beijer and de Blaey [9]
National hospital data > AC226 2001 Spain Carrasco-Garrido et al. [11]
A major teaching hospital > £637 2005 England Davies et al. [16]
National hospital data > AC272 2006 Spain Carrasco-Garrido et al. [11]
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These studies did not follow a commonly accepted approach and metric in identifying
and quantifying the problem of ADRs, owing in part to differing circumstances, and so
there are no universally accepted estimates and the exact magnitude of the problem is
not known [1, 38]. However, the fact that ADRs constitute a huge medical and economic
burden is a ubiquitous theme that runs through all of them. The picture becomes even
more serious when one considers that the huge cost of ADRs estimated by these studies
does not include indirect costs - injuries and intangible costs to patients, costs due to
misconduct; liability, claims or litigation costs [1, 35].
The need to search for ways of detecting unknown but serious adverse effects of drugs
is all the more exigent when one considers the fact that an appraisal of FDA’s drug review
process, over the period 1976-1985, released in 1990 reported that 51.5 percent of the drugs
approved over the decade entered the market with unknown side effects [37]. In the UK, at
least 12 drugs underwent some form of regulatory action between the period from 1992 to
2002 because of discovery of adverse reactions after they had been approved [66] whilst at
least 24 drugs were withdrawn from marketing or distribution over the period 1978 - 2001 in
the US owing to safety concerns that emerged after approval [89]. There is cause to believe,
as will be seen in Chapter 2 and attested to by the continual safety information that comes
from the FDA [31] and other regulatory bodies, that the situation would have been worse
had it not been for the role drug regulatory bodies play in preventing potentially harmful
drugs from getting onto the market, as drug sponsors evolve and explore new bio-chemical
agents to help combat medical conditions that have hitherto proven intractable.
The problem of ADRs is multifaceted but can be dealt with from three fundamen-
tal angles: taking steps to forestall the occurrence of preventable ADRs, taking steps to
ameliorate the effects of ADRs that cannot be prevented and hunting for unknown ADRs,
particularly those associated with newly marketed drugs. While acknowledging the in-
evitability of side-effects, no effort must be spared in curtailing the burden ADRs present
and achieving the health imperative of optimizing the risk-benefit ratio of drugs and making
sure that risks are handled in an efficient and effective way.
It is in this vein that this work was undertaken. In particular, this work concerns the
third of the approaches mentioned above, with a focus on developing a statistical model for
analyzing SRS databases, so drug boards, swamped by drug safety data, could be assisted
to effectively detect unknown side-effects of drugs as soon as possible.
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1.4 Objective(s) of the Research
As pointed out in the foregoing paragraph, the main objective of this work was to ex-
plore and develop a statistical model that can assist in the detection of unknown side-
effects associated with drug use via the identification of drug and adverse event pairs with
higher-than-expected or disproportionate frequencies for further scrutiny. Pursuant to this
objective, the research also engaged the following sub-objectives:
1. To identify patterns, if any, in relevant variables connected with the problem of
adverse events in drug use and how they relate to it,
2. To identify covariates (of number of reports linking a given drug and adverse event)
for screening purposes and
3. To explore the data with the view to unearthing any unsuspected characteristics.
1.5 Outline of the Rest of the Thesis
The rest of the thesis is organized as follows: Chapter 2 presents the results of a preliminary
analysis of FDA SRS data with a view to elucidating some of the issues raised in Chapter
1. Chapter 3 provides a brief review of the theory of some key methods used in the
main research work while Chapter 4 proposes new quantitative signal detection model(s)
and describes their implementation. The chapter begins with an overview of some of the
existing quantitative methods. Chapter 5 presents the results of an application of the
proposed models to FDA SRS data, with some discussion. A further discussion of the
results is presented in Chapter 6, where one of the models is identified as most suitable for
the data. Some thoughts on the results, the highlights of the work and the potential for
further research are the subject matter of the last chapter, Chapter 7.
Chapter 2
Preliminary Analysis
This chapter presents the results of a preliminary analysis carried out on one of two data
sets used in the work reported in this thesis. It first describes the nature of the data set
which is the focus of this chapter and gives hints of what is involved in restructuring it for
subsequent use, and why the second data set is needed. A description of the second data
set is given in Chapter 5. The analysis was carried out to throw more light on some of
the issues raised in Chapter 1, pursue the sub-objectives presented in Section 1.4 and gain
an appreciation of what it takes to process the raw data into forms suitable for further
analysis. The results are first presented with minimal discussion which is then followed by
a full discussion of the results and some comments.
2.1 Data: Nature and Treatment
Food and Drugs Adminstration Data, 2004 - 2010
The data which is the subject of the analysis whose results follow were obtained from the
Food and Drug Administration’s website [29], which makes available to the public data
from its Adverse Events Reporting System (AERS) database. The data cover the seven-
year period from 2004 to 2010 and were downloaded between April 2010 and April 2011.
It is made up of seven anonymized and linked quarterly extracts from the AERS database.
These seven quarterly files, which are in ASCII format, come along with four other files
(made up of two MS Word documents and two text files) which describe and give further
information on the seven data files. The seven data files: Demographic and Administrative,
Drugs, Reaction, Outcome, Report Source, Therapy and Indication hold between them 44
variables (including key or link variables) [29], but only 15 of these variables which were
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deemed germane to the objectives of this study were used in the analysis. The selected
variables are presented in Table 2.1; an expanded version can be found in Appendix A.
The collection process of these data allows for the presence of duplicate records, which
must, under some circumstances, be removed before any meaningful analysis could be
carried out. One of the informational files (ASC_NTS.DOC) [29] accompanying the data
states that:
... such “duplicates” ... (multiple reports of the same event) will normally have
the same CASE number (but different ISR numbers). Users wishing to remove
such duplicates can identify a “best ISR” for the case by use of the CASE
and FDA_DT fields - for reports with the same CASE number, select the
latest (most recent) FDA_DT. For those occasions when both the CASE and
FDA_DT fields are the same, select the report with the higher ISR number.
(This procedure would remove “duplicates" not only in the sense just discussed
– paper and e-sub reports – but also “duplicates” in the sense of initial and
follow-up reports) [29].
The above algorithm was followed to remove the duplicates observations from the data.
Reports of adverse events occurring outside the United States were excluded. So are
reports of adverse events occurring in studies (of sponsors) or in the literature. This was to
ensure that the remaining data was as homogeneous as possible. As pointed out by Moore
et al. [53] in “Serious Adverse Drug Events Reported to the Food and Drug Administration,
1998-2005”, reports of adverse events occurring in studies, literature or coming from outside
the United States may bring in additional variation because they do not fit the description
of ‘spontaneous’ or had to meet different criteria for reports not originating from within
the United States.
The Drugs, Reaction and Outcome files contain variables that are of the ‘multiple
response’ type – the values these variables can take are not mutually exclusive; the variables
can hold more than one ‘response’ per subject. This has an effect on the way the analysis
can be carried out. For this reason one is constrained to dichotomize patient outcomes as:
death and all other outcomes or hospitalization and all other outcomes et cetera depending
on what one is looking for.
Adverse events reports to the FDA are of three types, namely expedited, periodic and
direct. Expedited reports are those that concern serious adverse events not described in
the product information and are unexpected – "not been previously observed" [31] in the
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Table 2.1: Selected variables and their description.
Variable Description
ISR Primary link variable identifying each individual
report received, across all seven data files.
CASE Unique number identifying a given subject (record).
FDA_DT Date report was received by the FDA.
REPT_COD Holds codes identifying type of report made.
AGE The age of a subject.
AGE_COD Holds codes for unit in which age was measured.
GNDR_COD Holds codes identifying the sex of a subject.
OCCP_COD Holds codes for the occupation of the original
reporter.
E_SUB Holds codes for mode of submission of report.
ROLE_COD Holds codes identifying the reported role of drug in
adverse event.
DRUGNAME Holds names of drugs involved in the adverse event, either the
"Valid Trade Name" or the "Verbatim" name as stated
on report.
VAL_VBM Holds codes showing whether name of drug is the
Valid Trade Name or the Verbatim name.
PT Holds the Preferred Terms (PT) for describing the
observed reaction to drug(s) using the Medical
Dictionary for Regulatory Activities (MedDRA).
OUTC_COD Holds codes identifying the outcome of the adverse
experience.
RPSR_COD Holds codes identifying the initial report source.
Source: ASC_NTS.DOC, US Food and Drugs Administration [29].
context of use of the drug in question. Such adverse events must be reported to the FDA by
sponsors within 15 days. Periodic reports concern serious adverse events that are described
in the product information. This type of report is usually submitted on a quarterly basis
for newly approved drugs. Direct reports refer to those submitted to the FDA without
recourse to the sponsor [31].
Reporters of adverse events can express the age of the subject in hours, days, weeks,
months, years or decades [29]. All values of age expressed in units other than years were
converted to years. Age was then recoded into three groups, viz: 0-17, 18-44, 45-64, and
65 and over. The rationale behind this categorization was to see how the active population
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compares with the non-active population.
A reporter of an adverse event is required to specify the sex of a subject as M for male
and F for female. Two additional codes (UNK and NS) are provided to cater for situations
where sex is not known (can not be determined, such as that of a fetus) or not specified
respectively [29].
An attempt was made to cross-classify the data set described above into an n × m
table of drugs against adverse events, stratified on the basis of sex, age and time for use
in developing the model for generating hypotheses about the relationship between drugs
and adverse events, but it became clear that the data required careful clean-up. The
clean-up include correcting misspellings of names of drugs and adverse events, finding all
descriptions in the data that point to the same adverse event and recoding them into the
Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term (PT) [83] and
finding all the different names in the data that indicate the same drug (active ingredients)
and recoding them into a commonly accepted drug name. As noted by DuMouchel [20], it
is an exercise that is time-consuming even with expert opinion. We therefore turned to a
second data set, which was ready for use. This second data set is described in Chapter 5.
The analysis of the data described above was carried out with the aid of SAS software
[76] and R software [68]. The SAS software was key in dealing with database and data
processing issues.
The data described above are secondary; as such we cannot understand the data to
the same extent as those who compiled it. Indeed it has to be pointed out (as alluded
to elsewhere) that the data comes with a couple of challenges, notably missing values; a
considerable number of the cases have missing values for some of the variables. The extent
of the problem, in some cases, may call into question the validity of the analysis in respect
of these variables. However, we proceeded to assess the situation based on the available
data as there is hardly any other way of obtaining data on these variables. At least they
shed some light on the nature of the problem of adverse events associated with use of drugs
and their reporting.
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2.2 Results of Preliminary Analysis
2.2.1 Overall Number of Reports and Trend Over Time
After removing reports of adverse events coming from foreign sources, studies or occuring
in literature, a total of 1,919,848 adverse events reports remained for analyses for the seven-
year period under consideration. Annual volume of adverse events reports to the FDA more
than tripled from 165,229 in 2004 to 501,778 in 2010 (Table 2.2). This translates to an
average annual increase of 20.3%, and in the last year (2010) alone the number of reports
rose by 55.9%, relative to that of 2009.
Table 2.2: Annual and overall values for death, other outcomes and all reported adverse
events.
Year Total Number Deaths Other Total Deaths Other
(all of % outcomes (excluding % outcomes
events) deaths % cases with %
missing
values)
2004 165,229 16,008 9.7 90.3 103,597 15.5 84.5
2005 190,147 18,924 10.0 90.0 134,298 14.1 85.9
2006 208,693 17,928 8.6 91.4 146,441 12.2 87.8
2007 243,219 18,622 7.7 92.3 159,438 11.7 88.3
2008 288,845 26,776 9.3 90.7 183,292 14.6 85.4
2009 321,937 34,216 10.6 89.4 219,226 15.6 84.4
2010 501,778 54,327 10.8 89.2 313,477 17.3 82.7
Total 1,919,848 186,801 9.7 90.5 1,259,769 14.8 85.2
The trend in the number of reports submitted per 10,000 people in the US population
over the years is as shown Figure 2.1. The trend in the figure indicates that the number of
adverse event reports received per year is growing at a faster rate than the population size.
The growth is particulary high for 2010. The increasing trend could be due to increasing
awareness of the need to report adverse events or increasing incidence of adverse events or
both.
2.2.2 Patient Outcomes
For the seven-year period under consideration, 660,079 (34.4%) out of the total of 1,919,848
cases (Table 2.3a) had missing patient outcome values.
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Figure 2.1: Number of reports per 10,000 people against time, 2004 – 2010.
Table 2.3a: Patient Outcomes, 2004-2010.
Cases
Valid Missing Total
Count % Count % Count %
1,259,769 65.6 660,079 34.3 1,919,848 100
Of the remaining 1,259,769 cases, 186,801 (14.8%) had an outcome of death (Table
2.3b). As pointed out in Section 2.1, reporters of adverse events are permitted to describe
the event by more than one of the outcome categories. This explains why the sum of the
figures in Table 2.3b exceed 100%. The overall trend in the number of deaths suggest
an increase over time, but the actual number of deaths decreased in 2006 (compared to
that of 2005 in spite of increase in the number of reports) and then picked up from 2007
onwards. Figures 2.2a and 2.2b present a comparison of the trends in the annual number
of deaths, other outcomes, all cases and all non-missing cases; and Figure 2.3 shows the
annual percentage deaths for all the cases, and for all non-missing cases. Figures 2.2b and
2.3 were produced as a way of assessing the effect, if any, of the problem of missing values
on the trend in the number of deaths over time.
Over the period, the proportion of reported cases of adverse events which had an
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Table 2.3b: Patient Outcomes, 2004-2010.
Outcome Cases %
Death (DE) 186,801 14.8
Life-threatening (LT) 79,207 6.3
Hospitalization - initial or prolonged stay (HO) 514,807 40.9
Disability (DS) 61,155 4.9
Congenital anomaly (CA) 9,490 0.8
Required intervention to prevent permanent impairment
or damage (RI) 38,614 3.1
Other (OT) 670,991 53.3
outcome of death in the US assumed a low of 11.7% in 2007 and a high of 17.3% in 2010.
The figures come to a low of 7.7% in 2007 and a high of 10.8% in 2010 if the denominator
is changed to number of all cases, assuming none of the missing outcomes is death. Of
course the estimates would be higher if we assume that all the missing outcomes values are
deaths – either of these assumptions is hardly possible, though. But this approach allows
us to see what conservative estimates are likely to be.
The proportion of reported cases of adverse events in the US in which the subject
had a hospital admission (initial or resulting in prolongation of hospital stay) over the
period under consideration stands at 40.9% (excluding missing cases). This high figure
just shows that spontaneous reports are more likely to involve serious adverse events. The
minimum for the period is 39.7% and the maximum is 43.4%. The corresponding values
when the denominator is changed to all cases, as was done for death, are 24.8% and 30.5%
respectively. Values for other outcomes are presented in Appendix B (Tables B.1 and B.2).
The trend in the bars plotted with percentages determined from the number of all
annual adverse events (lightblue colour) compares with that plotted with percentages de-
termined from the number of annual non-missing cases (mistyrose colour) except that of
2005 (Figure 2.3). Thus the missing values appear not to have had any serious effect on
the proportion of deaths reported.
2.2.3 Occupation of Reporters
FDA requires the identification of the occupation of the original reporter of a case of
adverse event, submitted directly or not. The occupation of the original reporters of 290,833
(15.1%) of the cases were not accounted for (missing), for the period under consideration
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Figure 2.2a: Chart showing the trends in the number of deaths, other outcomes and all
non-missing cases.
(Table 2.4a).
Table 2.4a: Occupation of original reporters, 2004-2010.
Cases
Valid Missing Total
Count % Count % Count %
1,629,015 84.9 290,833 15.1 1,919,848 100
Health professionals were the original reporters of more than half (869,507, 53.4%) of
the remaining 1,629,015 cases (Table 2.4b). The annual values follow a similar structure
except 2007 when the non-professional source (consumers or their legal representatives)
was greater than the professional one by 3.6% (Figure B.1).
2.2.4 Types of Report
Of the total 1,919,848 reports submitted in the period under discussion, 186,636 (9.7%)
were direct reports, 949,291 (49.5%) were expedited reports and 783,921 (40.8%) were
periodic reports (Table 2.5).
Expedited reports have been accounting for the highest number of reports since 2005
CHAPTER 2. PRELIMINARY ANALYSIS 22
2004 2005 2006 2007 2008 2009 2010
Year
N
um
be
r o
f C
as
es
0e
+0
0
1e
+0
5
2e
+0
5
3e
+0
5
4e
+0
5
5e
+0
5
Deaths
Other outcomes
All events
Figure 2.2b: Chart showing the trends in the number of deaths, other outcomes and all
events.
Table 2.4b: Occupation of original reporters, 2004-2010.
Occupation Cases %
Physician (MD) 461,287 28.3
Pharmacist (PH) 120,930 7.4
Other Health-Professional (OT) 287,290 17.6
Lawyer (LW) 66,087 4.1
Consumer (CN) 693,421 42.6
when it overtook periodic reports, with direct reports accounting for the least number of
reports throughout the period under discussion. The reporting structure has remained
pretty much the same since 2005 although the 2009 percentage for expedited report in-
creased by 6.1 percentage points over that of 2008 and then dropped by 4.2 points in 2010
and that of periodic dropped by 5.2 points in 2009 then increased by 9.0 points in 2010
(Figure B.2, Appendix B).
2.2.5 Mode of Submission of Reports
Overall, 68.6% (Table 2.6b) of the reports were submitted via the internet, with the re-
maining 31.4% in hard copy. The trend in the annual figures suggest that more reports are
increasingly being submitted via the internet; while the number of reports submitted by
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Figure 2.3: Chart showing the trends in the percentage of death in all the reports and in
the non-missing cases.
Table 2.5: Report types, 2004-2010.
Type of report Cases %
Direct 186,636 9.7
Expedited 949,291 49.5
Periodic 783,921 40.8
this mode accounted for 33.1% in 2004, it had grown by 53.8 percentage points to 86.9%
by 2010.
2.2.6 Sex of Subjects
As much as 160,054 (8.3%) of the reports submitted over the period had the sex of the
subject to be indeterminate – the sex of the subject is not known, not specified or missing
(Table 2.7a).
Of the 1,759,794 (91.7%) remaining reports, 61.3% were female and 38.7% were male
(Table 2.7b). The dominance of reports on female subjects, which is consistent with the
observation of Wysowski and Swartz [89], was a constant feature over the seven-year pe-
riod, contributing about three-fifth of the total number of reports annually (Figure B.3,
Appendix B).
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Table 2.6a: Report format, 2004-2010.
Cases
Valid Missing Total
Count % Count % Count %
1,919,846 100.0 2 0.0 1,919,848 100
Table 2.6b: Report format, 2004-2010.
Electronic submission Cases %
Yes 1,316,720 68.6
No 603,126 31.4
2.2.7 Age of Subjects
As can be seen from Table 2.8a, the ages of a large number 833,188 (43.4%) of the cases
were unaccounted for (missing). Of the remaining 1,086,660 cases (Table 2.8b), 65,916
(6.1%) were in the group 0-17, 268,273 (24.7%) were in the group 18-44 and the groups
45-64 and 65 and over accounted for 37.9% (411,978) and 31.3% (340,493) respectively.
A study of the annual data shows an increasing trend in the number and percentage of
missing values up to 2009. The percentage missing dropped from 55.4 in 2009 to 40.6 in
2010. However the age structure of the annual non-missing cases has not only been fairly
consistent from year to year since 2005 but also with the overall age structure for the period
under consideration (Figure B.4, Appendix B).
2.2.8 Age and Sex Load of Adverse Events
Table 2.9 presents a cross classification of the number of reports on the basis of age and
sex. It also presents percentage values for the size of the age groups in the overall US
population, adjusted percentages (expected) for likelihood of drug use and the ‘proportion’
(p) of each of these age groups in the overall number of reports relative to the size of these
age groups in the overall US population. The ‘proportion’ p for each age group was found
in two stages: the number of non-missing cases for each age group for a particular year
was divided by the number of people in that age group in the US population for that year,
and then multiplied by 10,000. This gives the ‘proportion’ for that age group for that year.
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Table 2.7a: Sex of subjects, 2004-2010.
Cases
Valid Missing Total
Count % Count % Count %
1,759,794 91.7 160,054 8.3 1,919,848 100
Table 2.7b: Sex of subjects, 2004-2010.
Sex Cases %
Female 1,079,434 61.3
Male 680,360 38.7
The value of p for an age group for the period under consideration is then given by the
geometric mean of the annual ‘proportions’ for that age group.
Table 2.9 shows that even though there are generally more reports on females than on
males, the age group 0-17 is an exception; it has more reports on males than on females.
It is also clear that the percentages of people 17 years or younger and between 18 and 44
years inclusive reported to be involved in adverse events are less than that in the overall US
population, even when it has been adjusted for potential drug use. The reverse is true for
the percentages of people between 45 and 64 years inclusive and 65 years or older; they are
greater than the percentage in the overall US population and that of the adjusted values.
The percentage for the ‘active’ age group 18-64 (that is combining the age groups 18-44
and 45-64 together) is almost on par with both the adjusted and overall US population
percentages (Figure B.5, B). This result is consistent with that observed by Moore et
al [53]. It is also worthy of note that the value of the ‘proportion’, p, increases down the
table. A graphical rendition of the pattern in the values of the ‘proportion’ over the period
under consideration is presented in Figure B.6 of Appendix B.
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Table 2.8a: Age of subjects, 2004-2010.
Cases
Valid Missing Total
Count % Count % Count %
1,086,660 56.6 833,188 43.4 1,919,848 100
Table 2.8b: Age of subjects, 2004-2010.
Age range Cases %
≤ 17 65,916 6.1
18 - 44 268,273 24.7
45 - 64 411,978 37.9
≥ 65 340,493 31.3
Table 2.9: Age and sex load of adverse events, 2004-2010.
Age range Female Male Total 2010 Exp’d Prop’n
Cases % Cases % Cases % US casesξ p
Pop’n %
ζ
%
≤ 17 27,681 2.6 34,978 3.3 62,659 5.9 24.0 12.5 1.2
18 - 44 177,882 16.6 86,571 8.1 264,453 24.7 36.5 28.3 3.2
45 - 64 2,425,424 22.9 161,538 15.1 406,962 38.0 26.4 35.1 5.5
≥ 65 192,462 18.0 143,340 13.4 335,802 31.4 13.1 24.1 12.3
Total 643,449 60.1 426,427 39.9 1,069,876 100.0 100.0 100.0
ζ From 2010 US population census [13]. ξ Population adjusted for potential drug use based on
the 2005-2008 data on prescription drug use [57].
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2.3 Discussion and Comments
We saw in Section 2.2.1 that the number of adverse events reported is growing at an annual
rate of 20.3% and it more than trebled over the period under consideration, with a 55.9%
increase in 2010 alone, over the 2009 figure. The rate of growth in the number of reports is
relatively fast for a population which is growing at an approximate rate of 0.93% per annum
(based on the 2000 and 2010 US population census) [13]. This could be explained in two
ways: either there is growing awareness of the need to contribute to the pharmacovigilance
process and hence the increase in the number of reports, when viewed against the well
know phenomenon of under reporting [4,70] or the number of adverse events is growing at
an increasing rate or both.
The trend in the plot of the number of reports submitted per 10,000 people as captured
in Figure 2.1 suggests the number of reported cases is likely to continue to rise after 2010.
However the increase in the number of reported cases after 2010 is not likely to be as much
as that of 2010 or will be similar to the pattern before 2010 given the exceptional nature
of the increase in 2010.
Figures 2.2a and 2.2b appear to suggest an increasing trend in the number of cases with
an outcome of death reported over time even though there was a decrease in the number
of reported deaths from 2005 to 2006, in spite of an increase in number of reported cases of
adverse events from 2005 to 2006. Figure 2.3 shows that the percentage of reported cases
of adverse events that resulted in death in the US decreased from 2005 to 2007, and then
began to pick up in 2008.
From Section 2.2.2, one could infer that of the reported cases of adverse events in the
US in the period 2004 to 2010, at least 7.7% had an outcome of death and 24.8% had an
outcome of hospital admission (including prolongation of hospital stay).
The percentage of reports coming from consumers and lawyers is reasonably high com-
pared with that of health professionals (Section 2.2.3) and appears to suggest that there is
an appreciable level of awareness of the need to contribute to the pharmacovigilance pro-
cess amongst consumers and lawyers (compared to health professionals). This is in spite
of the fact that there is under-reporting generally.
Expedited reports have been in the majority since 2005 (Section 2.2.4). The prepon-
derance of expedited reports may be pointing to the lingering problem of uncommon but
serious adverse drug reactions, and underscores the urgency of finding a means to curtail
if not eliminate it.
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The increasing trend in the number of reports submitted electronically reflects the
growing importance of this unprecedented mode of information exchange in general, and
in pharmacovigilance in particular. Effort at improving the monitoring system should not
only focus on taking advantage of the speed of this mode of reporting but also on sensitizing
the stake holders, especially the general public, on the need to do accurate reporting as
improper description of drugs and adverse events is a problem militating against the optimal
and timely use of this unique source of information.
The picture presented by the values in Table 2.7b (Section 2.2.6) appears to raise a
number of questions: Are females more susceptible to adverse events than males, generally
speaking? This question arises because 2010 population census of the US puts the respec-
tive percentages of males and females at approximately 49.2 and 50.8; a ratio of almost one
to one. So why should the ratio of male cases to female cases be roughly 2:3 for cases whose
sex are known? Could this be attributed to the phenomenon of missing cases? Could there
be a reason for this phenomenon affecting males more than females?
We observed in Section 2.2.8 that the values of the percentages of the age groups 0-17
years and 65 years or older involved in adverse events do not compare with those in the
overall US population, even when adjusted for drug use. More specifically the values are
comparatively smaller for the group 0-17 and comparatively greater for the group 65 years
or over. This state of affairs is buttressed by the increasing trend in the value of p down
the table (Table 2.9), which together appear to demonstrates that the older segment of the
population are more susceptible to adverse drug reactions than the younger segment.
The situation of not being able to account for the ages of a large number of the cases
as seen from Table 2.8a does not augur well for pharmacovigilance, as the foregoing ob-
servations appear to lend credence to the fact that age and sex are potentially serious
candidates when it comes to keying out factors that are linked to occurrence of adverse
events [29], and hence their use as covariates of the number of reports in modeling and
inference regarding signaling drug and adverse event pairs that have higher than expected
frequencies.
Chapter 3
Review of Background Theory
This chapter presents a brief review of the theory of some key methods used in the rest of
the work.
3.1 Bayesian Inference
The Bayesian approach to inference allows one to factor into an analysis prior knowledge
or at least one’s prior beliefs about the parameter of interest. The parameter is thought
of as a random variable as opposed to the frequentist view of having a fixed but unknown
value. Interest lies in the posterior distribution π (θ|x) of the parameter θ = (θ1, θ2, · · · , θp)
given the observed data x = {x1, x2, ..., xn}. The posterior distribution represents the most
current state of knowledge which results from combining the prior distribution with the
observed data x in the form of the likelihood [33, 44].
3.1.1 Bayes’ Theorem
Given the prior distribution h(θ) and the likelihood f (x|θ), Bayes’ theorem leads to the
following:
π (θ | x) =
f (x|θ)h(θ)∫
f (x|θ)h(θ)dθ
(3.1)
∝ f (x|θ)h(θ)
Expression (3.1) forms the basis of Bayesian inference [10, 44].
29
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3.1.2 Prior Specification
A key consideration in the specification of a prior distribution is that it should sufficiently
represent the prior knowledge (before the ‘observation’ of data) about the parameter of
interest. Another thing that impinges on the choice of prior distributions is the potential for
simplifying the derivation of posterior distributions and the associated computations [10].
In this regard the prior is often chosen so that the posterior belongs to the same class
of distributions as the prior distribution, with the posterior differing from the prior in
terms of only the parameters. Such a prior is said to be conjugate to the likelihood
[10, 47]. For instance independently and identically distributed data x = {x1, x2, ..., xn}
from an exponential distribution Exp(θ) with θ ∼ Ga(α, β) a priori, leads to the posterior
Ga(α+ n, β + nx¯). Thus Ga(α, β) is conjugate to Exp(θ).
A prior chosen to reflect the paucity of knowledge about the parameter of interest is
referred to as a noninformative prior. For example, if we do not have information about
a discrete parameter, θ, except that θ = {θ1, θ2, . . . θn}, then we could assign the discrete
Uniform distribution p(θi) = 1/n, i = 1, 2, . . . n, on θ. Such a prior distribution is regarded
as noninformative as it assigns the same probability value to all the possible values θ,
yielding no further information about θ [10]. One could also specify a hierarchy of priors
by placing a secondary prior (hyperprior) on the prior parameters (hyperparameters) in
lieu of noninformative priors as a way of diffusing the effect of any prior assumptions on the
posterior [44,47]. Given independently and identically distributed data x = {x1, x2, ..., xn}
from the Poisson distribution Pois(λ), the prior specification λ ∼ Ga(a, b) with a ∼ Exp(θa)
and b ∼ Inv-Exp(θb) is an instance of a hierarchical prior.
3.1.3 Prior Sensitivity
The question of how the posterior distribution is affected by different prior specifications
often comes up in Bayesian analysis. As prior elicitation is not easy, particularly in cases
where prior knowledge about the parameters of interest is scant, it is useful to assess how
robust the posterior is to different prior specifications. This assessment is referred to as
prior sensitivity analysis [10, 44]. For example, how does the posterior resulting from an
exponential distribution prior compare with that resulting from an inverse exponential
distribution prior.
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3.1.4 Hierarchical Models
As alluded to above, a Bayesian hierarchical model is one in which the prior is made
up of multiple levels of probability distributions. In other words, at the least, the prior
parameters are themselves regarded as random variables, which are assumed to come from
some given probability distribution. This approach is useful for modeling in a relatively
simple and effective way data with complicated structure, such as data on a universe of
interest made up of interrelated subgroups or units with unique characteristics [10, 33,
60]. The mean effect ψj of group j , j = 1, . . . , J are estimated with the data of all the
other groups under the assumption that the mean effects ψj are drawn from a common
distribution G. That is ψj|ϕ ∼ G(ϕ), where ϕ is the mean effect of the common distribution
G [60]. The pooling of the data from the groups results in a pulling of the ψj ’s towards the
mean effect of the common distribution from which the groups obtain. This phenomenon
is referred to as the shrinkage effect. Thus this modeling technique takes into consideration
the interdependence between the cognate parameters ψj to produce results that are thought
to be more reliable [33, 60].
3.1.5 Posterior Inference
Point estimates such as mean, median and mode of posterior parameters are commonly
used to describe the location of the posterior distribution while the spread is estimated
by the standard deviation (or the variance). Also used to describe the spread is the
central 100(1 − α)% credible interval – a Bayesian analogue of the classical confidence
interval [33, 44]. The choice of which summary statistics to use is often dictated by the
problem on hand (or the data) and the objectives of the analysis.
3.2 Stochastic Simulation
As with all probability distributions, a knowledge of the moments and quantiles of the pos-
terior distribution (or associated conditional and marginal distributions) may be required to
understand it. Estimating these quantities from samples drawn from the posterior is crucial
in this regard where it is not possible to do so analytically, especially in high-dimensional
problems [10,33]. The technique of using simulation to obtain summary estimates of a given
distribution is referred to as the Monte Carlo method. The Law of Large Numbers ensures
that the estimates so obtained tend to the true values of the estimands as the sample size
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grows large [10]. There are routines that facilitate the generation of independent identically
distributed random samples from standard distributions. However nonstandard posterior
distributions arise that cannot be sampled using these routines (they play an intermediate
role at best) and another approach must be used to sample these distributions [33]. The
methods of Markov Chain Monte Carlo (MCMC), based on Markov chains provide a con-
venient way of sampling from posterior distributions under such circumstances, especially
in high-dimensional problems [10, 33].
3.2.1 Markov Chains
A Markov chain is a sequence of correlated random variables {θ(t)}∞t=0 such that
P
(
θ(t+1)|θ(0), θ(1), θ(2), . . . , θ(t)
)
= P
(
θ(t+1)|θ(t)
)
(3.2)
Thus the conditional distribution of the next state θ(t+1), given all the past states, depends
only on the current state θ(t) [44, 72]. The right hand side of the conditional probability
(3.2), written as K
(
θ(t), θ(t+1)
)
, is referred to as the transitional kernel. The θ(t)s take
values from a set Ω called the state space [72].
For a Markov chain to be useful in the Bayesian setting, it must have a stationary
distribution or converge to a target probability distribution, which distribution is the pos-
terior distribution π(θ|x) (equivalently written as π(θ)) from which samples are desired.
Stationarity implies that the Markov chain is irreducible and aperiodic (a condition that
is satisfied if K(θ, φ) > 0, ∀ θ, φ ∈ Ω, including the possibility of the chain remaining in
the current state). A Markov chain with the above attributes will converge to the limiting
distribution π(θ) irrespective of the initial state [44, 72]. It follows from the Law of Large
Numbers that given the realizations θ(1), θ(2), · · · , θ(n) from the steady state of a Markov
chain and any integrable function g [44, 72]:
g¯n =
1
n
n∑
i=1
g(θ(i))→ Epi[g(θ)] as n →∞ (3.3)
Relation (3.3) expresses what is called the Ergodic Theorem [44, 72]. It guarantees that
one can estimate features of the distribution π(θ) such as Epi[g(θ)] using time averages.
3.2.2 Metropolis-Hastings (MH) Algorithm
In the Metropolis-Hastings (MH) algorithm, we construct the transition kernel K(θ, φ) by
finding a candidate generating distribution q(φ|θ), which generates the candidate value φ
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of the chain dependent only on the current value θ. If the reversibility condition (3.4) is
satisfied by the Markov chain so created, then the chain will converge to π(θ) [14, 44, 72].
π(θ)K(θ, φ) = π(φ)K(φ, θ) (3.4)
To achieve this, a candidate value φ, generated according to the proposal distribution
q(φ|θ), is accepted with probability α(θ, φ) [14, 44] given by
α(θ, φ) = min
{
1,
π(φ)q(θ|φ)
π(θ)q(φ|θ)
}
(3.5)
The MH algorithm is thus given by
1. Given the current state θ(t), generate a candidate value φ ∼ q(φ|θ(t)) and u ∼ U(0, 1).
2. Set θ(t+1) = φ if u ≤ α(θ, φ), else set θ(t+1) = θ(t)
3. Return to Step 1.
The MH algorithm can be used to update a single parameter or a block of parameters
at a time (often used to reduce correlation between parameters). It is to be noted that
the algorithm can be used even if the normalizing constant of the target distribution is
not known since it occurs in the numerator and denominator of the ratio of the target
in α(θ, φ). However, the proposal density q(φ|θ) has influence on the performance of the
algorithm and its selection typically requires some experimentation. In this regard the
proposal density should be such that the resulting Markov chain can explore the whole
support of the target distribution in good time [14, 44, 72].
The MH algorithm takes several forms which are determined by the proposal density
used. Two such forms, Random Walk Metropolis and Gibbs Sampling, which are relevant
to this work, are described below.
Random Walk Metropolis Algorithm
In the random walk Metropolis algorithm, the candidate value is given by φ = θ(t) + δ
where δ ∼ g is a random displacement and g is some distribution [14,44,72]. The proposal
density is then q(φ|θ) = g(φ − θ). Symmetric distributions such as the normal, uniform
and the t distribution are commonly used for g as they simplify the acceptance probability
α(θ, φ) if they are centered on zero [14, 44, 72]. In such a case q(φ|θ) = q(θ|φ) and the
acceptance probability is given by
α(θ, φ) = min
{
1,
π(φ)
π(θ)
}
(3.6)
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Gibbs Sampling
Given the target distribution π(θ) where θ = (θ1, θ2, · · · , θp), the distribution π(θj|θ−j)
of θj , conditional on the rest of the parameters θ−j = (θ1, θ2, · · · , θj−1, θj+1, · · · , θp), is
called the full conditional distribution of θj. Full conditional distributions are the main
ingredients of a special case of the MH algorithm called Gibbs sampling [32, 44, 72]. The
transition from θ(t) to θ(t+1) in Gibbs sampling is as outlined below [32,44, 72]:
Generate θ
(t+1)
1 from π
(
θ1|θ
(t)
−1
)
Generate θ
(t+1)
2 from π
(
θ2|θ
(t+1)
1 , θ
(t)
3, , · · · , θ
(t)
p
)
Generate θ
(t+1)
3 from π
(
θ3|θ
(t+1)
1 , θ
(t+1)
2 , θ
(t)
4, , · · · , θ
(t)
p
)
...
...
Generate θ
(t+1)
j from π
(
θj|θ
(t+1)
1 , θ
(t+1)
2 , · · · , θ
(t+1)
j−1 , θ
(t)
j+1, · · · , θ
(t)
p
)
...
...
Generate θ
(t+1)
p from π
(
θp|θ
(t+1)
−p
)
Gibbs sampling is relatively easy to use if all the full conditionals are of standard
form. However computational problems may arise if some of the full conditionals are not
of standard form and are not easy to sample from using existing routines. In which case
the (general) MH algorithm may be used to sample the nonstandard conditionals. Gibbs
sampling is therefore often used in conjunction with the MH algorithm. On the other hand
the MH algorithm requires some calibration of the proposal density, which is not required
in Gibbs sampling [44, 72].
3.2.3 Convergence and Related Issues
The essence of MCMC rest on the following: Given a Markov chain {θ(t)}∞t=0 with the
attributes outlined in Section 3.2.1, there is some value k such that for t > k , θ(t) is
thought to come from the target distribution π(θ|x). The chain is then said to have
converged and realizations from the steady state, which are seen to be coming from the
posterior distribution, can be used for inference [33, 44, 72].
The algorithm then must be run long enough to reach k and to ensure that the starting
values have no influence on the draws. The first k iterates are then discarded as they are
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assumed not to come from the posterior distribution. This initial part of the run which is
discarded is referred to as the burn-in [33, 44, 72]. The question then is how large should
be the burn-in? Linked to the forgoing question is the performance of the Markov chain.
These and other related issues are explored in the following sections:
Trace Plots
A basic approach in deciding the length of the burn-in is to examine the trace plots of the
parameters and posterior density. The practice is to run multiple chains from dispersed
starting points and then display the parameter values from different runs on the same
plot. As the stationary distribution is unique, the trajectory of the trace plots of the
different runs should gravitate towards a common range of values with increasing number
of iterations. The point at which these trace plots merge should give an idea of the length
of the burn-in [33, 44, 60]. Running multiple chains also provides some guarantee that all
the modes of the posterior distribution have been visited, if the chains assume a common
range of values after some reasonable number of iterations. This is critical in a multi-modal
posterior as a mode may be missed by a single chain leading to the wrong impression that
the stationary state has been reached [33, 44].
Gelman-Rubin Diagnostic
One could also use the Gelman-Rubin (GR) criterion to assess convergence. It revolves
around the idea that the draws from the multiple chains are coming from the same distri-
bution at convergence and hence the between-chain variance and the within-chain variance
should be roughly equal [33, 44]. The criterion comes in different forms. One form in Gel-
man et al. [33] suggest running m chains and drawing a sample of n iterates apiece. The
between-chain B and within-chain W variances are then computed as follows:
ψ¯.j =
1
n
n∑
i=1
ψij ψ¯.. =
1
m
m∑
j=1
ψ¯.j
where ψij , i = 1, 2 . . . , n, j = 1, 2 . . . ,m are the draws for parameter ψ.
s2j =
1
n− 1
n∑
i=1
(
ψij − ψ¯.j
)2
B =
n
m− 1
m∑
j=1
(
ψ¯.j − ψ¯..
)2
W =
1
m
m∑
j=1
s2j
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A measure of agreement of the two variances is given by the GR statistic [33]:
Rˆ =
√
n− 1
n
+
B
nW
Their recommendation is to run the chains until the Rˆ for each of the parameter under
consideration is close to one. The next nm iterates could then be used for inference. Values
of Rˆ below 1.1 are said to be acceptable, with higher levels of accuracy required for sensitive
applications [33].
Mixing, Autocorrelation and Acceptance rate
The parameter values drawn from a Markov chain are correlated [72]. Given sample iterates
θ(1), θ(2), ...θ(n) from a stationary Markov chain: the autocorrelation in the iterates, the
mixing attributes of the chain, the acceptance rate and convergence of the chain are all
intertwined. A gentle decline in the autocorrelation values, which can be ascertained with
an autocorrelation function (acf) plot, is an indication of a slow mixing chain [14,44,60,72].
What it means is that either the proposal steps in the MH algorithm are small, leading
to proposal values that are similar to the current value and are therefore accepted, with
corresponding high acceptance rate, or the proposals are far out in the periphery of the
parameter space leading to a rejection. This will lead to a low acceptance rate and a
repetition of the same values over a number of iterations. Both situations will lead to a
delayed convergence. On the other hand a sharp decline in the autocorrelation values is
an indication of a good mixing chain, a reasonable acceptance rate and a fast convergence
[14, 44, 60, 72].
The performance of a chain can be improved by adjusting the proposal variance. An
increase in the proposal variance is associated with a decrease in the acceptance rate and
vice versa [14, 44]. Mixing can also be improved by jointly updating (block update) pa-
rameters that are a posteriori correlated. Parameters that are correlated tend to constrain
the range of acceptable values of each other if they are updated individually [44].
Beyond adjusting the proposal variance, high autocorrelation could be dealt with by
changing the candidate generating density altogether or by thinning – keeping only every
j th iterate value from the sampled sequence [44, 60].
Chapter 4
Data Models
The need for timely release of information about side-effect of drugs by drug regulatory
agencies, after marketing approval has been given, has led to the development of a number
of statistical tools aimed at assisting in the generation of signals – “hypothesis about a
possible drug safety problem” [87]; manual evaluation of the case reports by expert panels
is prohibitive both in terms of the time and cost, owing to the volume of data in a typical
pharmacovigilance database [6]. These statistical methods, aim at discriminating against
occurrences in an SRS data set that are not attributable to the association between drug
and adverse event [24], so that the potential nature of the association – whether causal
or not – can be inferred tentatively. They are intended to give a measure of the degree
to which the association between a drug and adverse event departs from what would be
expected if the adverse event is independent of the drug [25, 46]; the methods are said to
be ‘disproportionality’ [6] measures . We review some of the existing quantitative methods
in this chapter and then propose new model(s) based on the Conway-Maxwell-Poisson
distribution [43, 78] in a hierarchical framework. We begin by first describing a simplified
version of an SRS database.
4.1 Simplified SRS Database
In terms of drug and adverse events, a Spontaneous Reporting System (SRS) database can
be conceived as an I by J contingency table linking I drugs with J adverse events as shown
in Table 4.1 [3, 19]. For any drug and adverse events pair, Table 4.1 could be reduced to
Table 4.2 [3, 19].
37
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Table 4.1: A cross-tabulation of drugs and adverse events.
Adverse Event
Drug
E1 E2 · · · Ej · · · EJ
D1 N11 N12 · · · N1j · · · N1J N1.
D2 N21 N22 · · · N2j · · · N2J N2.
...
...
...
. . .
. . .
. . .
...
...
Di Ni1 Ni2
. . .
. . .
. . . NiJ Ni.
...
...
...
. . .
. . .
. . .
...
...
DI NI1 NI2 · · · NIj · · · NIJ NI.
N.1 N.2 · · · N.j · · · N.J N..
Table 4.2: A cross-tabulation of drug i and adverse events j .
Adverse Event
Drug
Ej ∼ Ej
Di Nij Nij¯ Ni.
∼ Di Ni¯j Ni¯ j¯ Ni¯.
N.j N.j¯ N..
Di : The i
th drug
∼ Di : Drugs other than the i
th one
Ej : The j
th adverse event
∼ Ej : Adverse events other than the j
th one
Nij : Number of cases involving the i
th drug and the jth adverse event
Nij¯ : Number of cases involving i
thdrug and adverse events other than the jth one
Ni¯j : Number of cases involving j
th adverse event and drugs other than the ith one
Ni¯ j¯ : Number of cases not involving i
th drug nor the jth adverse event
Ni. : Total number of cases involving the i
th drug
Ni¯. : Total number of cases not involving the i
th drug
N.j : Total number of cases involving the j
th adverse event
N.j¯ : Total number of cases not involving the j
th adverse event
N.. : Total number of adverse event cases across all cells
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4.2 Some Existing Methods
4.2.1 Relative Report Rate (RR)
Under the assumption of no association between drug i and adverse event j, the Relative
Report Rate (RR) [19] given by
RRij =
Nij
Eij
Eij =
Ni .N.j
N..
(4.1)
Eij : Expected frequency of the ij
th cell
is expected to be roughly equal to 1 [19], so that values of RR > 1 could be thought
of as interesting; requiring further scrutiny to determine whether indeed the relationship
between the drug and the adverse event is causal.
In order to address problems of confounding due to covariates, Nij and Eij could be
redefined as:
Nij =
∑
k
Nijk
Eij =
∑
k
Ni .kN.jk
N..k
where k is the number of strata resulting from potential confounding factors such as sex
and age [19].
4.2.2 Proportional Reporting Ratio (PRR)
The Proportional Reporting Ratio (PRR) introduced by Evans et al. [25] relates the pro-
portion of an adverse event in the database cited with a given drug to the proportion of
the same event cited with all other drugs. It is defined as
PRR =
Nij/Ni.
Ni¯j/Ni¯.
.
Like RR, PRR is expected to have a value of 1 under the assumption of no association
between drug and adverse event. However the authors use a different criterion to define
a signal. A signal is deemed to be present when all the conditions: PRR ≥ 2, Nij ≥ 3
and χ2 ≥ 4 are satisfied, where the χ2 test of independence of drug and adverse event
is based on Table 4.2. The condition χ2 ≥ 4 is an approximation to the exact critical
value (χ2 = 3.841) for a chi-square test of independence at 5% significance level with 1
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degree of freedom; a PRR of at least 2 suggest the drug and adverse event combination is
being reported at a rate that is at least twice as much as would be expected if the drug
and adverse event are independent; and an observed count of at least three represents a
trade-off between not permitting too many false positives due to the presence of drug and
adverse event pairs with weak data support and not encouraging false negatives because
the number of drug and adverse event pairs required for signal generation has been set too
high.
4.2.3 Reporting Odds Ratio (ROR)
The Reporting Odds Ratio (ROR) is a method allied to PRR [24, 52]. It relates the odds
of an adverse event cited with a given drug to the odds of the same event cited with all
other drugs, which is defined by
ROR =
Nij/Nij¯
Ni¯j/Ni¯ j¯
.
The above methods are prone to large numbers of false positive signals [19, 24]. This
is the case because drug and adverse events with very small Eij tend to have relatively
higher Ni¯ j¯ and Ni¯. leading to very large values of the above measures [24, 34], which do
not correspond with the observed count.
To address the issue of uncertainty and reduce the level of false positives, two Bayesian
methods, the Gamma Poisson Shrinker (GPS) [19] and the Bayesian Confidence Propaga-
tion Neural Network (BCPNN) [7], were developed. Their strength lies in the ability to
shrink RR towards the null value of 1. The shrinkage tends to be more pronounced for
drug and adverse event pairs for which the observed count or the expected count is very
low [6], thereby reducing the numbers of false positives.
4.2.4 Gamma Poisson Shrinker (GPS)
The GPS, proposed by DuMouchel [19], assumes that each observed count Nij is indepen-
dently poisson distributed with parameter µij. For drug i and adverse event j , the quantity
of interest is λij , where λij = µij/Eij . Thus
Pr(Nij = nij | λij,Eij) =
e−λijEij (λijEij)
nij
nij !
.
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Probability Nij takes on value nij , after integrating out λij , given λij ∼ Ga(α, β), is given
by
Pr(Nij = nij | α, β,Eij) =
(
1 +
β
Eij
)−nij (
1 +
Eij
β
)−α Γ(nij + α)
nij !Γ(α)
(4.2)
which is the negative binomial with parameter 1/
(
1 + β
Eij
)
.
The posterior distribution of λij, when a value nij of Nij has been observed, given a
Ga(α, β) prior distribution on λij is given by
λij | α, β,nij ∼ Ga(α+ nij , β + Eij) (4.3)
If, however, instead of supposing a single gamma distribution on λij , we consider a mixture
of two gamma distributions [19], then
λij ∼ [̺Ga(α1, β1) + (1− ̺)Ga(α2, β2)]
where ̺ is the proportion of the λij’s that come from Ga(α1, β1) and 1 − ̺ otherwise. It
follows from (4.3) that
λij | α1, β1, α2, β2,Nij = nij ∼ ωijGa(α1 + nij , β1 + Eij) + (1− ωij)Ga(α2 + nij , β2 + Eij)
where ωij , the posterior probability that λij came from the first component of the mixture,
is given by [19]
ωij =
̺Pr(Nij = nij | α1, β1,Eij)
̺Pr(Nij = nij | α1, β1,Eij) + (1− ̺)Pr(Nij = nij | α2, β2,Eij)
and
Pr(Nij = nij | α1, β1,Eij)
is as given in (4.2).
The values of α1, β1, α2, β2 and ̺ are estimated by the method of maximum likelihood
estimation, in which the product of the marginal densities given by (4.4) is maximized [19].
Pr(Nij = nij|α1, β1, α2, β2, ̺,Eij) =
̺Pr(Nij = nij | α1, β1,Eij) + (1− ̺)Pr(Nij = nij | α2, β2,Eij) (4.4)
Drug and adverse event pairs are assessed on the basis of either the geometric mean of
the posterior distribution of λij, called the Empirical Bayes Geometric Mean (EBGM) [19],
or on the basis of the 5% quantile of the posterior distribution of λij (EB05) [21]. Szarfman
et al. [82] proposed EB05 > 2 as a condition for the generation of a signal, which was arrived
at through empirical studies.
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4.2.5 Bayesian Confidence Propagation Neural Network
(BCPNN)
The BCPNN model [7] uses what is referred to as the Information Component (IC) to
generate signals. The IC for drug i and adverse event j is given by
ICij = log2
(
γij
ηi · ξj
)
.
The ICs are found via the Bayesian paradigm as follows [7]:
Nij ∼ Bin(N.., γij), where γij ∼ Beta(αij , βij)
Ni. ∼ Bin(N.., ηi), ηi ∼ Beta(α1i, β1i)
N.j ∼ Bin(N.., ξj), ξj ∼ Beta(α2j , β2j)
It follows that
γij |Nij ∼ Beta(αij + Nij, βij +N.. − Nij)
ηi|Ni. ∼ Beta(α1i + Ni., β1i + N.. − Ni.)
ξj|N.j ∼ Beta(α2j + N.j, β2j + N.. − N.j)
Independence is assumed throughout.
The prior parameter values are chosen as follows [7]:
αij = α1i = β1i = α2j = β2j = 1
which amount to specifying U [0, 1] prior on ηi and ξj , assuming equal probability owing to
the lack of further information. The value of βij is specified in one of two ways; either
i. βij =
1
E[ηi|Ni.]·E[ξj |N.j ]
thereby introducing information from the data through the prior of γij. This choice
takes cognisance of the assumption that if Nij is zero, then drug and adverse event
are independent and so ICij should tend to 0 as Nij tends to 0 [7, 61],
or
ii. βij =
1
E[ηi]·E[ξj]
− 1
which, given α1i = β1i = α2j = β2j = 1, is equal to 3 [7, 36].
Alternative prior specifications, taking into account the possible dependencies in γij , ηi
and ξj have been proposed by Norén et al. [58] as part of an extension of the model by
Bate et al. [7].
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A signal is deemed to be present for a drug and adverse event pair if the lower limit of
the 95% confidence interval of the associated IC is greater than 0. The distribution of ICij
is approximated by the normal distribution whose mean and variance is given by E [ICij ]
and Var[ICij ] respectively. The values of E [ICij] and Var[ICij] are estimated by the delta
method [7] or by a more accurate moments method when the sample size is small [36],
using the posterior distributions of γij , ηi and ξj .
4.2.6 Simple shrinkage Method
Norén et al. [59] have recently developed a ‘shrinkage transformation’ [59] of the observed-
to-expected ratio (Nij/Eij ) given by
Nij + α1
Eij + α2
(4.5)
where the presence of α1 and α2 causes shrinkage in the direction of α1/α2. To achieve
shrinkage towards a given value k , one sets α1 = kα2. Thus choosing k = 1 causes
shrinkage in the direction of the null situation of no association between drug and adverse
event. The extent of shrinkage achieved, which decreases as the observed and expected
counts increases, is determined by the choice of α1 and α2. The higher the values of α1
and α2, the more reliable the safeguard they offer against false signaling [59]. The ratio
Nij + α1
Eij + α2
is said to be analogous to the posterior mean of a parameter µij where Nij ∼ Pois(µij ·Eij ),
µij ∼ Ga(α1, α2) and µij |α1, α2,Nij ∼ Ga(Nij + α1,Eij + α2) [59].
The lower and upper bound of an approximate 95% ‘credibility interval’ estimate for
log2
(
Nij + α1
Eij + α2
)
(4.6)
is respectively given by
log2
(
Nij + α1
Eij + α2
)
− 3.3 · (Nij + α1)
−1/2 − 2 · (Nij + α1)
−3/2
and
log2
(
Nij + α1
Eij + α2
)
+ 2.4 · (Nij + α1)
−1/2 − 0.5 · (Nij + α1)
−3/2.
Norén et al. [59] report that (4.6) provides a very good approximation to the IC measure
of the BCNPP model when α1 = α2 = 1/2 and the number of records is greater than or
equal to 1000.
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4.2.7 Confounding and Other Methods
The ‘innocent bystander effect’ and ‘masking’ [46] are some of the other sources of con-
founding that beset the use of SRS data for signal detection, apart from age, sex and time.
The innocent bystander refers to a relatively innocuous drug for which a false signal is
generated because it is often co-prescribed with the drug which is the cause of an ADR –
its association with the culprit drug makes the innocent drug come under the suspicion of
being the cause of the ADR, by virtue of its value on a disproportionality measure [6,19,46].
Masking is a phenomenon that results from the interrelationship between combinations of
drugs and adverse events. The value of a disproportionality measure for a given drug and
adverse event pair X is not independent of that of other pairs having the same adverse
event or drug in combination X [6]. A large increase in the observed count (Nij) for com-
bination X will cause an increase in the expected counts of other drug and adverse event
pairs having the same adverse event or drug in combination X. This may cause the value of
a disproportionality measure for these other combinations to decrease below the threshold
for signal generation. A sudden increase in the rate of reporting of a drug and adverse
event pair resulting from regulatory action or media attention could create such a situa-
tion [6, 46]. It may be necessary to remove combination X at some stage of the analysis
to ensure that no signals are obscured [6]. An adverse event which has a high observed
count (Nij) with several drugs will have a relatively large marginal total count (N. j) and
the expected counts of all drugs that are reported with it will be large. This will make the
value of a disproportionality measure for a new drug which is reported with the adverse
event relatively small because of its relatively low observed count, which may result in the
hiding of disproportionate reporting of the new drug and the adverse event [6].
A slightly different situation arises when the observed counts (Nij) of the drugs reported
with an adverse event are not significantly different but the marginal total counts (Ni .) of
the drugs differ substantially, then the drugs with lower marginal total counts may easily
generate a signal than the ones with higher marginal total counts because of their lower
expected counts [6].
Other approaches aimed at addressing some of the problems confronting ‘quantitative
signal detection’ [6], beyond stratifying along the lines of sex, age and time, and hence
the problem of false signaling have recently been explored. They include a method which
employs the idea behind PRR and ROR by exploiting information from additional sources
(which are not always available) supplementary to SRS data [34], an extension of the ex-
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isting Bayesian methods to incorporate the concepts of false discovery rate (FDR) and
false negative rate (FNR) [2], and the use of logistic regression [12,46]. The latter method,
which can uncover masking, involves regressing each adverse event on all the drugs, an
exercise which involves estimating several thousand regression coefficients for each adverse
event. Madigan et al. [46] report that the conventional logistic regression could be ham-
pered by “lack of convergence, large estimated coefficient variances and poor predictive
accuracy” [46], and so they opt for Bayesian logistic regression to address these issues
using model (4.7) [12, 46]
Pr(yi = +1|β, x) = ψ(β
T x) (4.7)
where the value yi indicates the inclusion or otherwise of an adverse event in the i
th report,
x is a vector of binary variables including a leading 1 to accord with the intercept β0
and whose values indicate the presence or otherwise of a given drug, and ψ is the logistic
link function. The values of β are thought to be analogous to those of the logarithm of
ROR [12]. Madigan et al. [46] present two possible prior specifications for β. Either
i. βj ∼ N(0, τ), τ > 0
or the hierarchical prior distribution given by
ii. βj ∼ N(0, τj) where τj|γ ∼ Exp
(γ
2
)
, γ > 0
which amount to a double exponential or Laplace prior when τj has been integrated
out [46].
Estimating the maximum a posteriori (MAP) value of β is likened to ridge logistic re-
gression in the case of (i) or Lasso logistic regression in the case of (ii) [12, 46]. Efficient
implementation of the method is said to be computationally involving and requires heavy
parallel computing [12, 46]. While this method holds promise for dealing with problems
that come with confounding, its regular use could be hampered by peculiar computational
demands [12] and there are drug safety problems that it is unable to detect as quickly as
the other methods. However, it can also detect other drug safety problems quicker than
the other methods [46].
Indeed the various quantitative methods have their limitations. The limitations are
partly due to the very character of SRS data [6]. The need to develop the signal detection
process to the highest level dictates that we continue to study the attributes of the existing
quantitative signal detection methods with the view to having a deeper understanding of
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their abilities and inabilities [6], and to see how and when they could be used in comple-
mentary roles. By the same token we must continue to explore other quantitative signaling
methods. We, therefore, propose another Bayesian shrinkage model as described in the
next section.
4.3 Proposed Model(s)
4.3.1 Background of Model(s)
The COM-Poisson (CMP) distribution is a generalization of the Poisson distribution devel-
oped by Conway and Maxwell [43,78]. We have the special case of the Poisson distribution
when ν = 1. The probability mass function of the CMP distribution is defined by
Pr(N = n) =
τn
(n!)ν
·
1
z (τ, ν)
z (τ, ν) =
∞∑
s=0
τ s
(s!)ν
where the parameters are τ and ν (dispersion parameter), with ν > 1 indicating under-
dispersion and ν < 1 over-dispersion [41, 78].
Approximate expressions for the first and second moments, as given in Shmueli et
al. [78] and Guikema and Goffelt [41], are respectively
E[N ] ≈ τ1/ν +
1
2ν
−
1
2
Var[N ] ≈
1
ν
τ1/ν .
A reparameterization of the above density, by Guikema and Goffelt [41], using ρ = τ1/ν
yields
Pr(N = n) =
(
ρn
n!
)ν
·
1
z (ρν , ν)
(4.8)
with the corresponding moments being
E[N ] ≈ ρ+
1
2ν
−
1
2
(4.9)
Var[N ] ≈
ρ
ν
. (4.10)
The parameter ρ = τ1/ν is the mode of the CMP distribution [41]. Parameterization (4.8) is
preferred because it provides a clear centering parameter in ρ. It will be used in the rest
of the thesis and will be denoted by CMP(ρ, ν).
CHAPTER 4. DATA MODELS 47
4.3.2 Models C-G and P-G
The modeling proceeds as follows: each cell count Nij is assumed to be distributed as
Nij | φij , ν ∼ CMP(φijEij, ν), i = 1, 2, . . . , I ; j = 1, 2, . . . , J . . . independently. (4.11)
where φij is a scale factor, the ratio between the mode of Nij and the expected count Eij
as given in (4.1). Values of φij larger than one correspond to a distribution of Nij with
more mass assigned to values larger than Eij.
The φij ’s are assumed to come from a common gamma distribution with parameters α
and β which are, in turn, assumed to be exponentially distributed with respective param-
eters θα and θβ. The parameter ν which is also assumed to be exponentially distributed
with parameter θν is thought of as a general dispersion parameter. Thus we have
φij | α, β ∼ Ga(α, β) i = 1, 2, . . . , I ; j = 1, 2, . . . , J . . . i.i.d. (4.12)
ν | θν ∼ Exp(θν)
α | θα ∼ Exp(θα)
β | θβ ∼ Exp(θβ)
The likelihood is therefore given by
f (N | φ, ν,E ) =
∏
ij
(φijEij )
νNij
(Nij!)ν
·
1
z [(φijEij)ν , ν]
(4.13)
where
N = (Nij , i = 1, 2, . . . , I , j = 1, 2, . . . , J )
E = (Eij , i = 1, 2, . . . , I , j = 1, 2, . . . , J )
φ = (φij , i = 1, 2, . . . , I , j = 1, 2, . . . , J )
and the prior is given by
h(φ, ν, α, β) =
∏
ij
βα
Γ(α)
φα−1ij e
−βφij × θνe
−θνν× θαe
−θαα× θβe
−θββ (4.14)
Thus the joint density of all the random quantities in the model, conditional on the Eij s,
which are assumed constant, is
π(φ, ν, α, β,N | E ) =
∏
ij
(φijEij )
νNij
(Nij!)ν
·
1
z [(φijEij)ν , ν]
×
∏
ij
βα
Γ(α)
φα−1ij e
−βφij
× θνe
−θνν× θαe
−θαα× θβe
−θββ (4.15)
∝
βIJαe−β(
∑
ij φij+θβ)−ν(
∑
ij logNij !+θν)−θαα
[Γ(α)]IJ
∏
ij
E
νNij
ij φ
νNij+α−1
ij
z [(φijEij)ν , ν]
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It follows that the full conditional of β is given by
π(β|·) ∝ βIJαe−β(
∑
ij φij+θβ) (4.16)
where |· means given all other variables in the model. Thus
β | · ∼ Ga

[IJα+ 1],

∑
ij
φij + θβ




When ν = 1, the likelihood 4.13 reduces to the Poisson likelihood, given by
f (N | φ,E ) =
∏
ij
e−φijEij (φijEij )
Nij
Nij!
(4.17)
with the corresponding joint density of the random quantities being
π(φ, α, β,N | E ) ∝
βIJαe−β(
∑
ij φij+θβ)−
∑
ij logNij !−θαα−
∑
ij φijEij
[Γ(α)]IJ
∏
ij
E
Nij
ij φ
Nij+α−1
ij (4.18)
The full conditional for β remains as given in (4.16).
We designate the model based on (4.11) and (4.12) as C-G and that based on the Poisson
distribution and (4.12) as P-G . In both cases the full conditionals of the parameters, apart
from β, are not of standard form, so values of α, β, ν, and φ may be generated from a
Gibbs and Metropolis-Hastings scheme as outlined below.
For C-G, using (4.15) and (4.16) we have:
1. Set initial values: α0, β0, ν0 and φ0.
2. For (t in 1 : niter) {
Generate β(t) from Ga
(
[IJα+ 1], [
∑
ij φij + θβ]
)
Update α(t) with a Metropolis-Hastings move.
Update ν(t) with a Metropolis-Hastings move.
For (i in 1 : I ) and (j in 1 : J ) {
Update φ
(t)
ij with a Metropolis-Hastings move.
}
}
Model P-G does not involve ν so the parameter updates, using (4.16) and (4.18), could
be done as follows:
1. Set initial values: α0, β0 and φ0.
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2. For (t in 1 : niter) {
Generate β(t) from Ga
(
[IJα+ 1], [
∑
ij φij + θβ]
)
Update α(t) with a Metropolis-Hastings move.
For (i in 1 : I ) and (j in 1 : J ) {
Update φ
(t)
ij with a Metropolis-Hastings move.
}
}
Updating the Parameters
This section describes how the parameter values were simulated.
The parameter β was updated using a Gibbs move, that is, the next value β(t+1) of
β was generated from the Gamma distribution using the current values α(t) and φ(t) of α
and φ respectively, as outlined above.
Values of α were generated by a random walk Metropolis Hastings (MH) move [14,33,
44]. The candidate value α˜ of α was proposed by
α˜ = α∗ + δ, δ ∼ g
where α∗ is the current state of α and g is a symmetrical distribution made up of three
uniform distributions which have been superimposed such that they share a common mean
of zero, as shown in the Figure 4.1. Distribution g is defined by
0
2ζ × 10−1
2ζ
2ζ × 10
Figure 4.1: Density of the proposal distribution for α and ν (not to scale).
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δ =


v× 10−1 if w < 13
v× 10 if w > 23
v Otherwise
where
v ∼ U [−ζ, ζ] and w ∼ U [0, 1]
The need to ensure that the proposal steps are of the right magnitude (not always too
small or too large) so that there is good mixing is the motivation for using this approach.
It follows from (3.6) that the acceptance probability is
a(α∗, α˜) = min
{
1,
π(α˜)
π(α∗)
}
and the updating scheme [14, 33, 44] is given by:
1. Given the current value α(t) = α∗, generate the candidate value α˜ as outlined above
and u ∼ U [0, 1].
2. Set α(t+1) = α˜ if u ≤ a(α∗, α˜), else set α(t+1) = α(t)
Values of ν were generated in the same way as in the case of α.
The technique used to generate values of φ is different from that of α and ν; the candidate
value φ˜ij of φij was proposed by
φ˜ij = φij · e
u , u ∼ U [−ǫ, ǫ]
=⇒ u = log φ˜ij − log φij
It follows that
du
dφ˜ij
=
1
φ˜ij
and
q(φ˜ij |φij) = f(u) ·
∣∣∣∣∣ dudφ˜ij
∣∣∣∣∣
=
1
2ǫ
·
1
φ˜ij
Similarly
q(φij |φ˜ij) =
1
2ǫ
·
1
φij
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and
q(φij |φ˜ij)
q(φ˜ij |φij)
=
φ˜ij
φij
= eu
It follows from (3.5) that, given the current value φ∗ij , the acceptance probability is given
by
a(φij
∗, φ˜ij) = min
{
1,
π(φ˜ij)
π(φij
∗)
· eu
}
The updating scheme follows the same steps as in the case of α. This updating technique
was used to curtail autocorrelation in the iterates.
The MCMC samplers described above were implemented in Fortran and the samples
dumped to files. The R statistical software was then used to make plots and compute
posterior summaries.
4.3.3 Models C-IG and P-IG
One is expected to investigate how other prior specifications impact φ and ν a posteri-
ori. For instance, the Inverse Gamma distribution is known to have longer tails than the
Gamma distribution and could accommodate values of φ that are large much better than
the Gamma distribution. We could, therefore, look at the alternative situation where φs
are rather drawn from a common Inverse Gamma (instead of Gamma) distribution with pa-
rameters ϕ and ψ, where the ϕ and ψ are in turn exponentially distributed with respective
parameters θϕ and θψ. The parameter ν is also exponentially distributed with param-
eter θν . The role assigned to the Exponential distribution is not exclusive, the Inverse
Exponential distribution could be used. Indeed the potential of the Inverse Exponential
distribution was explored and preliminary results showed it has similar effect as the Expo-
nential distribution. Owing primarily to the constraint of time the models described below
were restricted to the use of the Exponential distribution. Thus, we look at the situation
where
φij | ϕ,ψ ∼ Inv-Ga(ϕ,ψ) i = 1, 2, . . . , I ; j = 1, 2, . . . , J . . . i.i.d. (4.19)
ν | θν ∼ Exp(θν)
ϕ | θϕ ∼ Exp(θϕ)
ψ | θψ ∼ Exp(θψ)
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In which case joint densities (4.15) and (4.18) become respectively:
π(φ, ν, ϕ, ψ,N | E ) ∝
ψIJϕe−ψ(
∑
ij 1/φij+θψ)−ν(
∑
ij logNij !+θν)−θϕϕ
[Γ(ϕ)]IJ
∏
ij
E
νNij
ij φ
νNij−ϕ−1
ij
z [(φijEij)ν , ν]
(4.20)
and
π(φ,ϕ, ψ,N | E ) ∝
ψIJϕe−ψ(
∑
ij 1/φij+θψ)−
∑
ij logNij !−θϕϕ−
∑
ij φijEij
[Γ(ϕ)]IJ
∏
ij
E
Nij
ij φ
Nij−ϕ−1
ij
(4.21)
The models represented by joint densities (4.20) and (4.21) will be referred to as C-IG and
P-IG respectively. In each case, the full conditional of ψ is given by:
π(ψ|·) ∝ ψIJϕe−ψ(
∑
ij 1/φij+θψ)
and
ψ | · ∼ Ga

[IJϕ+ 1],

∑
ij
1/φij + θψ




The parameters in C-IG and P-IG were simulated by the same techniques as used for
parameters in C-G and P-G described in Section 4.3.2.
Chapter 5
Application of Proposed Model(s) to
FDA SRS Data
The results of analysis illustrating the proposed models outlined in Section 4.3 with data
from the Food and Drugs Administration’s SRS database are presented in this chapter.
We reiterate that the data set (referred to as the second data set in Chapter 2) used in the
analysis presented in this chapter and described in Section 5.1 is different from the data set
used in the analysis presented in Chapter 2. Ideally the data set used in the analysis pre-
sented in Chapter 2 should have been used throughout the investigation in order to present
a holistic view of the data concerning adverse events associated with the use of medica-
tions. However it became necessary to use a different data set for the analysis presented in
this chapter because the data used in the analysis presented in Chapter 2 requires careful
clean-up. As noted in Chapter 2, the clean-up involves correcting misspellings of names of
drugs and adverse events, finding all descriptions in the data that point to the same adverse
event and recoding them into the Medical Dictionary for Regulatory Activities (MedDRA)
Preferred Term (PT) [83] and finding all the different names in the data that indicate the
same drug (active ingredients) and recoding them into a commonly accepted drug name.
The clean-up is an expensive work both in terms of the time and the expertise required
to do it [20], which the current research endeavour can not afford. A description of the
original data set along with that of two other derivative data sets used in this chapter is
given in the next section.
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5.1 Data
The original data, which cover the United States and span the thirty-year period from
1969 to 1998, has 1398 drugs and 952 events. The observed count of each drug and adverse
event pair was collated from 18 strata arising from six five-year periods and three sex
categories – male, female and unspecified sex. The data is the same as the one used in
the analysis reported in the article “Bayesian data mining in large frequency tables, with
an application to FDA spontaneous reporting system” [19], except it does not include the
expected count of drug and adverse event pairs with zero observed count. The data can
be found at this web address: ftp://ftp.research.att.com/dist/gps/. The data has 385734
drug and adverse event pairs (cells); the number of pairs would have been 1330896 had the
data included drug and adverse event pairs with zero observed count. We designate this
data set as Data 2. Two other data sets, Data 1 and Data 3, were obtained from Data
2. Data 1 was derived from Data 2 by imputing the expected count of drug and adverse
event pairs whose observed count is zero with values computed with (4.1), the equation for
calculating the expected count (Eij) for the unstratified situation. There are 1330896 drug
and adverse event pairs (cells) in this data. Data 3 includes only pairs (132037 of them)
whose observed counts are greater than or equal to five. It is worthy of note that the overall
and marginal totals that determine the expected counts in Data 2 are the same as those
that determine the expected counts in Data 3. In other words, Data 3 was derived from
Data 2 by simply removing drug and adverse event pairs (cells) with observed counts less
than five from Data 2 – a drug and adverse event pair present in Data 3 has the expected
count to be the same as it has in Data 2. For the sake of clarity we restate the three data
sets as follows:
Data 1: Data including all counts.
Data 2: Data including only counts N ≥ 1.
Data 3: Data including only counts N ≥ 5.
The rationale behind the data segmentation was to see how the models perform with
these different data sets. However, it must be emphasized that Data 2 and Data 3 are
essentially truncated versions of Data 1 but the models fitted to them are not for truncated
data, and this could result in biased estimates in the case of Data 2 and Data 3. Also one
is not oblivious of the fact that the φs are not independent a posteriori, and their estimates
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could be affected by the exclusion of cells with zero counts or counts less than five.
Of course there is the issue of what should inform the choice of a number as the
minimum threshold for the inclusion of a drug and adverse event pair in a quantitative
analysis [19]. One could use an arbitrary choice, as has been done here, as a starting point
and hope that the analysis will throw up something that could be used as a basis for setting
the minimum threshold in a formal way.
5.2 Results of Analysis
This section presents the results of the analysis carried out with the models described in
Section 4.3 with some discussion. We do a further discussion of the results in Chapter 6.
The information that follows covers eight model-data combinations. Again, for purposes
of clarity we restate the various models considered in the analysis:
C-G : CMP/Gamma model
P-G : Poisson/Gamma model
C-IG : CMP/Inverse Gamma model
P-IG : Poisson/Inverse Gamma model
5.2.1 Performance of algorithm
Three chains were run for each model-data combination and a sample of 1000 iterates were
drawn per chain at a thinning interval of 40, after a burn-in of 50,000 in the case of Data
1 and 20,000 in the case of Data 2 and Data 3. Thus a total of 90,000 iterations were
carried out for runs involving Data 1 and 60,000 for runs involving Data 2 and Data 3. A
shorter burn-in was used for Data 2 and Data 3 as examination of the ACF and trace plots
suggests convergence occurs faster compared to Data 1. The values of ζ and ǫ (see Section
4.3.2) used in the M-H moves for α, ϕ, ν and φ are shown in Table 5.1. From the results
of C-G and C-IG (see Tables 5.4b and 5.4c), it makes no sense to set ν = 1 for Data 2 and
Data 3 and so P-G and P-IG were deemed unsuitable for these two data sets.
The ACF and trace plots of α, β, ν and the logarithm of the target distribution for
C-G model and Data 1 are shown in Figures 5.1 and 5.2 respectively. The corresponding
figures for the remaining seven model-data pairs, along with other diagnostic graphs are
shown in Appendix A through Appendix D. The sharp fall in the ACF values of α, β,
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Table 5.1: Values of ζ and ǫ used in the runs.
Model
Data 1 Data 2 Data 3
ζ ǫ ζ ǫ ζ ǫ
α, ϕ ν φ α, ϕ ν φ α, ϕ ν φ
C-G/C-IG 0.01 0.01 1.0 0.01 0.01 1.0 0.01 0.005 1.0
P-G/P-IG 0.01 0.01 1.0 – – – – – –
ν and the logarithm of the target distribution is an indication of a good mixing Markov
chain. There are three chains in each trace plot, coloured red, blue and black, which are
overlapping quite well (with some oscillating pattern though, particularly, in the case of α,
which is resulting from a relatively large lag 1 autocorrelation).
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Figure 5.1: Acf plots of α, β, ν and the logarithm of the target distribution using C-G and
Data 1.
The Gelman-Rubin Rˆ [33] values for α, β, ϕ, ψ, ν and the logarithm of the target
distribution for various model-data combinations were computed. The largest of the Rˆ
values across all model-data combinations considered is 1.005. The corresponding values
for the φs of 100 randomly selected drug and adverse event pairs for each of the model-
data pairs are also all approximately equal to 1. As pointed out by Gelman et al. [33]
convergence of the algorithm can be assumed if Rˆ is close 1. Values of Rˆ below 1.1 are
said to be acceptable.
Based on Rˆ values, the sharp fall in the ACF values and the stable chains of the trace
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Figure 5.2: Trace plots of α, β and the logarithm of the target distribution for three chains
using C-G and Data 1.
plots, the algorithm was assumed to have converged. In terms of convergence, the results
of the other seven model-data pairs are similar to that of C-G and Data 1 described above.
Table 5.2 shows the acceptance rate of the candidate values of the parameters. The
first of the two values shown against φ is the average acceptance rate for φ for the given
model-data pair and the second, which is in square brackets, is the associated standard
deviation. There appear to be no major issues with the values.
The times it takes to run the models with the three data sets for the specified total
number of iterations and to generate replicate data are shown in Table 5.3. It may come
as a surprise that it requires comparatively more time to run C-G and C-IG for 60,000
iterations (including burn-in) with Data 2 and Data 3, which are about a one-third and
one-tenth respectively of Data 1, than to run them for 90,000 iterations with Data 1. The
situation is explained by the fact that the time required to evaluate the function z (ρν , ν)
in C-G and C-IG increases as the value of ν gets smaller and smaller below one. The
value of ν for C-G and C-IG with Data 2 and Data 3 are less than 0.3 (see Tables 5.4b
and 5.4c), hence the situation. Indeed the presence of z (ρν , ν) in C-G and C-IG accounts
for the dramatic difference between the times required to run C-G/C-IG and P-G/P-IG,
which is the principal motivation for running the MCMC samplers in Fortran. However,
the time used in the runs is also a function of the magnitude of the proposal steps. For
instance changing ζ from 0.005 to 0.01 (with all other things fixed) in the case of ν for
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Table 5.2: Acceptance rate (%) of candidate values of the parameters.
Model Parameter Acceptance Rate
Data 1 Data 2 Data 3
C-G
α 23.7 37.2 47.2
ν 36.9 22.0 20.9
φ 78.5[14.7] 73.2[11.4] 72.0[8.7]
P-G
α 24.2 – –
φ 78.3[14.5] – –
C-IG
ϕ 31.5 42.3 51.9
ν 37.2 25.3 27.2
φ 70.5[12.0] 65.7[10.0] 64.1[8.3]
P-IG
ϕ 32.0 – –
φ 70.5[11.5] – –
Data 3 decreases the run time by seven days. The change in value of ζ from 0.005 to 0.01
increases the magnitude of the proposal step, δ (see Section 4.3.2) for ν, which results in
the Markov chain traversing the parameter space faster and hence the decrease in time
used. The acceptance rate for ν is lower at the bigger value of ζ than at the smaller value.
For instance the acceptance rate for ν in the case of C-G and Data 3 are 11.6% and 20.9%
for ζ = 0.01 and ζ = 0.005 respectively. However the posterior summaries corresponding
to the two values of ζ are roughly the same.
Table 5.3: Running times of the models.
Model Unit of time Time Required
Data 1 Data 2 Data 3
C-G / C-IG Days 16 14 24
P-G / P-IG Hours 21 – –
5.2.2 Parameter Estimates
Estimates for α, β, ϕ, ψ and ν for the various model-data combinations are shown in Tables
5.4a through 5.4c. A close scrutiny of the values in Table 5.4a shows that, for the common
parameters, the mean values obtained via C-G and P-G agree to at least the first decimal
place for Data 1. This observation also holds for values of the parameters common to C-IG
and P-IG. The corresponding standard deviations are the same to the third decimal place.
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The Poisson distribution is a special case of the CMP distribution, where ν = 1, and the
prior distributions for φ in C-G is the same as in P-G. Again the prior distributions for φ in
C-IG is the same as in P-IG. Models P-G and P-IG are therefore special cases of C-G and
C-IG respectively. The level of agreement between the values of the parameters common
to C-G and P-G and also C-IG and P-IG, when Data 1 is used, is therefore not unlikely
given that the posterior mean of ν is close to 1 (Table 5.4a) for this data.
Table 5.4a: Parameter estimates for the various models using Data 1.
Data 1
Model Parameter Mean Standard Cred. Inter.
Value Deviation 2.5% 97.5%
C-G
α 0.666 0.002 0.663 0.669
β 0.674 0.002 0.670 0.679
ν 1.031 0.003 1.025 1.036
P-G
α 0.663 0.002 0.660 0.667
β 0.682 0.002 0.678 0.687
C-IG
ϕ 1.544 0.004 1.537 1.552
ψ 0.627 0.002 0.623 0.632
ν 1.087 0.003 1.081 1.092
P-IG
ϕ 1.569 0.004 1.562 1.576
ψ 0.618 0.002 0.614 0.623
Table 5.4b: Parameter estimates for C-G and C-IG using Data 2.
Data 2
Model Parameter Mean Standard Cred. Inter.
Value Deviation 2.5% 97.5%
C-G
α 1.223 0.006 1.212 1.234
β 1.386 0.007 1.373 1.400
ν 0.205 0.001 0.204 0.207
C-IG
ϕ 2.165 0.009 2.148 2.183
ψ 1.115 0.007 1.102 1.129
ν 0.259 0.001 0.257 0.261
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Table 5.4c: Parameter estimates for C-G and C-IG using Data 3.
Data 3
Model Parameter Mean Standard Cred. Inter.
Value Deviation 2.5% 97.5%
C-G
α 1.518 0.013 1.493 1.544
β 1.832 0.017 1.799 1.868
ν 0.054 0.0004 0.053 0.055
C-IG
ϕ 2.442 0.017 2.407 2.475
ψ 1.436 0.014 1.407 1.464
ν 0.083 0.001 0.082 0.084
5.3 Diagnostics
5.3.1 Validation of the distribution of φ
For the C-G model, Figures 5.3 and C.11(b) and C.16(b) of Appendix C suggest a fit be-
tween the distribution of the φs and the Gamma distribution corresponding to the MCMC
estimates of the posterior means of α and β, for all three data sets. Figure D.1 also sug-
gests a fit between the distribution of the φs and the Gamma distribution corresponding
to the MCMC estimates of the posterior means of α and β for P-G and Data 1. As in
the case of C-G and P-G, the distribution of the φs generated via C-IG and P-IG fit the
Inverse Gamma distribution corresponding to the MCMC estimates of the posterior means
of ϕ and ψ generated from these models (see Figures E.1, E.11(b), E.16(b) and F.1). A
misfit between the distribution of the φs and the Gamma distribution corresponding to
the MCMC estimates of the posterior means of α and β would have meant that something
is amiss with the model (C-G or P-G); for instance the model is not generating φs from
the required Gamma distribution because the model is not suitable for the data or some-
thing has gone wrong with the implementation of the model. The same reasoning goes for
the relationship between the distribution of the φs and the Inverse Gamma distribution
corresponding to the MCMC estimates of the posterior means of ϕ and ψ, for C-IG and
P-IG.
5.3.2 Posterior Predictive Check
As a posterior predictive check, Bayesian p-value scatter plots of the logarithm of X2
(determined from replicate counts) against X1 (determined from observed counts) using
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Figure 5.3: Histogram of φs for C-G and Data 1. The superimposed density curve (in red)
represents the Gamma distribution corresponding to the MCMC estimates of the posterior
means of α and β.
Equations 5.1 and 5.2 [33] were produced for all model-data combinations considered. The
quantity θ(t) is the tth MCMC draw for θ, where θ is as defined in (5.3), and N
(t)
ij is the
tth replicate count.
X
(t)
1 =
I∑
i=1
J∑
j=1
(
Nij − E
[
N
(t)
ij |θ
(t)
])2
Var
[
N
(t)
ij |θ
(t)
] (5.1)
X
(t)
2 =
I∑
i=1
J∑
j=1
(
N
(t)
ij − E
[
N
(t)
ij |θ
(t)
])2
Var
[
N
(t)
ij |θ
(t)
] (5.2)
where
θ =

 (φ, ν) if model is C-G or C-IGφ if model is P-G or P-IG (5.3)
The N
(t)
ij s were generated via the simulation method of inversion [33] using θ
(t). The p-
value scatter plot for C-G and Data 1 based on X1 and X2 is shown in Figure 5.4 (a);
those for other model-data pairs are shown in the appendices.
The models were also assessed on the basis of what is referred to as the deviance [33,
p. 175], defined as
D(x, θ) = −2ℓ(x|θ) (5.4)
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Figure 5.4: Bayesian p-value scatter plots for C-G and Data 1. (a) Plot of logarithm of
X2 against logarithm of X1, and (b) Plot of logarithm of SD against logarithm of OD .
The red line is the line of equality.
where ℓ(x|θ) is the logarithm of the likelihood, x is the data (in our case the observed data
N or the simulated data N (t)) and θ is the parameter. Thus, in our case, the observed
deviance (OD) and the simulated deviance (SD) are respectively given by
OD (t) = D(N |θ(t),E ) (5.5)
SD (t) = D(N (t)|θ(t),E ) (5.6)
where θ is as defined in (5.3).
The scatter plot for C-G model and Data 1 based on the deviance is shown in Figure
5.4 (b), and the Bayesian p-values for model-data pairs considered are shown in Table 5.5.
The p-values are given by P (X1 ≥ X2) or P (OD ≥ SD) as the case may be [10,33]. Apart
from C-G which has both p-values for Data 1 within the recommended 95% probability
range of (0.025, 0.975) [10, 80], all other model-data pairs have both p-values outside the
interval or one of the values is within the range and the other is outside.
Table 5.5: Bayesian p-values for all model-data pairs condidered.
Model
p-value
Data 1 Data 2 Data 3
(X1, X2) (OD,SD) (X1, X2) (OD,SD) (X1, X2) (OD,SD)
C-G 0.969 0.497 0.000 0.492 0.000 0.515
P-G 0.435 0.000 – – – –
C-IG 1.000 0.513 0.000 0.504 0.000 0.497
P-IG 0.000 0.000 – – – –
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5.4 Other Observations
5.4.1 Comparison of φ Values Generated from the Three Data Sets
Figures 5.5(a) and 5.5(b) were produced to assess how the values of φ generated via the
C-G model (was done for C-IG too) compare across Data 1, Data 2 and Data 3. Figure
5.5(a) compares the values of φ generated from Data 1 with those generated from Data 2
and Figure 5.5(b) does so for Data 1 and Data 3. In each case, the plots were made with
the top 10000 corresponding values from the two data sets under consideration. In both
figures almost all the points are above the line of equality with a strip pattern. Figure 5.6
is a recast of Figure 5.5(a) using the observed count as the plot character. Each coloured
strip in the figure represents an observed count of a given magnitude. We observe that
strips of higher counts are nearer the line of equality than strips of lower counts (more
noticeable in Figure 5.7). The comparison between the φs generated from the three data
sets with C-IG show a similar pattern to that of C-G (see Figures 5.7, E.6(a) and E.6(b))
but the strips are more distinct than in the case of C-G. The figures show that φs generated
from Data 1 tend to be larger than those from Data 2 and Data 3 with the disparity being
larger for smaller observed counts. As acknowledged in Section 5.1, Data 2 and Data 3 are
truncated versions of Data 1 but the models fitted to them are not for truncated data, and
this could be the reason for which the φ’s generated from Data 2 and Data 3 are smaller
than those from Data 1.
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Figure 5.5: (a) Scatter plot of logarithm of posterior means of φ for Data 1 against
corresponding values for Data 2, and (b) Scatter plot of logarithm of posterior means of φ
for Data 1 against corresponding values for Data 3, using results from C-G. The plots were
made with the top 10000 corresponding values from the two data sets under consideration.
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Figure 5.6: Scatter plot of logarithm of posterior means of φ for Data 1 against corre-
sponding values for Data 2 using results from C-G. This is a recast of Figure 5.5(a) using
the number of counts as the plot character. Each colour strip represent a given observed
count.
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Figure 5.7: Scatter plot of logarithm of posterior means of φ for Data 1 against correspond-
ing values for Data 2 using results from C-IG.
CHAPTER 5. APPLICATION OF PROPOSED MODEL(S) TO FDA SRS DATA 65
5.4.2 Comparison of Mean Replicate Count with Observed Count (N)
Tables C.1 and D.1 present the observed counts, mean replicate counts, expected counts,
RR and φ values of 50 randomly sampled drug and adverse event pairs for C-G and P-
G when Data 1 is used. The tables show that some of the mean replicate counts are
substantially different from the observed count. The expected counts of these pairs are
very small relative to the observed count, with the value of RR very high and substantially
larger than the associated φ value. However these φ values are greater than one. The
foregoing observation holds for Data 2 and Data 3 as well, for C-G, but some of the φ
values of C-G are less than one in the case of Data 3. Unlike C-G and P-G, C-IG and P-IG
tend to generate replicate counts that are closer to the observed count (than by C-G and P-
G) when the expected count is small, for Data 1. For Data 2 and Data 3, C-IG’s behaviour
is not consistent as there are instances of generation of replicates that are relatively smaller
than the observed count.
The size of the φs generated by the models have an affect on the replicate counts
since the replicate counts are proportional to the φs. The ability of the Inverse Gamma
distribution to accommodate φs that are larger than can be accommodated by the Gamma
distribution explains why the replicate counts generated by C-IG and P-IG are closer to
observed counts than by those generated by C-G and P-G for Data 1. Model C-IG’s
behaviour for Data 2 and Data 3 is not consistent with its behaviour for Data 1 because
the φs generated from Data 2 and Data 3 tend to be smaller than those generated from
Data 1 as seen in Section 5.4.1.
5.4.3 Credible Intervals of φ
Figure 5.8(a) shows the logarithm of the 95% credible intervals of φ plotted against the
logarithm of the relative report rate (RR) for 500 randomly selected drug and adverse event
pairs using results from the C-G model and Data 1.
For drug and adverse event pairs with small values of RR, there is general agreement
between RR and the posterior median of the corresponding φ while for pairs with large
RR values the associated posterior median of the φs tend to be much smaller. The credible
intervals are also shorter for some drug and adverse event pairs than others.
To have a clearer picture of what is happening, Figure 5.8(b) was produced from the
medians of the φs of 1000 drug and adverse event pairs randomly sampled from the results
from C-G and Data 1. The figure shows a fanning out of the points to the right below the
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Figure 5.8: (a) Logarithm of the 95% posterior intervals of φ against the logarithm of the reporting
rate RR for C-G. The plotted values are for 500 drug and adverse event pairs randomly sampled
from Data 1, and (b) Logarithm of posterior medians of φ against the logarithm of the reporting
rate RR for C-G. The plotted values are for 1000 drug and adverse event pairs randomly sampled
from Data 1.
line of equality (in red) for drug and adverse event pairs with comparatively higher RR,
while the opposite occurs to a much smaller degree for pairs with comparatively lower RR.
The phenomenon described above holds for all other model-data combinations considered
but to a less or greater degree (see Figures C.10(b), C.15(b), D.5(b), E.5(b), E.10(b),
E.15(b) and F.5(b)). Figure 5.8(b) shows an interesting pattern in which the points appear
to separate into strips. Figure 5.9 is another rendition of Figure 5.8(b) but using the number
of reports (observed count) of the drug and adverse event pairs as the plot character, which
shows the points separate into strips according to the magnitude of the observed count,
so that pairs with small counts are further away below the line of equality with increasing
RR and further away above the line with decreasing RR. For each strip (given number
of reports), the further to the right a point is, the smaller the associated expected count
Eij . The median (of the φs) increases with increasing RR albeit more slowly than RR and
only up to certain values of RR, beyond which the median remains essentially constant.
This pattern is unequivocal only for the smallest numbers of reports. The results described
above show that large RR values associated with combinations with small observed and
expected counts are shrunk considerably; the shrinkage is more pronounced where the
expected count is very small.
We next take a look at how the lower bounds (RR025) of the 95% confidence inter-
val estimates for RR compare with the lower bounds (φ025) of the 95% credible interval
estimates for φ.
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Figure 5.9: Logarithm of posterior medians of φ against the logarithm of the relative report
rate, RR, for C-G. This ﬁgure is a recast of Figure 5.8(b) using the number of counts as the plot
character. Each colour strip represents a given observed count.
The value of RR025 for each drug and adverse event pair was estimated by the inversion
of the Poisson cumulative distribution function, assuming each observed count is Poisson
distributed. We solve for the critical Poisson value, Q025 – the 2.5% quantile corresponding
to the observed count N – and divide it by expected count E. That is:
Q025 = qpois(0.025, N)
RR025 =
Q025
E
Figure 5.10(a) shows the scatter plot of the logarithm of φ025 against the logarithm
of RR025 for C-G and Data 1 using the set of drug and adverse event pairs involved in
Figure 5.9. The plots for the other model-data pairs are shown in the appendices. The
strip pattern relating to small observed counts occurring to the right of the line of equality
(broken line) in Figure 5.9 are not present in Figure 5.10(a). This is due to the fact that
some drug and adverse event pairs with small observed counts have RR025 values that are
considerably smaller than the corresponding RR values. This leads to instances where the
RR value is greater than the associated φ but the RR025 value is slightly greater than or
less than φ025 value, shifting the corresponding points (plot character) closer to or to the
left of the line of equality in Figure 5.10(a). An example of such a pair is Propoxyphene-
Asphyxia, which has observed and expected counts of 5 and 0.598 respectively. The RR
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value for the pair is 8.36 which is greater than the φ value of 4.13, but the value of RR025
(1.67) is less than the value of φ025 (1.69). In particular drug and adverse event pairs with
very small counts have the value of RR025 to be 0. The points (plot character) of such pairs
do not appear in the figure when plotted on the logarithmic scale since the logarithm of 0
is undefined. On the ordinary scale such points are concentrated on the line RR025 = 0. It
appears from Figure 5.10(a) that the bigger values of RR025 tend to be greater than their
associated φ025 values while there is a large number of drug and adverse combinations for
which the φ025 value is greater than the RR025 value. This is in contrast to what is observed
in Figure 5.9, which suggest there is a large number of drug and adverse combinations for
which the φ value is smaller than the associated RR value.
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Figure 5.10: Scatter plot of logarithm of φ025 against the logarithm of RR025 for (a) C-G
and Data 1 and (b) C-IG and Data 1.
The behaviour of C-G with Data 2 and Data 3 appears to be different from that of
Data 1 (see Figures E.11(a) and E.16(a)); the RR025 values appear be generally greater
than the associated φ025 values. The situation for P-G and Data 1 is essentially like that
of C-G and Data 1 as Figure D.6 shows. For C-IG and Data 1, Figure 5.10(b) suggests
majority of the RR025 values are quite close to their associated φ025 values as most of
the points lie close to or along the line of equality, except for the smaller values of RR025
where the associated φ025 values are larger and so the points occur to the left of the line of
equality as in Figure 5.10(b) or do not appear in the figure since RR025 = 0, as explained
in the case of C-G. Figures E.11(a) and E.16(a) show that in the case of C-IG with Data 2
and Data 3, majority of the RR025 values are greater than their corresponding φ025 values
except, as in the case of Data 1, the smaller values of RR025 tend to be less than their
associated φ025 values. It is unsurprising that for Data 2 and Data 3 the RR025 values are
generally greater than the associated φ025 values, recall that φs tend to be smaller in the
CHAPTER 5. APPLICATION OF PROPOSED MODEL(S) TO FDA SRS DATA 69
case of Data 2 and Data 3, as pointed out in Section 5.4.1. Model P-IG’s behaviour with
Data 1 with respect to the relationship between φ025 and RR025 is similar to that of C-IG
as depicted by Figure F.6.
Tables C.2a through C.2c of Appendix C show the top hundred drug and adverse event
combinations selected by C-G based on the lower bound (φ025) of the 95% credible interval
estimate for φ, using Data 1. The tables for other model-data pairs are in the respective
appendices. The drug and adverse event combinations have been ordered in descending
magnitude of φ025. Tables C.2a through C.2c also present the ranks assigned to the drug
and adverse event combinations based on the values of RR, RR025, φ and φ025, which are
designated RK1, RK11, RK3 and RK33 respectively.
The ranks presented in Tables C.2a through C.2c for C-G and Data 1 suggest that
the agreement between the ranks based on φ (RK3) and φ025 (RK33) is higher than that
between the ranks based on RR (RK1) and RR025 (RK11). For instance the (RK1, RK11)
values for the pair Metformin-Acidosis Lactic are (437, 94) and the (RK3, RK33) values
for the same pair are (20, 19), showing a greater disparity between the ranks based on RR
and RR025 than that based on φ and φ025. There are many such examples in the tables.
The disparity between RK1 and RK11 and the close agreement between RK3 and RK33
appear to be general; the (RK1, RK11) correlation coefficient is 0.14, indicating there is
virtually no correspondence between RK1 and RK11, while the (RK3, RK33) correlation
coefficient is 0.79, indicating a strong correspondence between RK3 and RK33. Table 5.6
gives the (RK1, RK11) and (RK3, RK33) rank correlation coefficients for RR and all the
proposed models for the three data sets.
Table 5.6: Rank correlation coefficients for models.
Model Ranks Correlation Coefficients
Data 1 Data 2 Data 3
RR RK1, RK11 0.14 0.14 0.89
C-G RK3, RK33 0.79 0.86 0.89
P-G RK3, RK33 0.79 – –
C-IG RK3, RK33 0.82 0.86 0.88
P-IG RK3, RK33 0.83 – –
The correlation coefficients in the Table 5.6 show that the disparity between RK1 and
RK11 holds for Data 2 as well, but not for Data 3. The difference in the way RR and RR025
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rank the drug and adverse event pairs is explained by the fact that RR gives preference
to drug and adverse event pairs with low observed and expected counts, especially pairs
with very low expected counts, while RR025 does not appear to have such preference. In
the absence of low counts as is the case for Data 3, RR’s behaviour, with respect to the
ranking of the drug and adverse event pairs, is similar to that of RR025 and hence the
correspondence between RK1 and RK11 for Data 3 as evidenced by the high correlation
coefficient of 0.89. Neither φ nor φ025 appear have preference for drug and adverse event
pairs with low observed and expected counts and so the presence or absence of such pairs
does not influence the ranking by φ and φ025. This is the reason for the high (RK3, RK33)
correlation coefficient for all three data sets.
5.5 Selection of Drug and Adverse Event Pairs
Table 5.7a shows the number of drug and adverse event pairs common to the top 1000
combinations selected by the possible model pairs based on the posterior mean of φ for
the three data sets and Table 5.7b shows the corresponding Spearman rank correlation
coefficient for the ranks assigned by the models. The large number of drug and adverse
event pairs common to the top 1000 selection of C-G and P-G and also C-IG and P-IG show
how close these pairs of models are in their selection performance when Data 1 are used,
more so when the high correlation coefficient between them is taken into consideration –
not only do they have a large number in common, the ranks they assign to the drug and
adverse event pairs are almost the same as far as the top 1000 pairs are concerned when
Data 1 are used.
Table 5.7a: Number of drug and adverse event combinations common to the top 1000
combinations selected by all possible model pairs based on the point estimate of φ.
Data 1 Data 2 Data 3
Model C-G P-G C-IG P-IG C-G C-IG C-G C-IG
C-G – 992 555 586 – 529 – 593
P-G 992 – 553 582 – – – –
C-IG 555 553 – 961 529 – 593 –
P-IG 586 582 961 – – – – –
Values for model pairs whose φs do not have the same prior specification (such as C-G
and C-IG) suggest a difference in the way they select the top 1000 drug and adverse event
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Table 5.7b: Spearman rank correlation values for the possible model pairs using the ranks
of the top 1000 selected combinations, based on the point estimate of φ.
Data 1 Data 2 Data 3
Model C-G P-G C-IG P-IG C-G C-IG C-G C-IG
C-G – 0.999 0.359 0.383 – 0.258 – 0.406
P-G 0.999 – 0.337 0.355 – – – –
C-IG 0.359 0.337 – 0.989 0.258 – 0.406 –
P-IG 0.383 0.355 0.989 – – – – –
pairs as they have a lower number of common pairs and lower correlation coefficient for all
the data sets, in particular Data 2.
Table 5.8a: Number of drug and adverse event combinations common to the top 1000
combinations selected by all possible model pairs based on the estimate for φ025.
Data 1 Data 2 Data 3
Model C-G P-G C-IG P-IG C-G C-IG C-G C-IG
C-G – 989 690 705 – 634 – 684
P-G 989 – 685 700 – – – –
C-IG 690 685 – 983 634 – 684 –
P-IG 705 700 983 – – – – –
The number of drug and adverse event combinations common to the top 1000 combi-
nations selected by the possible model pairs based on the lower bound (φ025) of the 95%
credible interval estimate of φ for the three data sets and the corresponding rank corre-
lations are shown in Tables 5.8a and 5.8b respectively. Tables 5.7a through 5.8b show
that both the number of drug and adverse event combinations selected in common and the
corresponding correlation coefficients are higher when the selection is based on the lower
bound (φ025) of the 95% credible interval estimate of φ than when the selection is based
on the point estimate of φ, except for the model pair C-G and P-G, where the number of
common combinations drop marginally from 992 to 989 and the correlation also drop from
0.999 to 0.998. Thus in general, the behaviour of the proposed models are more similar
when compared on the basis of the lower bound (φ025) of the 95% credible interval estimate
of φ than on the basis of the point estimate of φ.
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Table 5.8b: Spearman rank correlation values for the possible model pairs using the ranks
of the top 1000 selected combinations, based on the estimate for φ025.
Data 1 Data 2 Data 3
Model C-G P-G C-IG P-IG C-G C-IG C-G C-IG
C-G – 0.998 0.516 0.529 – 0.466 – 0.558
P-G 0.998 – 0.494 0.508 – – – –
C-IG 0.516 0.494 – 0.993 0.466 – 0.558 –
P-IG 0.529 0.508 0.993 – – – – –
Table 5.9: Average difference between the point estimates and between the lower bounds
of 95% confidence/credible interval estimates for all possible model pairs.
Data 1
Model Pairs Average of Average of
|φ1− φ2| |φ1025 − φ2025|
(∆ave) (∆025ave)
C-G, P-G 0.026 0.018
C-G, C-IG 0.462 0.207
C-G, P-IG 0.459 0.201
P-G, C-IG 0.459 0.210
P-G, P-IG 0.451 0.201
C-IG, P-IG 0.084 0.039
Data 2
Model Pairs Average of Average of
|φ1− φ2| |φ1025 − φ2025|
C-G, C-IG 0.251 0.197
Data 3
Model Pairs Average of Average of
|φ1− φ2| |φ1025 − φ2025|
C-G, C-IG 0.355 0.248
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To see why the number of drug and adverse event combinations common to the top
1000 combinations selected by the possible model pairs and the corresponding correlation
coefficients are higher when the selection is based on the lower bound (φ025) of the 95%
credible interval estimate of φ than when the selection is based on the point estimate of
φ, we denote the φ generated for a drug and adverse event combination from one of the
models, say C-G, as φ1 and the φ generated for the same combination from another model,
say P-G, as φ2, and their lower bounds (φ025) of the 95% credible interval estimates of φ
as φ1025 and φ2025 respectively. Table 5.9 shows the average of the difference |φ1 − φ2|
(∆ave) and the average of the difference |φ1025 − φ2025| (∆025ave) for all possible model
pairs for the three data sets considered. From the table, every ∆ave value is greater than
the associated ∆025ave value. Thus for any model pair, the values of the models are closer
when the lower bounds (φ025) of the 95% credible interval estimates of φ are used than
when the point estimates of φ are used. This appears to be the major reason for which
the number of drug and adverse event combinations common to the top 1000 selected by
the possible model pairs are higher when the values of φ025 are used. Also both ∆ave
and ∆025ave are smaller where the models involved have the same prior specification for
φ (for example, C-G and P-G). This also appear to explain why such model pairs have a
higher number of common drug and adverse event combinations in their top 1000 selected
combinations than model pairs that do not have the same prior specification for φ.
5.6 Model Selection
The modeling process started with C-G model. The closeness of the posterior mean of
ν to one prompted the consideration of P-G. The smallness of the magnitudes of the
values of φ produced by these models (relative to the values produced by GPS) led to the
consideration of C-IG, and that in turn led to P-IG for the same reason as C-G led to
P-G. The question that arises is: which of these models is more plausible, given the data?
Formally, this question is answered by one of two approaches: namely by considering (i)
the Deviance Information Criterion (DIC) [79] values of the models or (ii) the posterior
model probabilities via Reversible Jump Markov chain Monte Carlo (RJMCMC) [40].
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5.6.1 DIC
Given the parameter θ (as defined in Equation 5.3), DIC and PD are given by
DIC = 2D(N |θ,E )−D(N |θ¯,E ) (5.7)
PD = D(N |θ,E )−D(N |θ¯,E ) (5.8)
where D(N |θ,E ) is the mean deviance across the sample MCMC iterates and D(N |θ¯,E )
is the deviance as computed from the MCMC estimate of the mean value θ¯ of θ. Suitable
models are characterized by smaller DIC values [79], for a given data. Values of DIC
and effective number of parameters (PD) for all model-data combinations considered are
presented in Table 5.10.
Table 5.10: Values of DIC and PD for the various model-data combinations.
Model Data 1 Data 2 Data 3
DIC PD DIC PD DIC PD
C-G 2280576 319531 1984702 105877 1040715 32753
P-G 2287577 313491 – – – –
C-IG 2342507 345650 1937525 118740 1014623 44375
P-IG 2366524 329726 – – – –
A comparison of the values in the table leads to the fact that for Data 1 C-G has the
smallest DIC value of 2280576 followed by P-G at 2287577, while for Data 2 and Data 3
C-IG has the smallest DIC values of 1937525 and 1014623 respectively. In all cases PD is
far smaller than the total number of parameters under estimation, with P-G having the
smallest PD value in case of Data 1 (313491). Model C-G has the smallest PD values in
the case of Data 2 (105877) and Data 3 (32753).
5.6.2 RJMCMC
We tried to discriminate between P-G and C-G through Reversible Jump Markov chain
Monte Carlo (RJMCMC). The technique of RJMCMC extends the MH algorithm such
that two or more models can be implemented via a single Markov chain, thereby allowing
the estimation of the posterior probabilities of the models, as the models themselves are
viewed as parameters [40, 44]. The posterior model probability π(m|x) of model m given
the data x is estimated as the fraction of the time the Markov chain is in model m, after
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the burn-in. In RJMCMC, the joint posterior density of the parameters and model is given
by
π(θm,m|x) ∝ f (x|θm,m)h(θm|m)p(m) (5.9)
where f (x|θm,m) is the likelihood of model m given its set of parameters θm, h(θm|m) is
the prior distribution of the parameters given model m, p(m) is the prior probability of
model m and x is the data. At each iteration, (i) we use the current model to update
the parameters using the MH algorithm and then (ii) update the model conditional on the
current set of parameters using RJMCMC algorithm [40, 44]. We describe the RJMCMC
algorithm, in our context, as follows: we designate
P-G as Model m1 : θ1 = {α, β, φ}
C-G as Model m2 : θ2 = {α, β, φ, ν}
We propose to move from state (θ,m)t at iteration t to state (θ
′
,m
′
). Suppose the
chain is in P-G at iteration t , we have m = m1 and θ = θ1, then we propose to move to
C-G, in which case m
′
= m2 and θ
′
= θ2. We set
α
′
= α
β
′
= β
φ
′
= φ
ν ′ = v
where v ∼ q(v), q is an arbitrary proposal distribution such that the set of possible values
of ν, Λ, satisfies Λ ⊆ Ω, where Ω is the support of q . We simulated v as v ∼ N(1.031, 0.01)
taking a cue from the MCMC estimate of ν in an earlier run of C-G.
The move to state (θ
′
,m
′
) is accepted with probability min (1,̟) where ̟ is given by
̟ =
π(θ
′
,m
′
|N )P(m|m
′
)
π(θ,m|N )P(m ′ |m)q(v)
∣∣∣∣∣ ∂(θ
′
)
∂(θ, v)
∣∣∣∣∣ (5.10)
where P(m|m
′
) is the probability of proposing to move to model m given the chain is
currently in model m
′
and P(m
′
|m) is the probability of proposing to move to model m
′
given the chain is currently in model m. Since there are only two models, we will always
be proposing to move from one to the other and so P(m|m
′
) = P(m
′
|m) = 1. The term
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|∂(θ
′
)/∂(θ, v)| in (5.10) is the Jacobian of transformation and is given by
∣∣∣∣∣ ∂(θ
′
)
∂(θ, v)
∣∣∣∣∣ =
∣∣∣∣∣∣∣∣∣∣∣∣∣∣
∂α
′
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∂β
′
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∂φ
′
11
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12
∂α · · ·
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IJ
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′
∂α
∂α
′
∂β
∂β
′
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∂φ
′
11
∂β
∂φ
′
12
∂β · · ·
∂φ
′
IJ
∂β
∂ν
′
∂β
...
...
...
...
. . .
...
...
∂α
′
∂v
∂β
′
∂v
∂φ
′
11
∂v
∂φ
′
12
∂v · · ·
∂φ
′
IJ
∂v
∂ν
′
∂v
∣∣∣∣∣∣∣∣∣∣∣∣∣∣
=
∣∣∣∣∣∣∣∣∣∣∣∣∣
1 0 0 0 · · · 0 0
0 1 0 0 · · · 0 0
...
...
...
...
. . .
...
...
0 0 0 0 · · · 0 1
∣∣∣∣∣∣∣∣∣∣∣∣∣
= 1
It follows that
̟ =
π(θ
′
,m
′
|N )
π(θ,m|N )q(v)
We set (θ,m)t+1 = (θ
′
,m
′
) if the move is accepted, else we set (θ,m)t+1 = (θ,m)t.
For a move from state (θ
′
,m
′
) to (θ,m), we set
α = α
′
β = β
′
φ = φ
′
v = ν ′
and the acceptance probability is given by min(1,̟−1).
Figure 5.11 shows the trace plots of the RJMCMC based on P-G and C-G when the
models are thought to be equipropable a priori, and Figure 5.12 shows the trace when
the prior probabilities have been re-weighted in favour of the P-G (0.999999). As the two
figures (Figures 5.11 and 5.12) show, the Markov chain was for the most time in C-G (model
2) in both cases. From Table 5.4a, the posterior mean and standard deviation of ν for C-G
are 1.031 and 0.003 respectively. Thus ν is more than 10 (10.33) standard deviations from
1, the value at which P-G is applicable. This explains why the Markov chain was for the
most time in C-G, and hence C-G is more plausible than P-G.
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Figure 5.11: Trace plots of α, β, ν, log of the target distribution and model for the RJMCMC
based on P-G and C-G when they are thought to be equiprobable a priori.
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Figure 5.12: Trace plots of α, β, ν, log of the target distribution and model for the RJMCMC
based on P-G and C-G when prior probability of P-G is set at 0.999999.
Chapter 6
Discussion of Results and Comments
We examine the findings of Chapter 5 and point out their implications in this chapter.
6.1 Suitable Model
The model(s) we are seeking, in the context of the problem on hand, is one that reasonably
adjust the observed counts (in the form of the replicate counts it yields), and generates φs
that reflect the nature of the association between drugs and adverse events. In a sense the
posterior distribution of φ could be regarded as the Bayesian analogue of RR. A desirable
model must therefore provide a vehicle for revising the values of RR in the form of the
φ values that result, and the replicate counts must be reasonably close to the observed
counts [33]. The ensuing discussion will focus on identifying the model(s) most suitable
for the data and then move the commentary from the global to the particular traits of the
chosen model(s).
6.2 Observations
Observation 1
It came up in Section 5.3.1 that there is a fit between the distribution of the φs and the
Gamma distribution corresponding to the MCMC estimate of the means of α and β for the
model-data pairs considered. This observation was also true for the distribution of the φs
and the Inverse Gamma distribution corresponding to the MCMC estimate of the means
of ϕ and ψ (see Figures 5.3, C.11(b), C.16(b), D.1, E.1, E.11(b), E.16(b) and F.1), so, on
this basis, nothing seems to be amiss with the models, where they are applicable to a given
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data.
Observation 2
In keeping with the idea of a suitable model outlined in Section 6.1, we sought an instrument
that allows us to determine whether or not the replicate data compares favourably with the
observed data at each iteration. That instrument was found in the deviance and variance
measures presented in Section 5.3.2. The idea is that a suitable model will produce replicate
data that is similar to the observed data [33], from the perspectives of the individual values
and variability thereof. The Bayesian p-values for C-G and Data 1 and P-G and Data 1,
using X1 and X2 (Section 5.3.2), were found to be 0.969 and 0.435 respectively, which
are within the recommended range of (0.025, 0.975) [10, 80]. However, the p-values for
the other six model-data pairs were found to be either zero or one. Thus C-G and P-G
are the ones amongst the four models that give favourable results for Data 1 and none of
the models yield positive results for Data 2 and Data 3 when assessed on the basis of X1
and X2. Using the deviance measures OD and SD , we found that the p-values for C-G
and C-IG are around 0.500 for the all three data sets while those for P-G and P-IG when
Data 1 are used are zero. Thus C-G is the only model that performs favourably on both
the deviance and variance criteria when Data 1 are used and none of the models score
favourably on both criteria for Data 2 and Data 3, where applicable.
As pointed out in Chapter 5, Data 2 and Data 3 are truncated versions of Data 1 but
the models fitted to them are not for truncated data. This explains why the parameter
estimates for Data 2 and Data 3 are biased as evidenced by the results presented in Chapter
5 (and recounted above), where the p-values obtained via the variance measures X1 and
X2 for Data 2 and Data 3 are all zero (Section 5.3.2) and the φs generated from Data 2 and
Data 3 are smaller than those from Data 1 (Section 5.4.1). Indeed the (marginal) posterior
distributions of the φs are not independent; by dropping the cells with counts equal to zero
or less than five, one is essentially doing away with the corresponding φ values needed to
‘accurately’ estimate the φs of the remaining cells. The case of the φs generated from Data
1 tending to be larger than those from Data 2 and Data 3 (Section 5.4.1) attest to the
‘underestimation’ of the φs when Data 2 and Data 3 are used. They (Data 2 and Data 3)
were, however, included in the investigation to see how the models fared with them. The
models are clearly not suitable for them.
Again, we saw in Section 5.4.2 that C-IG’s behaviour with Data 2 and Data 3 was
not consistent with its behaviour with Data 1 as, in some instances, the replicate counts
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generated by C-IG from Data 2 and Data 3 were considerably smaller than the observed
count, as opposed to the replicate counts generated from Data 1 being closer to the observed
counts. The replicate counts are proportional to the φs, so the replicate counts would be
small if the associated φ values are small, as it happens in the case of Data 2 and Data 3.
Observation 3
As observed in Section 5.6, we sought to discriminate between the models on the basis
of DIC. Model C-G was found to have the smallest DIC value followed by P-G (Section
5.6). This reinforces the view that C-G is the most suitable for modeling Data 1. Also,
an attempt was made to choose between C-G and P-G using RJMCMC initially, but
apparently the posterior probability of Model C-G is so high that the Markov chain was
for the most time in C-G. The reason for this, as pointed out in Section 5.6, is due to the
fact that the mean value of ν (1.031) is in the units of its standard deviation (0.003) far
removed from 1, the value at which P-G is valid.
6.3 Model of Choice
Given what has been noted under Observation 1 through Observation 3, one is inclined
to conclude that C-G is the most suitable amongst the four models for modeling Data 1.
The models considered are not suitable for modeling Data 2 and Data 3 as pointed out in
Section 6.2.
Turning to C-G as the suitable model for modeling Data 1, we saw in Figure 5.9 (Section
5.4.3) that the medians separate into strips, with those representing higher RR (usually
associated with low observed or expected count) being the farthest away below the line
of equality with increasing RR and those of lower RR slightly away above the line with
decreasing RR. Thus not only has there been a shrinkage effect in the φs, but the shrinkage
tended to be more pronounced in φs corresponding to drug and adverse event pairs with low
observed and expected count (especially those with very small expected counts) than those
of high observed or expected count. This is expected in a hierarchical model [10,33,60] as
the marginal mean effects (mean of each φij) gravitate towards the mean effect of common
distribution to which all the cells belong, owing to mutual sharing of information across
the cells. This attribute of C-G could be key in its overall performance, as it holds the
potential for reducing false positives.
Indeed Figure 5.10(a) also suggest there has been shrinkage; the bigger values of RR025
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tend to be greater than their associated φ025 values while the smaller values RR025 tend to
be less than their associated φ025 values, even though there is a large number of drug and
adverse combinations for which the φ025 value is greater than the RR025 value. However
the evidence of shrinkage is not as dramatic as seen in Figure 5.9, which suggest there is a
large number of drug and adverse event combinations for which the φ value is smaller than
the associated RR value. Particularly so for combinations with very small observed count
and even smaller expected count as observed above. Shrinkage appears to be subdued in
Figure 5.10(a) because values of RR025 corresponding to drug and adverse combinations
with very small observed and expected counts are relatively smaller.
The high (RK3, RK33) correlation coefficient of 0.79 for C-G and Data 1 is an indication
that the degree of agreement between the rankings based on φ and φ025 is higher than that
of the rankings based on RR and RR025, which has a (RK1, RK11) correlation coefficient of
0.14. Thus C-G appears to be more consistent in the ranking of the drug and adverse event
combinations than RR. As pointed out in Section 5.4.3, RR gives preference to drug and
adverse event pairs with low observed and expected counts, especially pairs with very low
expected counts, while RR025 does not have such preference, hence the lack of agreement
between the rankings of RR and RR025 for Data 1 and Data 2, which include drug and
adverse event combinations with small observed counts and often smaller expected counts.
6.3.1 Drugs Common and Uniquely Chosen by RR, C-G and GPS
We compare the three methods RR, GPS (DuMouchel’s method [19]) and C-G on the
basis of the point estimates of RR, λ and φ and also on the basis of the the lower bounds
RR025, λ025 and φ025 of the 95% confidence/credible interval estimates of RR, λ and φ
respectively. The C-G (φ) values used are the geometric mean of the posterior distribution
of φij . This was done to put C-G values on the same scale as the GPS (EBGM) values, so
that comparison between C-G and GPS is fair. The point estimate (EBGM) of λ and the
lower bound (λ025) of the 95% credible interval estimate of λ were obtained by fitting the
GPS model to Data 1. To do so, one has to estimate the values of the hyperparameters
α1, β1, α2, β2 and ̺ as described in Section 4.2.4; namely, by the method of maximum
likelihood estimation, in which the product of the marginal densities given by (4.4) is
maximized [19]. This was done by applying the R non-linear optimization function nlm
to the logarithm of the product of the likelihoods given by (4.4). The maximization took
26 iterations in about 4 minutes, with the starting values (α1 = 0.2, β1 = 0.1, α2 = 2,
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β2 = 4 and ̺ = 1/3) suggested by DuMouchel [19]. The estimated hyperparameter values,
denoted Est1, are shown in Table 6.1. The estimates of the hyperparameters obtained by
DuMouchel [19] with the original data, denoted Est2, are also show in the table. It can be
seen from an examination of the values that the two estimates, Est1 and Est2, are quite
close. Nevertheless the two data sets, Data 1 and the original data, are not exactly the
same and it is more objective to compare the three models, C-G, RR and GPS, on the
same data. Hence the λ (EBGM) and λ025 values used in the following comparisons are
based on Est1. The EBGM values are given by [19]
EBGMij = 2
EBlog2ij
where
EBlog2ij = E [log 2(λij)|Nij ]
= E [log(λij)|Nij ] /log(2)
and
E [log(λij)|Nij = nij] = ωij [Ψ(α1 + nij)− log(β1 + Eij)]
+(1− ωij) [Ψ(α2 + nij)− log(β2 + Eij)]
where ωij is as given in Section 4.2.4 and the digamma function Ψ(x) =
d
dx log[Γ(x))]. Each
λ025 value was determined as the mean of three 2.5% quantile values obtained from three
samples of size one million apiece from the posterior distribution of the corresponding λ.
Table 6.1: Hyperparameter estimates for the GPS model.
Estimates α1 β1 α2 β2 ̺
Est1 (Data 1) 0.1894 0.05764 1.4001 1.8299 0.1037
Est2 (Original [19]) 0.2041 0.05816 1.4150 1.8380 0.0969
Table 6.2 shows that 198 drug and adverse event pairs are common to the top 1000
pairs chosen by C-G, GPS and RR based on the point estimates of φ, λ (EBGM) and RR.
The first 100 of the actual drug and adverse event pairs involved are shown in Tables G.1a
through G.1c of Appendix G. The drug and adverse event pairs shown in Tables G.1a
through G.1c have been sorted in descending magnitude of RR. The ranks assigned to the
drug and event pairs by GPS based on the point estimate of λ (EBGM) and the lower
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bound (λ025) of the 95% credible interval estimate of λ have been designated RK2 and
RK22 respectively. Recall that the ranks assigned by RR and RR025 were designated RK1
and RK11 respectively, and those assigned by φ and φ025 were designated RK3 and RK33
respectively.
Based on the lower bounds RR025, λ025 and φ025 of the 95% confidence/credible interval
estimates, 662 combinations were found to be common to the top 1000 drug and adverse
event pairs selected by the three methods (Table 6.2). Thus the three methods are closer
in the way they select the top 1000 combinations when compared on the basis of RR025,
λ025 and φ025 than when compared on the basis of the point estimates, as the number they
have in common using the point estimates is less than a third of the number they select
in common when the lower bounds of the 95% confidence/credible interval estimates are
used. Tables G.2a through G.2c of Appendix G show the first 100 of the actual drug and
adverse event combinations involved. The drug and adverse event combinations have been
sorted in descending magnitude of RR025.
Table 6.2: Number of drug and adverse event pairs common to the top 1000 chosen by
combinations of the methods when Data 1 are used.
Number common
Based on the point estimates Based on the estimates of
Model combination of RR, φ and λ (EBGM) RR025, λ025 and φ025
C-G/GPS/RR 198 662
C-G/GPS 616 722
C-G/RR 198 662
GPS/RR 373 926
Table 6.2 also shows the number of drug and adverse event pairs common to the top
1000 selected by combinations of two from the three methods, based on the point estimates
and the lower bounds of the 95% confidence/credible interval estimates. The table shows
that the number of pairs common to the top 1000 selected by C-G and GPS, based on the
point estimates of φ and λ (EBGM) respectively, is more than three times the number in
common when all three approaches are considered. This reflects the diversity in the way
the three methods rank or select the drug and adverse event pairs and the fact that C-G
is closer to GPS than to RR in the way it selects the top 1000 drug and adverse event
pairs. However, the fact of GPS and RR having more drug and adverse event pairs (373)
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in common in their top 1000s than it is between C-G and RR (198) shows GPS is more
closely allied to RR in the ranking of the drug and adverse event pairs than to C-G.
The foregoing observation about the relationship between the methods parallels what
is observed when the top 1000 drug and adverse event pairs selected by combinations of
two from these three methods are compared on the basis of the lower bounds φ025, λ025
and RR025 of the 95% confidence/credible interval estimates. Here, the number of pairs
common to the top 1000 selected by C-G and GPS is 722, which is higher than when
all three approaches are considered (662). The number of combinations common to GPS
and RR (926) is more than that common to C-G and GPS (722), buttressing the above
observation that GPS is closer to RR in the ranking of the drug and adverse event pairs
than to C-G. Incidentally, in both the use of the point estimates and the lower bounds, the
number of combinations selected in common by C-G and RR in their top 1000 combinations
is not only the least when the methods are considered in pairs but is also the same as the
number selected in common by all three methods. Thus it appears drug and adverse
event combinations selected in common by all the three methods is determined by the
combinations selected in common by C-G and RR. This situation underscores the above
observation that C-G and RR are more different from each other than they are from GPS.
Table 6.3: Average difference between the point estimates and between the lower bounds
of 95% confidence/credible interval estimates.
Point Estimates Lower Bounds of 95% Confidence/
Credible Interval Estimates
Item Pairs Average Difference Item Pairs Average Difference
RR, φ 2.145 RR025, φ025 0.309
R, λ (EBGM) 2.015 RR025, λ025 0.285
φ, λ (EBGM) 0.381 φ025, λ025 0.219
The difference between an RR value and the corresponding φ value tends to be greater
than the difference between the associated RR025 and φ025 values; on average the absolute
difference between an RR value and the associated φ value is 2.145 while the absolute
difference between the corresponding RR025 and φ025 values is 0.309. Let ∆(item1,item2)ave
and∆025(item1,item2)ave denote the average of the difference |Item1−Item2|, where the items
are φ, λ and RR, and φ025, λ025 and RR025 respectively, so that ∆(φ,λ)ave is the average
of the difference |φ − λ| and ∆025(RR,λ)ave is the average of the difference |RR025 − λ025|
CHAPTER 6. DISCUSSION OF RESULTS AND COMMENTS 85
and so on. Table 6.3 gives the average of the absolute difference between the possible item
pairs for φ, λ and RR and also for φ025, λ025 and RR025. The values in the table show
that ∆(RR,λ)ave > ∆025(RR,λ)ave and ∆(φ,λ)ave > ∆025(φ,λ)ave. Thus the use of the lower
bounds of the 95% credible intervals can be viewed as a way of moderating the values of
RR and bridging the gap between the values of C-G, GPS and RR. This appears to explain
why the models have more drug and adverse event combinations in common in their top
1000 selections when the lower bounds are used than when the point estimates are used.
Further, the diversity between C-G and RR could be explained by the fact that ∆(RR,φ)ave
and ∆025(RR,φ)ave are the largest for the possible pairs of models for the point estimates
and the lower bounds of 95% confidence/credible interval estimates respectively, as Table
6.3 shows.
The top ten drug and adverse event pairs uniquely chosen by RR, GPS, C-G and LogP
in the top 1000 combinations selected by the point estimates of RR, λ (EBGM) and φ
respectively, and the values of LogP are shown in Table G.3 of Appendix G. LogP is the
negative of the logarithm of the Poisson probability of observing a count larger than or
equal to that of a drug and adverse event pair. An approximate expression for LogP, given
in Appendix G, was used whenever LogP grew large to avoid computational problems [19].
As the values in Table G.3 show, C-G places a premium on drug and adverse event pairs that
have relatively higher observed and expected counts (57 ≤ N ≤ 91, 1.668 < E < 2.911),
when compared with those of GPS (9 ≤ N ≤ 12, 0.098 < E < 0.135), which in turn are
higher than those of the combinations uniquely selected by RR (1 ≤ N ≤ 2, 0.0002 <
E < 0.0032). Yet the observed and expected counts of the pairs favoured by C-G are
comparatively lower than those favoured by LogP (2429 ≤ N ≤ 7530, 148.432 < E <
1003.651). Incidentally, combinations uniquely chosen by the point estimate of RR have
RR025 value of zero. Such pairs are not likely to generate a signal based on RR025 alone.
Table G.4 of Appendix G shows the top ten drug and adverse event pairs uniquely
chosen by RR, GPS and C-G in the top 1000 combinations selected by the respective lower
bounds RR025, λ025 and φ025 of the 95% confidence/credible interval estimates. LogP
was excluded from this comparison since it does not have such a thing as a lower confi-
dence/credible bound. All the drug and adverse event combinations uniquely chosen by
RR based on RR025 have an observed count of 4, with the expected counts lying between
0.0073 and 0.0202, which are larger than those of the combinations exclusively selected
by RR based on the point estimate of RR. Again the combinations uniquely selected by
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GPS have observed and expected counts (7 ≤ N ≤ 22, 0.100 < E < 0.624) which are
higher than those of the combinations uniquely selected by RR and smaller than those of
the combinations uniquely selected by C-G (134 ≤ N ≤ 5043, 5.532 < E < 259.502).
6.3.2 Other Characteristics of C-G
Model C-G, as in the case of GPS [19], appears not to be unduly swayed by very low
observed and expected counts. For instance the pair Emla-Hypalgesia, presented in Table
G.5 of Appendix G, has low observed and expected counts (1, 0.0009) with a high RR
of 1114.14, but the corresponding point estimates of φ and λ (EBGM) are 1.80 and 2.37
respectively. While RR put the rank of the pair at 12, the rank by C-G is 63130 and that
of GPS is 29826, indicating the ability of C-G and GPS to keep a ‘proper’ perspective on
pairs with low observed and expected count values when the assessment is based on the
point estimates. The behaviour of RR reverses when the three methods are assessed on the
basis of RR025, λ025 and φ025, taking an objective view of pairs with weak data support;
the rank (154785) it assigns to Emla-Hypalgesia is worse than when the point estimate of
RR is used. The values of RR025, λ025 and φ025 for the pair are 0.00, 0.94 and 0.23 and
the ranks assigned by GPS and C-G are 55171 and 186757 respectively (see Table G.5).
However, C-G appears to take a dimmer view of such pairs than GPS as it ranks the pair
worse than GPS on both criteria – using the point estimate and the lower bound of the
95% credible interval estimate. The difference in behaviour between C-G and GPS is not
unexpected as while they are both Bayesian, they differ fundamentally in their formulation;
C-G being a fully Bayesian hierarchical model and GPS a Bayesian mixture model which
appeals to the Empirical Bayes approach in the determination of the values of the prior
parameters.
To further understand the behaviour of C-G relative to RR and GPS, we take a look at
three other drug and adverse event pairs with combinations of the observed and expected
counts different from the one examined above:
The drug and adverse event pair Copper-Uter Dis has a bigger observed count and a
comparatively smaller expected count (4457, 46.398). The respective point estimates of
RR, λ (EBGM) and φ are 96.06, 95.93, and 94.76, which are quite close. The corresponding
ranks assigned by RR, GPS and C-G are 975, 155 and 30. Thus beyond being careful with
pairs with very low observed and expected counts, the relative magnitudes of the observed
and expected counts also matter more to GPS and C-G than to RR when it comes to
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the ranking. In other words, even though φ and λ have lower point estimates for the pair
relative to that of RR, these point estimates are higher relative to the values assigned by C-
G and GPS respectively to other combinations and so Copper-Uter Dis is relatively better
ranked by C-G and GPS than by RR when assessed on the basis of the point estimates,
more so in the case of C-G. The relative importance, in terms of the ranks, attached to
the pair by RR, GPS and C-G is maintained when the the methods are compared on the
estimates for RR025, λ025 and φ025. The ranks are 151, 94 and 22 with the RR025, λ025
and φ025 values being 93.26, 93.15 and 91.97 respectively.
The pair Vincristine-Purpura Thrombopen exemplify a situation where the expected
count is bigger than the observed count (2, 11.479). The point estimates of RR, λ (EBGM)
and φ are 0.17, 0.21 and 0.18 respectively. The ranks assigned by RR (373725), GPS
(374503) and C-G (373694) are all large. The point estimate for φ and the corresponding
rank assigned to Vincristine-Purpura Thrombopen by C-G, like those of RR and GPS, are
‘reasonable’ in the sense that if the observed count is considerably less than the expected
count, under the assumption of independence of drug and adverse event, then there is
probably no justification to suspect that the relationship between Purpura Thrombopen
and Vincristine is causal. The rank (375525) assigned to Vincristine-Purpura Thrombopen
based on the value of RR025 (0.00) is worse than that based on the point estimate of RR,
and the ranks assigned by GPS (372101) and C-G (360887) based on the estimates for
λ025 (0.07) and φ025 (0.04) are better than those based on the point estimates. However,
it remains that the ranks assigned to the pair by the methods using both criteria are not
meritorious and the relationship between Purpura Thrombopen and Vincristine is probably
not causal.
We next consider a drug and adverse event pair for which both the observed and
expected counts are large. The observed and expected counts of the pair Diltiazem-Rash
are large (1697,1374.890). All three measures have the same point estimate of 1.23. This
observation – the assignment of almost the same value by the three measures – is true for
most pairs for which the observed count is large, more so when the observed and expected
counts are both large. Some examples of such pairs are presented in Table G.5 of Appendix
G. The observation suggest that three approaches tend to converge in behaviour when the
observed and expected counts are large, in terms of the point estimates they assign to the
drug and event pairs. As RR places a premium on pairs with low observed and expected
counts, it ranks the pair 189850, worse than that of GPS (99124) and C-G (140633). The
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values of RR025 (1.18), λ025 (1.18) and φ025 (1.18) are also the same, lending credence
to the above observation that three approaches tend to converge in behaviour when the
observed and expected counts are large. The associated ranks 33326, 41473 and 34513
respectively are better than in the case of the use of the point estimates.
6.3.3 Genuine Drug Problems Within the Top Fifty Drug and Adverse
Event Combinations Selected by C-G, GPS and RR
Of the first fifty drug and adverse event combinations selected by C-G based on the posterior
mean of φ, shown in Tables G.6a and G.6b, about 41 of the adverse events involved
were found to be bona fide problems associated with the drug in the combination when
checked with the online version of Physicians’ Desk Reference (PDR) [62] and similar
resources [18, 75]. The corresponding values for GPS is 40 and that of RR is 36 (the first
fifty drug and adverse event combinations selected by GPS and RR are shown in Tables
G.7a and G.7b; and G.9a and G.9b respectively). The number of drug and adverse event
pairs, for which the adverse event was found to be a genuine problem associated with the
drug, selected by C-G, GPS and RR within the top fifty combinations based on the lower
bounds of the 95% confidence/credible interval estimates are 45, 43, and 40 respectively (see
Tables C.2a and C.2a; G.8a and G.8b; and G.10a and G.10b respectively). The remaining
drug and adverse event combinations could either not be verified for lack of information or
the available information did not confirm the adverse event as a problem associated with
the drug. The verification involved checking the adverse event in a drug and adverse event
combination against the adverse events and risks cited for the drug in the aforementioned
drug databases. Perhaps the higher number of combinations for which the adverse event
is a bona fide problem associated with the drug selected by C-G, GPS and RR within
the top fifty drug and adverse event combinations, when the lower bounds of the 95%
confidence/credible interval estimates are used, is an indication that the methods are more
able to give preference to genuine drug problems in the ranking of the drug and adverse
event pairs when the ranking is done by the lower bounds of the 95% confidence/credible
interval estimates than by the point estimates.
6.3.4 C-G values compared with that of GPS
Figure 6.1 shows plots of φ (C-G) against λ (EBGM, GPS) for various combinations of
the observed (N) and expected (E) counts and Figure 6.2 shows the plots of φ025 against
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λ025 for the same combinations of the observed (N) and expected (E) counts as in Figure
6.1. The figures show that the values of φ and φ025 are lower than or equal to those of λ
(EBGM) and λ025 respectively for all combinations of the observed and expected counts
(as all the points in the figures are on the line of equality or below it); φ and φ025 tend to
be equal to λ (EBGM) and λ025 respectively at higher values of the observed and expected
counts and tend to be lower than λ (EBGM) and λ025 respectively at lower values of the
observed and expected counts.
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Figure 6.1: Plots of φ against λ (EBGM) for various combinations of the observed and
expected counts. The red line is the line of equality.
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expected (E) counts. The red line is the line of equality.
Chapter 7
Conclusion
7.1 Concluding Remarks
The need to find unknown but bona fide side-effects of drugs as soon as possible after
marketing approval can hardly be overemphasized given the health and economic burden
they present, as clinical trials are unable to detect all side-effects of drugs before marketing
for reasons outlined in Chapter 1. Spontaneous Reporting System data has been found to
be useful in addressing this need [6, 54, 81].
It is imperative from the literature and the results presented in Chapter 2 to continue
to contribute to the evolution of spontaneous reporting system databases to the point
where extraneous factors that act against their optimal use are curtailed and to develop
complementary tools to facilitate the realization of its full potential.
The increasing trend in the number of reports submitted per 10,000 people, as observed
in Chapter 2, may be pointing to:
i. a growing awareness of the need to contribute to the pharmacovigilance process and
hence the increase in the number of reports, when viewed against the well known
phenomenon of under reporting [4, 70], or
ii. the number of adverse events is growing at an increasing rate, or
iii. both cases (i) and (ii) hold.
If the the first scenario holds, then there is the need to take action to sustain the trend
to the point where almost all adverse events are reported. In the second scenario, more
must be done to curtail avoidable adverse events and to sustain the hunt for unknown
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side-effects so that they can be found as soon as practicable. This is all the more urgent
when one considers the fact that expedited reports – which are related to serious adverse
events – have been in the majority since 2005 (Section 2.2.4). Other areas of concern have
been identified in Section 7.2 below.
It follows from the analysis presented in Chapter 5 that C-G is the model suitable for
modeling Data 1 and none of the models is suitable for modeling Data 2 and Data 3 as
stated in Section 6.1, where it was pointed out that Data 2 and Data 3 are essentially
truncated versions of Data 1 while the models fitted to them are not for truncated data.
Hence the misfit between the models and Data 2 and Data 3. In arriving at the above
conclusions, we took into consideration the Bayesian p-values for the models (Section 5.3.2).
Based on variance (X1, X2) and deviance (OD, SD) criteria (Section 5.3.2), model C-G
was the only model whose Bayesian p-values are within the recommended range of (0.025,
0.975) [10, 80] for Data 1, the rest of the models have either both p-values lying outside
the recommended interval or one of the values is within the range and the other is outside.
For Data 2 and Data 3, in the case of C-G and C-IG, Bayesian p-values using (X1, X2) are
all outside the recommended range, thereby ruling out C-G and C-IG as suitable models
for Data 2 and Data 3.
The behaviour of C-G with respect to the ranking of the drug and adverse event com-
binations was found to be consistent than that of RR as the (RK3, RK33) correlation
coefficient (0.79)(Section 5.4.3), which compares the ranking based on φ with that based
on φ025, is higher than the (RK1, RK11) correlation coefficient (0.14), which compares
the ranking based on RR with that based on RR025. However, GPS is more consistent
in the ranking of the drug and adverse event combinations than C-G; its (RK2, RK22)
correlation coefficient, which which compares the ranking based on λ (EBGM) with that
based on λ025, is 0.93, which is higher than the (RK3, RK33) correlation coefficient of 0.79.
The number of drug and adverse event combinations that is common to the top 1000
drug and adverse event combinations selected by the C-G, GPS and RR based on the
lower bounds φ025, λ025 and RR025 respectively of the 95% confidence/credible interval
is 662 (Section 6.3.1). This figure is more than three times the number (198) common
to the top 1000 combinations selected by the models when the point estimates of φ, λ
(EBGM) and RR are used. Thus the models are more similar in the way they select
the top 1000 combinations when the selection is based on the lower bounds φ025, λ025
and RR025 of the 95% confidence/credible interval estimates than when the selection is
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based on point estimates. Again, the results of Section 6.3.1 shows that as far as the
selection of the top 1000 combinations are concerned C-G is closer to GPS than to RR.
The above observations are supported by the fact that on average the difference between
corresponding point estimates assigned any two of C-G, GPS and RR are bigger than the
difference between their associated lower bounds of the 95% confidence/credible interval
estimates. In particular, not only is ∆(RR,φ)ave > ∆025(RR,φ)ave, both ∆(RR,φ)ave and
∆025(RR,φ)ave are the largest as far as the average difference between the point estimates
and the average difference between the lower bounds of the 95% confidence/credible interval
estimates assigned by any two of C-G, GPS and RR respectively, are concerned.
The number (45) of drug and adverse event combinations in which the adverse event
is a bona fide problem associated with the drug, selected by C-G within the top fifty
combinations, based on the lower bound (φ025) of the 95% credible interval estimate of φ
is higher than number (41) selected based on the posterior mean of φ (Section 6.3.3). This
appear to suggest that C-G is more able to give preference to genuine drug problems in
the ranking of the drug and adverse event pairs when the ranking is based on the lower
bound (λ025) of the 95% credible interval estimate of φ than when the ranking is based on
the point estimate of φ. Indeed this observation is also true for GPS and RR; GPS selects
43 when the values of λ025 are used and 40 when the values of λ (EBGM) are used, while
RR selects 40 when the values of RR025 are used and 36 when the values of RR are used.
As demonstrated in Chapter 6, model C-G could be helpful in sifting SRS databases
for signal generation and prioritizing. The examples provided in Section 6.3.2, show how
versatile C-G is;
(a) it keeps a ‘proper’ perspective on drug and adverse event combinations with very low
observed and expected counts when ranking the combinations, and
(b) takes a balanced view of the drug and adverse event pairs by assigning:
i. a higher φ value when the observed count is relatively bigger than the expected
count,
ii. a low φ value when the observed count is smaller than the expected count or
when observed count is close the expected count.
We conclude that model C-G has desirable attributes the stands it in good stead to
contribute positively to pharmacovigilance. Further work with a complete and more recent
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data is required to establish the most useful cut-off point or what should constitute the
minimum threshold for generating a signal. In the interim, the condition φ025 ≥ 2 is rec-
ommended as the minimum threshold for signal generation. This recommendation ensures
that a signal is generated only when the rate of reporting of a drug and adverse event
combination is at least twice as much as expected under the assumption of independence
of drug and adverse event, so as to keep false positives to a minimum. As seen in Section
6.3.4, the values of φ and φ025 are lower than or equal to those of λ (EBGM) and λ025
respectively and for all combinations of the observed and expected counts and therefore
C-G could help further reduce the level of false positives when well calibrated.
Model C-G has high computational requirements. It takes about 16 days to run C-G in
its current Fortran implementation on an Intel Xeon E class processor workstation, running
the CentOS 5.4 X86_64 operating system with 32Gb RAM and average speed of 3.0Ghz.
Additional RAM would be needed for data with size larger than that of Data 1. The high
computing time is due to the fact that the evaluation of the function z (ρν , ν) requires a
lot of time. The amount of time required to evaluate z (ρν , ν) is appreciated when one
considers the fact that P-G which does not involve z (ρν , ν) takes about 21 hours to run,
which is approximately 5.46 percent of the time required to run C-G. As the computational
time of any model impinges on its usefulness, research is needed to reduce the time required
to evaluate z (ρν , ν) and hence the implementation time of C-G.
7.2 Highlights of the Research
The research presented an opportunity to gain at first hand an appreciation of:
◦ the degree of the problem of missing values (as seen in Chapter 2) and to contemplate
the level of effort required to sensitize stake holders about the problem and the need
to, as much as possible, supply/fill all the required information/fields when reporting
an adverse event.
◦ the need for accurate reporting, especially the use of drug names and preferred terms.
It was evident from the preliminary analysis that some of the preferred terms required
to be used in describing adverse events were not properly used. For instance some
of the terms used to describe the adverse events include: ‘Chemotherapy’, ‘exposure’
and ‘drug level’. Clearly the descriptions of the adverse events in these instances
were inaccurate; the required preferred terms were either not properly used or were
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not applied at all.
◦ what it takes to transform raw data from an SRS database into forms suitable for
analysis. In particular, what is involved in converting the raw data into one of drug
and adverse event combinations for signal detection, either using only the primary
suspect drug or including the secondary suspect and the other drugs.
◦ how collaborative and interdisciplinary the field of pharmacovigilance is. It requires
a team of people of diverse but relevant backgrounds (statisticians, pharmacologists,
computer savvy professionals et cetera) to be able to competently assess circum-
stances relating to a drug and adverse event combination and successfully carry out
a pharmacovigilance exercise, at least from the perspective of using SRS and related
data.
◦ the extent and diversity of computer resources required to carry out a pharmacovig-
ilance exercise.
◦ the fact that small differences in the attributes of models can mean a lot in terms of
the difference in their performance.
7.3 Future Work
A number of areas remain to be explored in furtherance of this work. They include:
◦ Exploring the possibility of speeding up the computation of z (ρν , ν) so that the model
could be implemented within the shortest possible time.
◦ Exploring the possibility of using a more efficient updating scheme for the param-
eters. In particular a joint update for α and β or ϕ and ψ to further reduce the
autocorrelation in the iterates.
◦ Extension of the C-G model into the multiple comparison context as presented in
Müller et al. [56] and exemplified by Ahmed et al. [2], to further consolidate model
C-G’s potential for reducing false positive signals.
◦ Exploring the potential of C-G to signal ‘higher order dependencies’ [58] in an SRS
database. A higher order dependency refers to a situation where other causal factor(s)
beside a given drug are involved in the observed adverse event [58, 82]. An adverse
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event resulting from drug-drug interaction is a situation of a higher order dependency
(‘multi-item association’ [82]). Here more than two entities (three) are involved: the
two drugs and the adverse event.
Appendix A
Selected Variables and their
Description
Table A.1a: Selected variables and their description.
Variable Description
ISR
Primary link variable identifying each individual report received,
across all seven data files.
CASE Unique number identifying a given subject (record).
FDA_DT Date report was received by the FDA.
REPT_COD Holds codes identifying type of report made.
Code Meaning
EXP Expedited(within 15 days)
PER Periodic
DIR Direct
AGE The age of a subject.
AGE_COD Holds codes for unit in which age was measured.
Code Meaning
DEC Decade
YR Year
MON Month
WK Week
DY Day
HR Hour
Source: ASC_NTS.DOC, [29].
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Table A.1b: Selected variables and their description.
Variable Description
GNDR_COD Holds codes identifying the gender of a subject.
Code Meaning
UNK Unknown
M Male
F Female
NS Not Specified
OCCP_COD Holds codes for the occupation of the original reporter.
Code Meaning
MD Physician
PH Pharmacist
OT Other Health Professional
LW Lawyer
CN Consumer
E_SUB
Holds codes for mode of submission of report.
Yes for electronic submission and No otherwise.
ROLE_COD Holds codes identifying the reported role of drug in event.
Code Meaning
PS Principal Suspect
SS Secondary Suspect
C Concomitant
I Interacting
DRUGNAME
Holds names of drugs involved in the event, either the "Valid Trade
Name" or the "Verbatim" name as stated on report.
VAL_VBM
Holds codes showing whether name of drug is the
Valid Trade Name or the Verbatim name.
Code Meaning
1 Valid Trade Name
2 Verbatim Name
Source: ASC_NTS.DOC, [29].
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Table A.1c: Selected variables and their description.
Variable Description
PT
Holds the Preferred Terms (PT) for describing the observed reaction
to drug(s) using the Medical Dictionary for Regulatory Activities
(MedDRA).
OUTC_COD Holds codes identifying the outcome of the adverse experience.
Code Meaning
DE Death
LT Life-Threatening
HO Hospitalization – Initial or Prolonged
DS Disability
CA Congenital Anomaly
RI Required Intervention to prevent Permanent Damage
OT Other
RPSR_COD Holds codes identifying the initial report source.
Code Meaning
FGN Foreign
SDY Study
LIT Literature
CSM Consumer
HP Health Professional
UF User Facility
CR Company Representative
OTH Other
Source: ASC_NTS.DOC, [29].
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Some Selected Plots and Tables
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Figure B.1: Percentage of reports from health professionals and consumers and lawyers for
2004-2010.
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Figure B.2: Percentage of report types from 2004-2010.
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Figure B.3: Percentage of reports on male and female subjects from 2004-2010.
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Figure B.4: Percentage of reports for the various age groups for the period 2004-2010.
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Figure B.5: Age and gender load of reported adverse events associated with drug use.
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Figure B.6: ‘Proportion’ of the various age groups reported on for the period 2004 – 2010.
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Table B.1: Percentages for Patient Outcomes calculated with number of all cases as de-
nominator, 2004-2010.
Year DE LT HO DS CA RI OT
2004 9.68 5.12 25.71 3.73 0.33 4.00 28.93
2005 9.95 4.97 28.57 4.73 0.38 3.24 36.43
2006 8.59 4.13 30.49 4.96 0.39 2.66 36.94
2007 7.66 4.20 26.95 3.17 0.44 1.58 37.21
2008 9.27 4.43 25.63 2.67 0.68 1.90 33.56
2009 10.63 4.27 28.02 2.76 0.53 1.91 36.17
2010 10.83 3.17 24.83 2.27 0.54 0.96 34.47
Composite 9.73 4.13 26.81 3.19 0.49 2.01 34.95
Table B.2: Percentages for Patient Outcomes calculated with number of non-missing cases
as denominator, 2004-2010.
Year DE LT HO DS CA RI OT
2004 15.45 8.16 41.00 5.95 0.53 6.37 46.14
2005 14.09 7.03 40.46 6.70 0.53 4.59 51.58
2006 12.24 5.89 43.44 7.07 0.55 3.79 52.64
2007 11.68 6.41 41.11 4.84 0.67 2.41 56.77
2008 14.61 6.98 40.40 4.20 1.07 2.99 52.89
2009 15.61 6.26 41.14 4.05 0.77 2.81 53.11
2010 17.33 5.08 39.74 3.63 0.86 1.54 55.17
Composite 14.83 6.28 40.87 4.85 0.75 3.07 53.26
Appendix C
C-G Model Results
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Figure C.1: Histogram of φs for C-G and Data 1. The superimposed density curve (in red)
represents the Gamma distribution corresponding to the MCMC estimates of the posterior
means of α and β.
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Figure C.2: Acf plots of α, β, ν and the logarithm of the target distribution for C-G and
Data 1.
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Figure C.3: Trace plots of α, β, ν and the logarithm of the target distribution for three
chains, for C-G and Data 1.
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Figure C.4: Bayesian p-value scatter plots for C-G and Data 1. (a) Plot of logarithm ofX2 against
logarithm of X1, and (b) Plot of logarithm of SD against logarithm of OD . The red line is the line
of equality.
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Figure C.5: (a) Logarithm of the 95% posterior intervals of φ against the logarithm of the reporting
rate RR for the C-G model. The plotted values are for 500 drug and adverse event pairs randomly
sampled from Data 1, and (b) Logarithm of posterior medians of φ against the logarithm of the
reporting rate RR for C-G model. The plotted values are for 1000 drug and adverse event pairs
randomly sampled from Data 1.
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Figure C.6: (a) Scatter plot of logarithm of posterior means of φ for Data 1 against corresponding
values for Data 2, and (b) Scatter plot of logarithm of posterior means of φ for Data 1 against
corresponding values for Data 3. The plots were made with the top 10000 corresponding values
from the two data sets under consideration.
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Table C.1: Values of original counts, mean replicate counts, expected counts, RR and φ
for fifty randomly selected drug and side-effect pairs using C-G model and Data 1.
Count Mean Rep. Expected RR φ
Count Count
7 7.2 11.218 0.62 0.64
6 5.9 5.973 1.00 1.01
0 0.0 0.004 0.00 0.98
666 665.6 695.539 0.96 0.96
0 0.4 0.915 0.00 0.43
44 40.1 6.070 7.25 6.61
0 0.0 0.039 0.00 0.92
111 58.3 0.721 154.02 81.10
0 0.0 0.030 0.00 0.92
28 1.3 0.031 889.14 41.99
32 2.1 0.047 685.52 46.34
7 7.0 6.866 1.02 1.02
1 1.1 1.245 0.80 0.86
1 1.0 0.997 1.00 1.00
1 0.9 0.765 1.31 1.16
1 0.6 0.369 2.71 1.71
1 0.9 0.80 1.22 1.12
0 0.2 0.339 0.00 0.64
26 1.4 0.037 707.23 38.47
7 0.2 0.018 399.26 11.33
6 5.8 4.814 1.25 1.21
2022 2012.9 132.310 15.28 15.21
6 0.1 0.010 576.05 10.20
1021 1022.0 1701.710 0.60 0.60
637 636.3 606.791 1.05 1.05
1211 1210.3 739.652 1.64 1.64
933 933.3 854.123 1.09 1.09
1039 1037.8 380.965 2.73 2.73
56 10.3 0.147 381.61 70.79
1 0.6 0.409 2.44 1.57
46 4.6 0.073 628.21 64.17
2 1.9 1.625 1.23 1.16
3664 3655.6 325.306 11.26 11.24
1608 1608.4 1421.430 1.13 1.13
82 11.4 0.105 780.57 109.03
1 0.4 0.206 4.85 1.91
1032 1031.8 519.620 1.99 1.98
594 593.5 392.751 1.51 1.51
3 2.9 2.468 1.22 1.16
2 1.5 0.845 2.37 1.77
66 65.6 55.168 1.20 1.19
0 0.5 2.436 0.00 0.20
19 19.7 93.931 0.20 0.21
306 71.0 0.198 1543.39 359.07
306 71.0 0.198 1543.39 359.07
6 0.0 0.004 1577.25 10.09
10 0.4 0.023 431.67 15.66
1 0.4 0.198 5.05 1.96
3 2.6 1.432 2.09 1.78
5 5.1 4.914 1.02 1.03
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Table C.2a: Top hundred drug and adverse event pairs selected by C-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 9 3 358.53 320.87 1 1
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 349.02 311.32 2 2
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 323.51 293.66 3 3
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 26 9 267.66 238.76 4 4
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 256.19 230.43 5 5
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 91 25 184.3 163.13 6 6
DIETHYLSTILBESTROL ANOMALY CONGEN 2811 17.749 158.37 152.57 398 79 152.79 147.32 10 7
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 94 27 167.41 147.07 8 8
DIANEAL PERITONITIS 150 0.228 658.94 553.51 28 11 170.1 144.86 7 9
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 234 56 156.35 141.35 9 10
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 378 77 148.51 139.79 11 11
GEMCITABINE HYDROCHLORIDE CARCINOMA GI 225 0.952 236.39 205.92 200 51 139.78 122.77 12 12
TETRACYCLINE DISCOLOR TOOTH 1437 10.485 137.05 130 510 95 129.01 122.5 14 13
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 224 58 135.44 118.88 13 14
NONOXYNOL CERVIX DIS 1074 8.161 131.61 123.77 552 104 121.83 114.78 17 15
MIVACURIUM CHLORIDE INCREASED EFFECT 319 1.865 171.02 152.26 356 81 126.83 113.36 16 16
CORTISPORIN PAIN EAR 132 0.37 356.64 297.2 81 26 128.91 109.11 15 17
MYSTECLIN F DISCOLOR TOOTH 134 0.458 292.78 244.72 130 39 120.37 102.14 18 18
METFORMIN ACIDOSIS LACTIC 309 2.074 149.02 132.62 437 94 113.33 101.49 20 19
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 252 67 114.11 97.77 19 20
SELENIUM SULFIDE HAIR DISCOLOR 301 2.236 134.64 119.43 526 107 104.37 93.05 23 21
COPPER UTER DIS 4457 46.398 96.06 93.26 975 151 94.76 91.97 30 22
PHENFORMIN ACIDOSIS LACTIC 390 3.302 118.11 106.61 681 124 98.53 89.48 27 23
OPCON A PAIN EYE 267 2.015 132.49 116.61 547 109 100.08 88.99 26 24
DTP VACCINE SCREAMING SYND 966 9.643 100.18 93.95 897 147 93.9 88.19 31 25
ETIDOCAINE TRISMUS 82 0.105 780.57 618.74 17 7 108.42 87.88 21 26
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.329 315.65 257.98 108 34 105.76 87.46 22 27
RIFABUTIN UVEITIS 134 0.665 201.45 168.37 265 70 101.96 85.48 25 28
OXYTOCIN HEM POSTPARTUM 103 0.346 297.96 242.99 124 40 103.26 85.04 24 29
POLIOVIRUS VACCINE, LIVE, ORAL SCREAMING SYND 344 3.28 104.89 93.91 831 148 87.35 78.75 34 30
TETRAHYDROZOLINE PAIN EYE 187 1.43 130.77 112.59 557 117 89.85 77.83 33 31
LOMEFLOXACIN HYDROCHLORIDE PHOTOSENSITIVITY 481 5.137 93.64 85.27 1023 166 83.08 76.13 38 32
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 95.73 75.47 28 33
METHYSERGIDE FIBRO RETROPERIT 87 0.29 300.36 238.21 122 43 92.35 75.08 32 34
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Table C.2b: Top hundred drug and adverse event pairs selected by C-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
PERDIEM STENO ESOPH 65 0.024 2694.87 2072.98 3 1 95.5 74.3 29 35
POLIOVIRUS VACCINE, LIVE, ORAL SIDS 146 1.038 140.6 118.45 484 108 86.33 73.53 35 36
MITOMYCIN UREMIA 218 1.995 109.29 95.26 785 142 82.28 71.86 42 37
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM INTRACRAN 476 5.426 87.73 79.99 1150 184 78.28 71.37 46 38
CHOLINE KERATITIS 116 0.703 164.99 135.12 372 91 85.71 71.27 36 39
MENOTROPINS OVAR DIS 151 1.175 128.48 108.06 583 122 82.37 70 41 40
CEFOXITIN ENTEROCOL PSEUDOMEM 138 1.016 135.79 113.16 517 116 82.86 69.82 39 41
CHOLINE CORNEAL OPACITY 77 0.26 295.96 230.62 128 46 84.46 67.31 37 42
BENDECTIN ECTROMELIA 111 0.721 154.02 126.27 415 100 80.76 67.11 43 43
UROKINASE CHILLS 831 10.942 75.95 70.83 1426 220 71.64 66.8 51 44
DIPHTHERIA-TETANUS TOXOID-PERTUSSIS VA SCREAMING SYND 147 1.22 120.47 101.62 654 130 78.45 66.58 45 45
BSS KERATITIS 74 0.243 305.12 239.15 118 42 82.7 65.74 40 46
TETRAHYDROZOLINE CONJUNCTIVITIS 230 2.454 93.73 81.91 1021 174 74.12 65.21 50 47
HAEMOPHILUS B POLYSACCHARIDE VACCINE MENINGITIS 176 1.711 102.86 87.66 851 164 74.45 64.4 49 48
COPPER SALPINGITIS 1484 21.323 69.6 66.08 1635 238 67.56 64.19 58 49
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.093 647.58 485.69 30 14 80.63 62.31 44 50
SUPROFEN PAIN BACK 399 5.188 76.91 69.39 1404 227 68.47 62.01 56 51
NONOXYNOL LEUKORRHEA 603 8.344 72.27 66.51 1516 235 66.97 61.98 60 52
MICONAZOLE VAGINITIS 2262 34.851 64.9 62.24 1818 271 63.67 61.06 64 53
COPPER DEVICE MIGRATION 1490 22.868 65.16 61.88 1811 272 63.42 60.23 67 54
COPPER PAIN PELVIC 1962 30.696 63.92 61.12 1861 278 62.59 59.92 73 55
SODIUM HYALURONATE KERATITIS 70 0.274 255.2 196.87 167 55 75.42 59.2 48 56
CHOLINE OPHTHALMITIS 58 0.098 594.08 450.68 35 18 77 58.9 47 57
INTRAUTERINE DEVICE UTER DIS 251 3.127 80.26 70.35 1328 224 66.38 58.59 62 58
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM CEREBR 695 10.419 66.71 61.81 1744 274 62.8 58.33 71 59
PILOCARPINE MIOSIS 103 0.812 126.83 103.44 601 128 70.24 57.61 53 60
TRIAMCINOLONE ATROPHY INJECT SITE 439 6.303 69.65 63.14 1630 260 63.17 57.54 70 61
GONADOTROPIN, CHORIONIC OVAR DIS 86 0.567 151.69 119.94 423 106 70.3 56.8 52 62
TIOCONAZOLE VAGINITIS 268 3.558 75.32 66.33 1442 236 63.66 56.5 65 63
FLUNISOLIDE NASAL SEPTUM DIS 75 0.431 174.04 136.91 344 90 69.25 55.41 55 64
COPPER FERTIL DEC FEM 695 10.997 63.2 58.56 1899 294 59.69 55.35 79 65
OXYTOCIN FETAL DIS 95 0.759 125.14 100.11 616 133 67.04 55.01 59 66
ALCOHOL ALCOHOL INTOLER 169 2.006 84.26 71.8 1233 215 63.4 54.27 68 67
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Table C.2c: Top hundred drug and adverse event pairs selected by C-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
MICONAZOLE VULVOVAGINITIS 234 3.168 73.87 64.71 1471 248 61.35 54 76 68
TRAZODONE PRIAPISM 347 5.117 67.81 60.77 1701 282 60.08 53.96 78 69
NONOXYNOL DEVICE MIGRATION 800 13.275 60.27 56.12 2045 311 57.55 53.85 85 70
DINOPROSTONE UTER SPASM 56 0.147 381.61 286.21 72 30 70.17 53.31 54 71
RUBELLA VIRUS VACCINE, LIVE LYMPHADENO 115 1.162 98.97 80.9 925 179 63.36 52.78 69 72
BOTULINUM TOXIN A PTOSIS 60 0.238 252.56 189.42 173 59 67.7 52.33 57 73
OXYTOCIN LABOR ABNORM 105 1.043 100.68 81.5 887 176 61.99 51.12 75 74
BSS PLUS CORNEAL OPACITY 52 0.129 402.19 293.91 65 28 66.71 50.1 61 75
DORNASE ALFA HEMOPTYSIS 64 0.336 190.37 145.75 301 83 64.67 50.08 63 76
FLOSEQUINAN DEATH 109 1.204 90.5 73.89 1092 203 58.74 48.6 82 77
TICE BCG CYSTITIS 69 0.475 145.35 111.64 457 119 61.19 48.18 77 78
NAFARELIN ACETATE HEM VAGINAL 506 9.008 56.17 51.29 2260 349 52.29 48.02 95 79
ATRACURIUM BESYLATE PARALYSIS FLACCID 100 1.051 95.13 77.06 988 193 58.68 47.84 83 80
DURANEST W/EPINEPHRINE TRISMUS 46 0.073 628.21 450.67 33 19 63.54 47.75 66 81
NONOXYNOL BALANITIS 51 0.166 306.82 228.61 116 47 62.6 47.67 72 82
PRILOCAINE PARESTH CIRCUMORAL 200 2.995 66.77 57.75 1742 304 54.87 47.64 91 83
BUTORPHANOL DRUG DEPEND 457 8.165 55.97 50.95 2270 353 51.85 47.23 96 84
TICE BCG GRANULOMA 55 0.23 239.15 178.27 192 64 62.3 47.23 74 85
OXYTETRACYCLINE DISCOLOR TOOTH 74 0.599 123.49 96.79 633 138 58.99 46.82 81 86
SOMATROPIN OTITIS MED 101 1.147 88.07 71.5 1143 218 56.29 46.25 87 87
INSULIN NOVOLIN 70/30 HYPERGLYCEM 484 8.959 54.02 49.22 2408 370 50.43 46.22 108 88
PROCAINAMIDE LE SYND 471 8.679 54.27 49.43 2386 367 50.53 46.01 107 89
ISOTRETINOIN BLIND NIGHT 140 1.94 72.15 60.3 1524 286 54.11 45.91 92 90
FOSCARNET SODIUM HYPOCALCEM 99 1.149 86.18 69.64 1184 226 55.04 45.11 90 91
COPPER UTER RUPT 270 4.665 57.88 51.02 2170 352 50.76 45.09 104 92
RITONAVIR PARESTH CIRCUMORAL 217 3.566 60.84 52.99 2005 332 51.41 45.01 98 93
ISOTRETINOIN CHEILITIS 380 6.983 54.42 48.97 2372 374 49.73 44.96 115 94
CALCIPOTRIENE PSORIASIS 47 0.142 331 239.45 99 41 59.21 44.52 80 95
PHOTOPLEX PHOTOSENSITIVITY 156 2.359 66.13 55.96 1766 314 51.76 44.3 97 96
INFLUENZA VIRUS VACCINE GUILLAIN BARRE SYND 62 0.451 137.47 104.21 507 127 56.07 43.85 89 97
CLOMIPHENE OVAR DIS 163 2.567 63.5 53.76 1882 326 50.64 43.6 106 98
DTP VACCINE SIDS 207 3.495 59.23 51.21 2095 350 49.86 43.47 113 99
CEFACLOR SERUM SICK 3164 69.702 45.39 43.81 3063 438 44.96 43.34 134 100
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C.2 Data 2
0 5 10 15 20 25 30 35
0.
0
0.
4
0.
8
Lag
AC
F
alpha
0 5 10 15 20 25 30 35
0.
0
0.
4
0.
8
Lag
AC
F
beta
0 5 10 15 20 25 30 35
0.
0
0.
4
0.
8
Lag
AC
F
nu
0 5 10 15 20 25 30 35
0.
0
0.
4
0.
8
Lag
AC
F
ltarget
Figure C.7: Acf plots of α, β, ν and the logarithm of the target distribution for C-G and Data 2.
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Figure C.8: Trace plots of α, β, ν and the logarithm of the target distribution for three chains,
for C-G and Data 2.
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Figure C.9: Bayesian p-value scatter plots for C-G and Data 2. (a) Plot of logarithm ofX2 against
logarithm of X1, and (b) Plot of logarithm of SD against logarithm of OD . The red line is the line
of equality.
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Figure C.10: (a) Logarithm of the 95% posterior intervals of φ against the logarithm of the
reporting rate RR for the C-G model. The plotted values are for 500 drug and adverse event pairs
randomly sampled from Data 2, and (b) Logarithm of posterior medians of φ against the logarithm
of the reporting rate RR for C-G model. The plotted values are for 1000 drug and adverse event
pairs randomly sampled from Data 2.
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Figure C.11: (a) Scatter plot of logarithm of φ025 against the logarithm of RR025 for C-G and
Data 2, and (b) Histogram of φs for C-G and Data 2. The superimposed density curve (in red)
represents the Gamma distribution corresponding to the MCMC estimates of the posterior means
of ϕ and ψ.
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Table C.3: Values of original counts, mean replicate counts, expected counts, RR and φ
for fifty randomly selected drug and side-effect pairs using C-G model and Data 2.
Count Mean Rep. Expected RR φ
Count Count
1 0.2 0.000 2816.96 0.99
18 12.3 5.957 3.02 1.72
3 1.7 0.339 8.84 1.09
1 0.3 0.001 694.57 0.99
175 157.7 43.911 3.99 3.54
64 59.9 42.377 1.51 1.38
527 490.7 79.506 6.63 6.15
2 4.4 4.698 0.43 0.53
1 1.7 0.471 2.12 0.77
5 6.2 5.663 0.88 0.71
15 12.6 8.162 1.84 1.26
22 17.1 9.189 2.39 1.62
579 577.2 452.946 1.28 1.27
1481 1321.4 54.248 27.3 24.34
3 4.1 3.064 0.98 0.74
22 20.5 17.797 1.24 1.05
58 2.5 0.098 594.08 9.07
12 16.5 53.081 0.23 0.27
803 773.9 142.740 5.63 5.39
7 5.0 2.600 2.69 1.17
6 0.6 0.010 576.05 1.69
1 2.1 0.880 1.14 0.73
1 0.3 0.002 559.28 0.99
1 1.2 0.160 6.25 0.87
10 0.7 0.017 590.60 2.21
1 1.8 0.616 1.62 0.75
150 7.0 0.228 658.94 22.13
13 12.4 10.760 1.21 0.95
1 1.7 0.570 1.75 0.77
1 3.3 2.780 0.36 0.53
7 2.2 0.418 16.76 1.62
46 2.0 0.073 628.21 7.41
1 2.5 1.519 0.66 0.63
1 2.4 1.298 0.77 0.65
604 601.8 532.731 1.13 1.13
1 2.8 1.708 0.59 0.63
8 7.4 5.231 1.53 1.00
1 1.9 0.597 1.67 0.78
1006 1002.0 749.688 1.34 1.33
1196 1198.6 2962.320 0.40 0.40
1094 1065.8 202.805 5.39 5.24
642 642.2 775.209 0.83 0.83
773 704.1 62.563 12.36 11.21
1 1.6 0.431 2.32 0.75
1 3.4 3.125 0.32 0.52
37 1.5 0.041 895.62 6.20
1 3.2 2.429 0.41 0.57
1 2.7 1.623 0.62 0.63
3 4.3 3.55 0.85 0.69
18 19.6 30.366 0.59 0.59
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Table C.4a: Top hundred drug and adverse event pairs selected by C-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 2. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
DIETHYLSTILBESTROL ANOMALY CONGEN 2811 17.749 158.37 152.57 398 79 114.76 105.72 1 1
COPPER UTER DIS 4457 46.398 96.06 93.26 975 151 83.86 78.55 2 2
TETRACYCLINE DISCOLOR TOOTH 1437 10.485 137.05 130 510 95 83.4 74.3 3 3
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 378 77 81.66 71.71 4 4
NONOXYNOL CERVIX DIS 1074 8.161 131.61 123.77 552 104 72.2 63.12 5 5
DTP VACCINE SCREAMING SYND 966 9.643 100.18 93.95 897 147 59.09 51.17 6 6
MICONAZOLE VAGINITIS 2262 34.851 64.9 62.24 1818 271 54.45 49.55 7 7
COPPER PAIN PELVIC 1962 30.696 63.92 61.12 1861 278 52.47 47.38 10 8
COPPER SALPINGITIS 1484 21.323 69.6 66.08 1635 238 52.91 47.17 9 9
COPPER DEVICE MIGRATION 1490 22.868 65.16 61.88 1811 272 50.37 44.93 11 10
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 53.32 42.99 8 11
UROKINASE CHILLS 831 10.942 75.95 70.83 1426 220 46.97 40.36 13 12
CEFACLOR SERUM SICK 3164 69.702 45.39 43.81 3063 438 41.42 38.4 17 13
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 47.11 37.05 12 14
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 234 56 44.84 35.86 14 15
NONOXYNOL DEVICE MIGRATION 800 13.275 60.27 56.12 2045 311 40.05 34.34 21 16
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM CEREBR 695 10.419 66.71 61.81 1744 274 40.65 34.17 19 17
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 9 3 44.26 34.13 15 18
NONOXYNOL LEUKORRHEA 603 8.344 72.27 66.51 1516 235 40.03 33.49 22 19
COPPER FERTIL DEC FEM 695 10.997 63.2 58.56 1899 294 39.12 33.17 24 20
INSULIN HUMAN HYPERGLYCEM 6200 170.45 36.37 35.47 4270 560 34.99 33.03 30 21
LOMEFLOXACIN HYDROCHLORIDE PHOTOSENSITIVITY 481 5.137 93.64 85.27 1023 166 40.7 32.99 18 22
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 42.53 32.73 16 23
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM INTRACRAN 476 5.426 87.73 79.99 1150 184 39.12 32.04 23 24
BUTOCONAZOLE NITRATE VAGINITIS 1072 22.835 46.94 44.14 2902 434 36.33 31.83 27 25
CEFUROXIME COLITIS PSEUDOMEM 1063 22.881 46.46 43.7 2953 440 35.93 31.43 28 26
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 26 9 40.47 31.31 20 27
PHENFORMIN ACIDOSIS LACTIC 390 3.302 118.11 106.61 681 124 39.07 31.13 25 28
TRETINOIN DERM EXFOL 1213 29.963 40.48 38.21 3643 508 33.1 29.28 36 29
MIVACURIUM CHLORIDE INCREASED EFFECT 319 1.865 171.02 152.26 356 81 37.2 29.04 26 30
POLIOVIRUS VACCINE, LIVE, ORAL SCREAMING SYND 344 3.28 104.89 93.91 831 148 34.53 27.45 31 31
MINOXIDIL HIRSUTISM 1035 26.322 39.32 36.93 3802 532 31.32 27.37 40 32
CLONIDINE DERM CONTACT 964 23.784 40.53 38.01 3633 513 31.64 27.33 39 33
METFORMIN ACIDOSIS LACTIC 309 2.074 149.02 132.62 437 94 35.23 27.28 29 34
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Table C.4b: Top hundred drug and adverse event pairs selected by C-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 2. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
TRIAMCINOLONE ATROPHY INJECT SITE 439 6.303 69.65 63.14 1630 260 33.71 27.18 34 35
SUPROFEN PAIN BACK 399 5.188 76.91 69.39 1404 227 33.52 27.05 35 36
PRED-G PAIN EYE 644 13.125 49.07 45.33 2739 417 32.37 26.94 37 37
NAFARELIN ACETATE HEM VAGINAL 506 9.008 56.17 51.29 2260 349 32.14 26.3 38 38
SELENIUM SULFIDE HAIR DISCOLOR 301 2.236 134.64 119.43 526 107 33.74 26.17 33 39
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 91 25 34.32 25.71 32 40
MINOXIDIL HAIR DIS 928 24.654 37.64 35.25 4048 563 29.54 25.62 46 41
INSULIN NOVOLIN 70/30 HYPERGLYCEM 484 8.959 54.02 49.22 2408 370 30.86 25.31 41 42
PROCAINAMIDE LE SYND 471 8.679 54.27 49.43 2386 367 30.74 25 43 43
TIMOPTIC PAIN EYE 695 16.875 41.19 38.16 3539 509 29.49 24.87 48 44
BUTORPHANOL DRUG DEPEND 457 8.165 55.97 50.95 2270 353 30.78 24.73 42 45
CEFACLOR ARTHROSIS 1010 30.298 33.34 31.29 4809 673 27.27 23.75 53 46
TRAZODONE PRIAPISM 347 5.117 67.81 60.77 1701 282 29.26 23.32 50 47
OPCON A PAIN EYE 267 2.015 132.49 116.61 547 109 30.58 23.22 44 48
NONOXYNOL VAGINITIS 1141 36.497 31.26 29.45 5245 720 26.45 23.17 55 49
TRETINOIN SKIN DRY 750 21.028 35.67 33.15 4389 618 27.05 23.05 54 50
METHADONE WITHDRAW SYND 1233 41.143 29.97 28.32 5534 759 25.8 22.78 57 51
ISOTRETINOIN CHEILITIS 380 6.983 54.42 48.97 2372 374 27.78 22.22 51 52
CEFIXIME COLITIS PSEUDOMEM 421 8.596 48.98 44.32 2749 432 27.49 22.14 52 53
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 224 58 29.8 21.96 45 54
GEMCITABINE HYDROCHLORIDE CARCINOMA GI 225 0.952 236.39 205.92 200 51 29.48 21.87 49 55
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 94 27 29.54 21.73 47 56
CEFACLOR ERYTHEMA MULT 1481 54.248 27.3 25.92 6279 836 24.3 21.63 67 57
WARFARIN PROTHROMBIN INC 762 23.392 32.58 30.27 4966 706 25.31 21.53 60 58
TUBERCULIN, PURIFIED PROTEIN DERIVATIV INJECT SITE REACT 411 9.536 43.1 39.01 3301 500 25.35 20.39 59 59
NONOXYNOL PREGN UNINTEND 1173 43.993 26.66 25.14 6471 876 23.17 20.32 70 60
WARFARIN PROTHROMBIN DEC 4355 193.608 22.49 21.83 8172 1028 21.71 20.29 78 61
TIOCONAZOLE VAGINITIS 268 3.558 75.32 66.33 1442 236 26.18 20.25 56 62
ALENDRONATE SODIUM PAIN BONE 492 13.442 36.6 33.4 4231 609 24.45 20.07 65 63
BENOXAPROFEN NAIL DIS 382 8.665 44.09 39.7 3200 489 24.91 19.86 63 64
ENOXAPARIN SODIUM HEM 342 7.257 47.13 42.17 2891 454 24.42 19.31 66 65
RISPERIDONE PROLACTIN INC 360 7.978 45.12 40.49 3090 475 24.65 19.28 64 66
INTRAUTERINE DEVICE UTER DIS 251 3.127 80.26 70.35 1328 224 25.54 19.09 58 67
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Table C.4c: Top hundred drug and adverse event pairs selected by C-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 2. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
MOXALACTAM PROTHROMBIN DEC 683 23.759 28.75 26.6 5836 805 22.41 18.92 75 68
MITOMYCIN UREMIA 218 1.995 109.29 95.26 785 142 24.96 18.75 62 69
TETRAHYDROZOLINE CONJUNCTIVITIS 230 2.454 93.73 81.91 1021 174 25.17 18.72 61 70
MINOXIDIL HAIR DISCOLOR 433 12.27 35.29 32.03 4451 647 22.87 18.53 72 71
COPPER UTER RUPT 270 4.665 57.88 51.02 2170 352 23.72 18.07 69 72
CLINDAMYCIN COLITIS 625 22.373 27.94 25.75 6081 842 21.5 17.92 79 73
LEVONORGESTREL REACT UNEVAL 5043 259.501 19.43 18.9 9866 1209 18.95 17.79 105 74
SCOPOLAMINE WITHDRAW SYND 784 30.874 25.39 23.64 6869 935 20.89 17.72 83 75
MICONAZOLE VULVOVAGINITIS 234 3.168 73.87 64.71 1471 248 23.72 17.69 68 76
CLINDAMYCIN COLITIS PSEUDOMEM 672 25.375 26.48 24.51 6527 901 20.99 17.49 82 77
INSULIN HUMAN HYPOGLYCEM 1810 87.027 20.8 19.84 9040 1148 19.33 17.41 102 78
LOPERAMIDE PHARYNGITIS 590 21.605 27.31 25.13 6276 877 20.88 17.34 85 79
SCOPOLAMINE MYDRIASIS 269 5.256 51.18 45.09 2582 422 22.54 17.24 73 80
PHENYTOIN DRUG LEVEL DEC 1295 59.805 21.65 20.48 8585 1111 19.48 17.19 99 81
COPPER ENDOMETR DIS 334 8.68 38.48 34.45 3924 577 21.79 17.17 76 82
TETRAHYDROZOLINE PAIN EYE 187 1.43 130.77 112.59 557 117 23.09 16.75 71 83
TRETINOIN SKIN DIS 382 11.665 32.75 29.49 4926 718 20.77 16.52 86 84
VALPROIC ACID NPN INC 475 17.088 27.8 25.34 6124 867 20.03 16.41 93 85
NITRODISC APPLICAT SITE REACT 326 8.823 36.95 32.98 4176 621 21.04 16.39 81 86
PILOCARPINE PAIN EYE 303 7.996 37.89 33.64 4017 603 20.65 16.01 89 87
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 252 67 22.42 16 74 88
MINITRAN APPLICAT SITE REACT 340 9.98 34.07 30.46 4674 698 20.43 15.95 90 89
PRED-G CONJUNCTIVITIS 329 9.708 33.89 30.28 4703 704 20.01 15.8 94 90
ISOTRETINOIN HYPERLIPEM 726 32.758 22.16 20.58 8344 1103 18.4 15.8 114 91
MINOXIDIL SKIN DRY 1038 50.729 20.46 19.22 9239 1185 18.06 15.8 124 92
TETRACYCLINE TOOTH DIS 248 5.312 46.68 41.04 2932 466 20.73 15.71 87 93
RITONAVIR PARESTH CIRCUMORAL 217 3.566 60.84 52.99 2005 332 21.15 15.69 80 94
DIGOXIN DIGITALIS INTOX 1474 77.322 19.06 18.09 10121 1267 17.56 15.66 129 95
MINOXIDIL ALOPECIA 4479 262.608 17.06 16.56 11732 1407 16.64 15.61 145 96
PROCAINAMIDE ANA 300 8.28 36.23 32.25 4289 642 20.06 15.49 92 97
NITRO-DUR APPLICAT SITE REACT 592 25.651 23.08 21.25 7892 1057 18.37 15.33 116 98
DIANEAL PERITONITIS 150 0.228 658.94 553.51 28 11 21.77 15.17 77 99
EFIDAC/24 INSOMNIA 393 14.23 27.62 24.95 6171 883 18.8 15.09 108 100
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Figure C.12: Acf plots of α, β, ν and the logarithm of the target distribution for C-G and Data
3.
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Figure C.13: Trace plots of α, β, ν and the logarithm of the target distribution for three chains,
for C-G and Data 3.
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Figure C.14: Bayesian p-value scatter plots for C-G and Data 3. (a) Plot of logarithm of X2
against logarithm of X1, and (b) Plot of logarithm of SD against logarithm of OD . The red line
is the line of equality.
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Figure C.15: (a) Logarithm of the 95% posterior intervals of φ against the logarithm of the
reporting rate RR for the C-G model. The plotted values are for 500 drug and adverse event pairs
randomly sampled from Data 3, and (b) Logarithm of posterior medians of φ against the logarithm
of the reporting rate RR for C-G model. The plotted values are for 1000 drug and adverse event
pairs randomly sampled from Data 3.
−4 −2 0 2 4
−
4
−
3
−
2
−
1
0
1
Log of RR025
Lo
g 
of
 φ 0
25
(a)
φ
D
en
si
ty
0 5 10 15 20
0.
0
0.
2
0.
4
0.
6
0.
8
(b)
Figure C.16: (a) Scatter plot of logarithm of φ025 against the logarithm of RR025 for C-G and
Data 3, and (b) Histogram of φs for C-G and Data 3. The superimposed density curve (in red)
represents the Gamma distribution corresponding to the MCMC estimates of the posterior means
of ϕ and ψ.
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Table C.5: Values of original counts, mean replicate counts, expected counts, RR and φ
for fifty randomly selected drug and side-effect pairs using C-G model and Data 3.
Count Mean Rep. Expected RR φ
Count Count
10 10.5 3.771 2.65 0.82
684 581.8 141.379 4.84 4.03
23 24.3 19.812 1.16 0.78
527 518.1 477.337 1.10 1.07
89 87.6 88.794 1.00 0.89
527 389.9 79.506 6.63 4.79
28 3.3 0.031 889.14 1.55
1109 942.5 162.189 6.84 5.75
5 10.8 5.020 1.00 0.67
3164 2149.5 69.702 45.39 30.72
6 11.6 6.055 0.99 0.65
10 15.0 9.937 1.01 0.69
53 27.8 11.698 4.53 1.58
26 3.4 0.037 707.23 1.50
9 14.5 9.014 1.00 0.66
58 4.7 0.098 594.08 2.37
896 871.8 533.355 1.68 1.62
107 105.1 106.067 1.01 0.90
151 146.8 142.483 1.06 0.96
9 14.1 8.989 1.00 0.66
6 8.4 2.228 2.69 0.77
11 15.6 11.050 1.00 0.68
199 89.4 20.056 9.92 4.01
26 38.1 65.969 0.39 0.44
1062 1051.5 904.794 1.17 1.15
126 101.1 58.529 2.15 1.56
20 29.1 38.710 0.52 0.52
695 686.6 684.336 1.02 0.99
5 10.2 4.241 1.18 0.68
8 11.8 5.329 1.50 0.72
17 16.7 9.548 1.78 0.85
7 12.7 7.001 1.00 0.67
10 9.5 2.704 3.70 0.86
1404 1333.1 455.788 3.08 2.91
544 556.8 1218.600 0.45 0.45
557 565.9 917.305 0.61 0.61
1400 1333.9 472.530 2.96 2.81
843 834.2 756.036 1.12 1.09
26 35.2 46.838 0.56 0.56
579 530.5 198.300 2.92 2.60
580 571.6 505.762 1.15 1.11
9 14.0 9.005 1.00 0.67
306 9.0 0.198 1543.39 9.55
6 2.1 0.004 1577.25 0.95
14 14.1 6.678 2.10 0.85
55 67.5 119.829 0.46 0.49
387 15.1 0.542 714.05 11.69
293 8.6 0.185 1583.73 9.16
11 15.8 11.036 1.00 0.66
10 14.7 9.043 1.11 0.71
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Table C.6a: Top hundred drug and adverse event pairs selected by C-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 3. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
COPPER UTER DIS 4457 46.398 96.06 93.26 321 150 55.61 48.96 1 1
DIETHYLSTILBESTROL ANOMALY CONGEN 2811 17.749 158.37 152.57 165 79 54.62 46.44 2 2
MICONAZOLE VAGINITIS 2262 34.851 64.9 62.24 532 265 33 27.49 3 3
INSULIN HUMAN HYPERGLYCEM 6200 170.45 36.37 35.47 1123 545 30.35 27.25 7 4
CEFACLOR SERUM SICK 3164 69.702 45.39 43.81 845 426 30.63 26.35 5 5
TETRACYCLINE DISCOLOR TOOTH 1437 10.485 137.05 130 198 94 32.61 25.85 4 6
COPPER PAIN PELVIC 1962 30.696 63.92 61.12 543 272 30.46 25.24 6 7
COPPER SALPINGITIS 1484 21.323 69.6 66.08 487 233 26.97 21.55 9 8
COPPER DEVICE MIGRATION 1490 22.868 65.16 61.88 530 266 26.4 21.22 10 9
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 158 77 27.44 21.11 8 10
NONOXYNOL CERVIX DIS 1074 8.161 131.61 123.77 212 103 25.65 19.78 11 11
DTP VACCINE SCREAMING SYND 966 9.643 100.18 93.95 303 146 22.27 16.86 12 12
WARFARIN PROTHROMBIN DEC 4355 193.608 22.49 21.83 2019 989 19.17 16.86 13 13
LEVONORGESTREL REACT UNEVAL 5043 259.501 19.43 18.9 2392 1159 17.21 15.24 19 14
TRETINOIN DERM EXFOL 1213 29.963 40.48 38.21 982 494 19.12 14.82 14 15
CEFUROXIME COLITIS PSEUDOMEM 1063 22.881 46.46 43.7 817 428 18.84 14.62 16 16
BUTOCONAZOLE NITRATE VAGINITIS 1072 22.835 46.94 44.14 806 422 19 14.61 15 17
UROKINASE CHILLS 831 10.942 75.95 70.83 426 216 18.66 13.79 17 18
CEFACLOR ERYTHEMA MULT 1481 54.248 27.3 25.92 1609 809 16.93 13.58 21 19
MINOXIDIL ALOPECIA 4479 262.608 17.06 16.56 2834 1346 15.12 13.32 30 20
MINOXIDIL HIRSUTISM 1035 26.322 39.32 36.93 1006 518 17.35 13.16 18 21
METHADONE WITHDRAW SYND 1233 41.143 29.97 28.32 1426 737 16.53 12.94 23 22
CLONIDINE DERM CONTACT 964 23.784 40.53 38.01 980 499 16.86 12.8 22 23
NONOXYNOL DEVICE MIGRATION 800 13.275 60.27 56.12 590 304 17.14 12.8 20 24
NONOXYNOL VAGINITIS 1141 36.497 31.26 29.45 1352 699 16.36 12.6 24 25
PERMETHRIN NO DRUG EFFECT 4029 249.042 16.18 15.68 3032 1450 14.28 12.48 33 26
INSULIN HUMAN HYPOGLYCEM 1810 87.027 20.8 19.84 2194 1102 15.04 12.32 31 27
LEVONORGESTREL METRORRHAGIA 7530 524.28 14.36 14.04 3510 1664 13.52 12.26 38 28
CEFACLOR ARTHROSIS 1010 30.298 33.34 31.29 1261 653 15.9 12.17 27 29
MINOXIDIL HAIR DIS 928 24.654 37.64 35.25 1073 548 15.94 11.96 25 30
NONOXYNOL PREGN UNINTEND 1173 43.993 26.66 25.14 1650 845 15.17 11.69 29 31
NICOTINE APPLICAT SITE REACT 5085 358.599 14.18 13.79 3563 1699 12.97 11.44 42 32
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM CEREBR 695 10.419 66.71 61.81 514 268 15.91 11.34 26 33
COPPER FERTIL DEC FEM 695 10.997 63.2 58.56 553 287 15.67 11.28 28 34
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Table C.6b: Top hundred drug and adverse event pairs selected by C-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 3. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
INSULIN HYPERGLYCEM 2429 148.433 16.36 15.72 2992 1446 13.36 11.23 40 35
PHENYTOIN DRUG LEVEL DEC 1295 59.805 21.65 20.48 2100 1067 13.86 11 35 36
DIGOXIN DIGITALIS INTOX 1474 77.322 19.06 18.09 2458 1215 13.29 10.71 41 37
NONOXYNOL LEUKORRHEA 603 8.344 72.27 66.51 457 231 14.51 10.1 32 38
DIATRIZOIC ACID URTICARIA 5404 442.648 12.21 11.88 4306 2040 11.36 10.08 55 39
COPPER METRORRHAGIA 2022 132.31 15.28 14.62 3240 1582 12.23 10.07 47 40
PRED-G PAIN EYE 644 13.125 49.07 45.33 765 405 13.89 10.04 34 41
TIMOPTIC PAIN EYE 695 16.875 41.19 38.16 958 495 13.81 10.04 36 42
TRETINOIN SKIN DRY 750 21.028 35.67 33.15 1154 602 13.79 9.89 37 43
WARFARIN PROTHROMBIN INC 762 23.392 32.58 30.27 1298 686 13.48 9.84 39 44
MINOXIDIL SKIN DRY 1038 50.729 20.46 19.22 2240 1137 12.35 9.5 44 45
DTP VACCINE FEVER 2494 192.186 12.98 12.47 3992 1891 11.1 9.48 60 46
CLOZAPINE LEUKOCYTOSIS 1352 79.763 16.95 16.05 2854 1402 11.99 9.45 50 47
TRIAZOLAM AMNESIA 1108 59.977 18.47 17.39 2563 1273 11.89 9.09 51 48
SCOPOLAMINE WITHDRAW SYND 784 30.874 25.39 23.64 1736 904 12.24 9.02 46 49
ESTRADIOL APPLICAT SITE REACT 3664 325.306 11.26 10.9 4715 2283 10.22 8.9 77 50
IOTHALAMIC ACID URTICARIA 2924 248.904 11.75 11.32 4495 2174 10.36 8.87 74 51
ENALAPRIL COUGH INC 2033 157.884 12.88 12.32 4028 1929 10.65 8.79 69 52
INSULIN HYPOGLYCEM 1267 81.804 15.49 14.64 3186 1576 11.07 8.65 61 53
MOXALACTAM PROTHROMBIN DEC 683 23.759 28.75 26.6 1500 781 12.06 8.58 48 54
COPPER PREGN UNINTEND 1312 88.225 14.87 14.07 3356 1659 10.83 8.49 65 55
LOMEFLOXACIN HYDROCHLORIDE PHOTOSENSITIVITY 481 5.137 93.64 85.27 335 164 12.58 8.42 43 56
PHENYTOIN DRUG LEVEL INC 2321 206.125 11.26 10.8 4717 2318 9.72 8.15 84 57
NAFARELIN ACETATE HEM VAGINAL 506 9.008 56.17 51.29 636 341 12.02 8.15 49 58
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM INTRACRAN 476 5.426 87.73 79.99 364 182 12.26 8.13 45 59
ISOTRETINOIN HYPERLIPEM 726 32.758 22.16 20.58 2051 1059 11.04 8.12 62 60
CLINDAMYCIN COLITIS PSEUDOMEM 672 25.375 26.48 24.51 1667 870 11.55 8.12 52 61
ALCOHOL OVERDOSE INTENT 797 40.254 19.8 18.43 2330 1195 10.94 8.07 64 62
LORAZEPAM DRUG DEPEND 1023 64.888 15.77 14.81 3115 1562 10.5 8.01 71 63
CLINDAMYCIN COLITIS 625 22.373 27.94 25.75 1555 815 11.27 7.98 57 64
ALPRAZOLAM WITHDRAW SYND 1671 138.118 12.1 11.52 4348 2119 9.76 7.85 83 65
CLARITHROMYCIN TASTE PERVERS 1027 67.011 15.33 14.4 3225 1616 10.25 7.85 76 66
INSULIN NOVOLIN 70/30 HYPERGLYCEM 484 8.959 54.02 49.22 674 360 11.5 7.79 53 67
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Table C.6c: Top hundred drug and adverse event pairs selected by C-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 3. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
INTERFERON BETA FLU SYND 921 56.21 16.39 15.34 2989 1492 10.34 7.78 75 68
SELENIUM SULFIDE NO DRUG EFFECT 722 34.737 20.78 19.29 2196 1133 10.68 7.73 68 69
GLYBURIDE HYPOGLYCEM 919 57.378 16.02 14.99 3058 1542 10.15 7.68 78 70
PROCAINAMIDE LE SYND 471 8.679 54.27 49.43 666 357 11.32 7.48 56 71
LOPERAMIDE PHARYNGITIS 590 21.605 27.31 25.13 1608 846 10.8 7.47 66 72
ALBUTEROL ASTHMA 2226 215.526 10.33 9.9 5244 2576 8.93 7.43 102 73
LEVONORGESTREL AMENORRHEA 1583 140.522 11.27 10.71 4713 2343 9.15 7.41 98 74
INTERFERON BETA INJECT SITE REACT 1370 113.854 12.03 11.4 4370 2151 9.35 7.39 91 75
TRIAMCINOLONE ATROPHY INJECT SITE 439 6.303 69.65 63.14 483 254 11.11 7.34 59 76
BUTORPHANOL DRUG DEPEND 457 8.165 55.97 50.95 639 344 11.11 7.24 58 77
HEPARIN HEM CEREBR 734 39.875 18.41 17.08 2575 1302 10.05 7.22 81 78
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 12 5 11.42 7.21 54 79
LOVASTATIN CREATINE PK INC 1131 89.674 12.61 11.89 4143 2039 9.26 7.15 94 80
ALENDRONATE SODIUM PAIN BONE 492 13.442 36.6 33.4 1114 594 10.56 7.11 70 81
NITRO-DUR APPLICAT SITE REACT 592 25.651 23.08 21.25 1962 1016 10.08 7.1 80 82
ISOTRETINOIN SKIN DRY 673 34.791 19.34 17.91 2410 1232 9.95 7.09 82 83
FLUOXETINE HYDROCHLORIDE SUICIDE ATTEMPT 2452 259.476 9.45 9.08 5871 2831 8.4 7.06 121 84
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 111 56 10.94 6.93 63 85
PHENFORMIN ACIDOSIS LACTIC 390 3.302 118.11 106.61 247 123 10.72 6.79 67 86
SUPROFEN PAIN BACK 399 5.188 76.91 69.39 421 223 10.44 6.78 72 87
EFIDAC/24 NO DRUG EFFECT 932 70.661 13.19 12.35 3905 1918 8.97 6.78 101 88
HEPARIN HEM 1150 98.976 11.62 10.95 4549 2267 8.72 6.69 110 89
OPCON A MYDRIASIS 351 0.717 489.53 439.33 31 21 10.44 6.66 73 90
CLOZAPINE SALIVA INC 549 24.183 22.7 20.84 1999 1040 9.63 6.59 86 91
ANGIOVIST 282 URTICARIA 678 41.814 16.21 14.99 3020 1541 9.11 6.58 100 92
CEFIXIME COLITIS PSEUDOMEM 421 8.596 48.98 44.32 768 420 10.12 6.58 79 93
CEFAMANDOLE PAIN 780 55.197 14.13 13.15 3577 1781 8.87 6.46 107 94
TUBERCULIN, PURIFIED PROTEIN DERIVATIV INJECT SITE REACT 411 9.536 43.1 39.01 899 486 9.69 6.43 85 95
THEOPHYLLINE DRUG LEVEL INC 1646 173.187 9.5 9.05 5826 2844 8 6.41 135 96
LORAZEPAM WITHDRAW SYND 1297 127.043 10.21 9.66 5313 2654 8.12 6.39 128 97
MINOXIDIL HAIR DISCOLOR 433 12.27 35.29 32.03 1170 629 9.61 6.33 87 98
ENALAPRIL ANGIOEDEMA 1009 88.869 11.35 10.66 4666 2362 8.35 6.32 123 99
VALPROIC ACID NPN INC 475 17.088 27.8 25.34 1563 836 9.51 6.3 89 100
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Figure D.1: Histogram of φs for P-G and Data 1. The superimposed density curve (in red)
represents the Gamma distribution corresponding to the MCMC estimates of the posterior means
of α and β.
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Figure D.2: Acf plots of α, β and the logarithm of the target distribution for P-G and Data 1.
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Figure D.3: Trace plots of α, β and the logarithm of the target distribution for three chains, for
P-G and Data 1.
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Figure D.4: Bayesian p-value scatter plots for P-G and Data 1. (a) Plot of logarithm ofX2 against
logarithm of X1, and (b) Plot of logarithm of SD against logarithm of OD . The red line is the line
of equality.
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
*
*
*
**
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
−2 0 2 4
−
2
0
2
4
Log of RR
Lo
g 
of
 9
5%
 c
re
di
ble
 in
te
rv
a
l o
f φ
*  Median
(a)
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
* *
*
*
*
**
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
**
*
*
*
*
*
*
*
*
**
*
**
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
** *
*
*
*
*
*
*
*
*
*
**
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
*
*
*
* *
*
*
*
*
*
**
*
**
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
**
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
**
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
*
*
***
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
* *
* *
*
*
*
*
*
−2 0 2 4
−
2
0
2
4
Log of RR
Lo
g 
of
 m
ed
ia
n 
of
 φ
*  Median
(b)
Figure D.5: (a) Logarithm of the 95% posterior intervals of φ against the logarithm of the reporting
rate RR for the P-G model. The plotted values are for 500 drug and adverse event pairs randomly
sampled from Data 1, and (b) Logarithm of posterior medians of φ against the logarithm of the
reporting rate RR for P-G model. The plotted values are for 1000 drug and adverse event pairs
randomly sampled from Data 1.
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Figure D.6: Scatter plot of logarithm of φ025 against the logarithm of RR025 for P-G and
Data 1.
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Table D.1: Values of original counts, mean replicate counts, expected counts, RR and φ
for fifty randomly selected drug and side-effect pairs using P-G model and Data 1.
Count Mean Rep. Expected RR φ
Count Count
7 7.3 11.218 0.62 0.65
6 6.0 5.973 1.00 1.01
0 0.0 0.004 0.00 0.94
666 665.7 695.539 0.96 0.96
0 0.4 0.915 0.00 0.41
44 40.2 6.070 7.25 6.62
0 0.0 0.039 0.00 0.95
111 57.5 0.721 154.02 79.55
0 0.0 0.030 0.00 0.96
28 1.3 0.031 889.14 40.3
32 2.1 0.047 685.52 44.7
7 6.9 6.866 1.02 1.00
1 1.1 1.245 0.80 0.86
1 1.0 0.997 1.00 0.98
1 0.9 0.765 1.31 1.17
1 0.6 0.369 2.71 1.56
1 0.9 0.820 1.22 1.11
0 0.2 0.339 0.00 0.65
26 1.4 0.037 707.23 37.21
7 0.2 0.018 399.26 10.92
6 5.9 4.814 1.25 1.21
2022 2011.7 132.310 15.28 15.21
6 0.1 0.010 576.05 9.69
1021 1020.1 1701.710 0.60 0.60
637 636.5 606.791 1.05 1.05
1211 1211.4 739.652 1.64 1.64
933 933.1 854.123 1.09 1.09
1039 1039.6 380.965 2.73 2.73
56 10.0 0.147 381.61 68.35
1 0.6 0.409 2.44 1.53
46 4.5 0.073 628.21 61.73
2 1.9 1.625 1.23 1.16
3664 3658.6 325.306 11.26 11.25
1608 1609.9 1421.430 1.13 1.13
82 11.0 0.105 780.57 105.38
1 0.4 0.206 4.85 1.89
1032 1030.6 519.620 1.99 1.98
594 592.5 392.751 1.51 1.51
3 2.9 2.468 1.22 1.15
2 1.5 0.845 2.37 1.72
66 65.6 55.168 1.20 1.19
0 0.5 2.436 0.00 0.20
19 19.5 93.931 0.20 0.21
306 69.2 0.198 1543.39 348.6
306 69.2 0.198 1543.39 348.6
6 0.0 0.004 1577.25 9.74
10 0.4 0.023 431.67 15.28
1 0.4 0.198 5.05 1.87
3 2.5 1.432 2.09 1.74
5 5.0 4.914 1.02 1.02
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Table D.2a: Top hundred drug and adverse event pairs selected by P-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 9 3 348.02 310.9 1 1
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 337.76 300.84 2 2
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 316.29 286.65 3 3
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 26 9 261.16 233.31 4 4
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 251.17 227.51 5 5
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 91 25 180.34 158.82 6 6
DIETHYLSTILBESTROL ANOMALY CONGEN 2811 17.749 158.37 152.57 398 79 152.57 146.71 10 7
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 94 27 164.44 143.55 8 8
DIANEAL PERITONITIS 150 0.228 658.94 553.51 28 11 164.8 140.67 7 9
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 234 56 154.56 139.7 9 10
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 378 77 148.08 139.68 11 11
TETRACYCLINE DISCOLOR TOOTH 1437 10.485 137.05 130 510 95 128.71 122.38 14 12
GEMCITABINE HYDROCHLORIDE CARCINOMA GI 225 0.952 236.39 205.92 200 51 137.47 120.45 12 13
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 224 58 133.43 117.17 13 14
NONOXYNOL CERVIX DIS 1074 8.161 131.61 123.77 552 104 121.43 114.51 17 15
MIVACURIUM CHLORIDE INCREASED EFFECT 319 1.865 171.02 152.26 356 81 125.49 112.64 15 16
CORTISPORIN PAIN EAR 132 0.37 356.64 297.2 81 26 125.46 104.96 16 17
METFORMIN ACIDOSIS LACTIC 309 2.074 149.02 132.62 437 94 112.12 100.7 19 18
MYSTECLIN F DISCOLOR TOOTH 134 0.458 292.78 244.72 130 39 117.81 98.86 18 19
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 252 67 111.85 94.92 20 20
SELENIUM SULFIDE HAIR DISCOLOR 301 2.236 134.64 119.43 526 107 103.34 92.6 22 21
COPPER UTER DIS 4457 46.398 96.06 93.26 975 151 94.68 91.95 28 22
PHENFORMIN ACIDOSIS LACTIC 390 3.302 118.11 106.61 681 124 97.94 89.04 27 23
DTP VACCINE SCREAMING SYND 966 9.643 100.18 93.95 897 147 93.59 87.88 29 24
OPCON A PAIN EYE 267 2.015 132.49 116.61 547 109 99.16 87.53 26 25
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.329 315.65 257.98 108 34 103.2 85.07 23 26
RIFABUTIN UVEITIS 134 0.665 201.45 168.37 265 70 99.8 84.72 25 27
ETIDOCAINE TRISMUS 82 0.105 780.57 618.74 17 7 104.75 84.12 21 28
OXYTOCIN HEM POSTPARTUM 103 0.346 297.96 242.99 124 40 100.42 82.51 24 29
POLIOVIRUS VACCINE, LIVE, ORAL SCREAMING SYND 344 3.28 104.89 93.91 831 148 86.75 78.13 34 30
TETRAHYDROZOLINE PAIN EYE 187 1.43 130.77 112.59 557 117 88.48 76.48 33 31
LOMEFLOXACIN HYDROCHLORIDE PHOTOSENSITIVITY 481 5.137 93.64 85.27 1023 166 82.75 75.68 37 32
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 92.42 72.94 30 33
METHYSERGIDE FIBRO RETROPERIT 87 0.29 300.36 238.21 122 43 89.57 72.29 32 34
A
P
P
E
N
D
IX
D
.
P
-G
M
O
D
E
L
R
E
S
U
L
T
S
129
Table D.2b: Top hundred drug and adverse event pairs selected by P-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
POLIOVIRUS VACCINE, LIVE, ORAL SIDS 146 1.038 140.6 118.45 484 108 85.1 71.99 35 35
PERDIEM STENO ESOPH 65 0.024 2694.87 2072.98 3 1 92.29 71.98 31 36
MITOMYCIN UREMIA 218 1.995 109.29 95.26 785 142 81.59 71.55 39 37
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM INTRACRAN 476 5.426 87.73 79.99 1150 184 77.96 71.32 44 38
MENOTROPINS OVAR DIS 151 1.175 128.48 108.06 583 122 81.5 69.33 40 39
CHOLINE KERATITIS 116 0.703 164.99 135.12 372 91 83.86 68.96 36 40
CEFOXITIN ENTEROCOL PSEUDOMEM 138 1.016 135.79 113.16 517 116 81.46 68.87 41 41
UROKINASE CHILLS 831 10.942 75.95 70.83 1426 220 71.52 66.84 51 42
BENDECTIN ECTROMELIA 111 0.721 154.02 126.27 415 100 79.21 65.88 43 43
DIPHTHERIA-TETANUS TOXOID-PERTUSSIS VA SCREAMING SYND 147 1.22 120.47 101.62 654 130 77.29 65.54 46 44
CHOLINE CORNEAL OPACITY 77 0.26 295.96 230.62 128 46 82.02 65.53 38 45
COPPER SALPINGITIS 1484 21.323 69.6 66.08 1635 238 67.45 64.18 57 46
TETRAHYDROZOLINE CONJUNCTIVITIS 230 2.454 93.73 81.91 1021 174 73.32 64.12 50 47
HAEMOPHILUS B POLYSACCHARIDE VACCINE MENINGITIS 176 1.711 102.86 87.66 851 164 73.49 63.26 48 48
BSS KERATITIS 74 0.243 305.12 239.15 118 42 80 63.14 42 49
NONOXYNOL LEUKORRHEA 603 8.344 72.27 66.51 1516 235 66.87 61.67 58 50
SUPROFEN PAIN BACK 399 5.188 76.91 69.39 1404 227 67.96 61.61 54 51
MICONAZOLE VAGINITIS 2262 34.851 64.9 62.24 1818 271 63.66 61.08 63 52
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.093 647.58 485.69 30 14 77.43 60.05 45 53
COPPER DEVICE MIGRATION 1490 22.868 65.16 61.88 1811 272 63.29 60.05 64 54
COPPER PAIN PELVIC 1962 30.696 63.92 61.12 1861 278 62.51 59.72 70 55
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM CEREBR 695 10.419 66.71 61.81 1744 274 62.53 58.04 69 56
INTRAUTERINE DEVICE UTER DIS 251 3.127 80.26 70.35 1328 224 65.93 57.95 60 57
SODIUM HYALURONATE KERATITIS 70 0.274 255.2 196.87 167 55 73.47 57.95 49 58
CHOLINE OPHTHALMITIS 58 0.098 594.08 450.68 35 18 74.38 57.63 47 59
TRIAMCINOLONE ATROPHY INJECT SITE 439 6.303 69.65 63.14 1630 260 62.89 57.22 68 60
PILOCARPINE MIOSIS 103 0.812 126.83 103.44 601 128 69.02 56.83 52 61
TIOCONAZOLE VAGINITIS 268 3.558 75.32 66.33 1442 236 63.23 55.91 65 62
GONADOTROPIN, CHORIONIC OVAR DIS 86 0.567 151.69 119.94 423 106 68.82 55.58 53 63
COPPER FERTIL DEC FEM 695 10.997 63.2 58.56 1899 294 59.46 55.11 79 64
OXYTOCIN FETAL DIS 95 0.759 125.14 100.11 616 133 66.09 54.17 59 65
ALCOHOL ALCOHOL INTOLER 169 2.006 84.26 71.8 1233 215 62.93 54.15 67 66
TRAZODONE PRIAPISM 347 5.117 67.81 60.77 1701 282 59.86 53.76 78 67
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Table D.2c: Top hundred drug and adverse event pairs selected by P-G model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
NONOXYNOL DEVICE MIGRATION 800 13.275 60.27 56.12 2045 311 57.41 53.65 83 68
FLUNISOLIDE NASAL SEPTUM DIS 75 0.431 174.04 136.91 344 90 67.46 53.42 56 69
MICONAZOLE VULVOVAGINITIS 234 3.168 73.87 64.71 1471 248 60.83 53.36 74 70
DINOPROSTONE UTER SPASM 56 0.147 381.61 286.21 72 30 67.77 52.08 55 71
RUBELLA VIRUS VACCINE, LIVE LYMPHADENO 115 1.162 98.97 80.9 925 179 62.41 51.85 71 72
BOTULINUM TOXIN A PTOSIS 60 0.238 252.56 189.42 173 59 65.29 50.05 61 73
OXYTOCIN LABOR ABNORM 105 1.043 100.68 81.5 887 176 60.97 49.69 73 74
DORNASE ALFA HEMOPTYSIS 64 0.336 190.37 145.75 301 83 63.18 49.62 66 75
BSS PLUS CORNEAL OPACITY 52 0.129 402.19 293.91 65 28 64.17 48.66 62 76
FLOSEQUINAN DEATH 109 1.204 90.5 73.89 1092 203 57.94 47.97 81 77
NAFARELIN ACETATE HEM VAGINAL 506 9.008 56.17 51.29 2260 349 52.2 47.72 94 78
ATRACURIUM BESYLATE PARALYSIS FLACCID 100 1.051 95.13 77.06 988 193 57.81 47.2 82 79
TICE BCG CYSTITIS 69 0.475 145.35 111.64 457 119 59.9 47.2 77 80
BUTORPHANOL DRUG DEPEND 457 8.165 55.97 50.95 2270 353 51.71 47.13 95 81
PRILOCAINE PARESTH CIRCUMORAL 200 2.995 66.77 57.75 1742 304 54.39 47.11 90 82
OXYTETRACYCLINE DISCOLOR TOOTH 74 0.599 123.49 96.79 633 138 57.98 45.96 80 83
TICE BCG GRANULOMA 55 0.23 239.15 178.27 192 64 60.29 45.91 75 84
INSULIN NOVOLIN 70/30 HYPERGLYCEM 484 8.959 54.02 49.22 2408 370 50.16 45.85 104 85
PROCAINAMIDE LE SYND 471 8.679 54.27 49.43 2386 367 50.38 45.84 102 86
NONOXYNOL BALANITIS 51 0.166 306.82 228.61 116 47 60.25 45.61 76 87
ISOTRETINOIN BLIND NIGHT 140 1.94 72.15 60.3 1524 286 53.37 45.21 92 88
SOMATROPIN OTITIS MED 101 1.147 88.07 71.5 1143 218 55.28 45.21 86 89
COPPER UTER RUPT 270 4.665 57.88 51.02 2170 352 50.65 44.99 99 90
ISOTRETINOIN CHEILITIS 380 6.983 54.42 48.97 2372 374 49.59 44.92 108 91
DURANEST W/EPINEPHRINE TRISMUS 46 0.073 628.21 450.67 33 19 61.05 44.88 72 92
RITONAVIR PARESTH CIRCUMORAL 217 3.566 60.84 52.99 2005 332 51.12 44.54 97 93
FOSCARNET SODIUM HYPOCALCEM 99 1.149 86.18 69.64 1184 226 54.16 44.44 91 94
PHOTOPLEX PHOTOSENSITIVITY 156 2.359 66.13 55.96 1766 314 51.38 43.93 96 95
DTP VACCINE SIDS 207 3.495 59.23 51.21 2095 350 49.64 43.62 106 96
CEFACLOR SERUM SICK 3164 69.702 45.39 43.81 3063 438 44.97 43.44 131 97
CLOMIPHENE OVAR DIS 163 2.567 63.5 53.76 1882 326 50.17 43.18 103 98
PRED-G PAIN EYE 644 13.125 49.07 45.33 2739 417 46.64 43.11 122 99
BUTOCONAZOLE NITRATE VAGINITIS 1072 22.835 46.94 44.14 2902 434 45.58 42.9 126 100
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Figure E.1: Histogram of φs for C-IG and Data 1. The superimposed density curve (in red)
represents the Gamma distribution corresponding to the MCMC estimates of the posterior
means of ϕ and ψ.
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Figure E.2: Acf plots of ϕ, ψ, ν and the logarithm of the target distribution for C-IG and
Data 1.
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Figure E.3: Trace plots of ϕ, ψ, ν and the logarithm of the target distribution for three
chains, for C-IG and Data 1.
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Figure E.4: Bayesian p-value scatter plots for C-IG and Data 1. (a) Plot of logarithm of X2
against logarithm of X1, and (b) Plot of logarithm of SD against logarithm of OD . The red line
is the line of equality.
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Figure E.5: (a) Logarithm of the 95% posterior intervals of φ against the logarithm of the reporting
rate RR for the C-IG model. The plotted values are for 500 drug and adverse event pairs randomly
sampled from Data 1, and (b) Logarithm of posterior medians of φ against the logarithm of the
reporting rate RR for C-IG model. The plotted values are for 1000 drug and adverse event pairs
randomly sampled from Data 1.
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Figure E.6: (a) Scatter plot of logarithm of posterior means of φ for Data 1 against corresponding
values for Data 2, and (b) Scatter plot of logarithm of mean of φ for Data 1 against corresponding
values for Data 3. The plots were made with the top 10000 corresponding values from the two
data sets under consideration.
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Table E.1: Values of original counts, mean replicate counts, expected counts, RR and φ
for fifty randomly selected drug and side-effect pairs using C-IG model and Data 1.
Count Mean Rep. Expected RR φ
Count Count
7 6.7 11.218 0.62 0.60
6 5.3 5.973 1.00 0.90
0 0.0 0.004 0.00 1.04
666 665.2 695.539 0.96 0.96
0 0.4 0.915 0.00 0.50
44 42.4 6.070 7.25 7.00
0 0.0 0.039 0.00 0.93
111 109.4 0.721 154.02 152.10
0 0.00 0.030 0.00 0.92
28 26.7 0.031 889.14 848.22
32 30.4 0.047 685.52 652.89
7 6.2 6.866 1.02 0.92
1 0.9 1.245 0.80 0.70
1 0.8 0.997 1.00 0.80
1 0.7 0.765 1.31 0.91
1 0.5 0.369 2.71 1.43
1 0.7 0.820 1.22 0.87
0 0.2 0.339 0.00 0.63
26 24.6 0.037 707.23 668.36
7 5.6 0.018 399.26 320.48
6 5.2 4.814 1.25 1.08
2022 2021.1 132.310 15.28 15.27
6 4.7 0.010 576.05 451.76
1021 1021.2 1701.710 0.60 0.60
637 635.7 606.791 1.05 1.05
1211 1209.4 739.652 1.64 1.64
933 932.4 854.123 1.09 1.09
1039 1037.8 380.965 2.73 2.73
56 54.4 0.147 381.61 371.58
1 0.5 0.409 2.44 1.30
46 44.5 0.073 628.21 610.41
2 1.5 1.625 1.23 0.94
3664 3663.3 325.306 11.26 11.26
1608 1607.9 1421.430 1.13 1.13
82 80.7 0.105 780.57 768.57
1 0.3 0.206 4.85 1.82
1032 1030.1 519.620 1.99 1.98
594 592.9 392.751 1.51 1.51
3 2.3 2.468 1.22 0.96
2 1.2 0.845 2.37 1.50
66 65.0 55.168 1.20 1.18
0 0.8 2.436 0.00 0.35
19 20.6 93.931 0.20 0.22
306 303.9 0.198 1543.39 1534.57
306 303.9 0.198 1543.39 1534.57
6 4.5 0.004 1577.25 1221.66
10 8.6 0.023 431.67 373.13
1 0.3 0.198 5.05 1.84
3 2.2 1.432 2.09 1.54
5 4.5 4.914 1.02 0.91
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Table E.2a: Top hundred drug and adverse event pairs selected by C-IG model based on the lower bound (φ025) of the 95% credible interval
estimate of φ using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
PERDIEM STENO ESOPH 65 0.024 2694.87 2072.98 3 1 2608.96 2037.79 1 1
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 1572.53 1405.13 3 2
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 9 3 1532.35 1371.54 4 3
TROLAMINE OTITIS EXT 14 0.007 1895.68 947.84 4 4 1643.85 939.7 2 4
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 711.35 644.78 11 5
ETIDOCAINE TRISMUS 82 0.105 780.57 618.74 17 7 764.01 615.81 10 6
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 776.1 615.65 9 7
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 26 9 674.91 602.98 13 8
HYDROCORTISONE-NEOMYCIN-POLYMYXIN B PAIN EAR 37 0.041 895.62 629.35 13 6 848.96 597.62 7 9
BSS OPHTHALMITIS 28 0.031 889.14 571.59 14 10 833.56 571.76 8 10
DIANEAL PERITONITIS 150 0.228 658.94 553.51 28 11 650.64 555.34 15 11
PANCRELIPASE STENO INTEST COLON 34 0.047 727.21 491.94 18 13 686.62 486.88 12 12
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.093 647.58 485.69 30 14 627.95 486.86 18 13
COLFOSCERIL PALMITATE HEM LUNG 41 0.06 681.25 481.86 25 15 650.23 476.81 16 14
KOATE HIV SYND 7 0.004 1578.59 451.03 7 17 1160.35 453.69 5 15
DURANEST W/EPINEPHRINE TRISMUS 46 0.073 628.21 450.67 33 19 604.22 452.32 19 16
BSS PLUS OPHTHALMITIS 32 0.047 685.52 449.87 24 20 642.83 445.76 17 17
CHOLINE OPHTHALMITIS 58 0.098 594.08 450.68 35 18 573.9 440.61 20 18
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 486.96 438.27 23 19
CHLOROXINE HAIR DISCOLOR 26 0.037 707.23 462.42 21 16 656.26 437.09 14 20
HEMOFIL M HEPATITIS HBSAG 6 0.004 1577.25 525.75 8 12 1103.44 406.05 6 21
METIPRANOLOL IRITIS 22 0.035 623.42 368.39 34 22 573.82 373.22 21 22
SODIUM HYALURONATE IRITIS 21 0.038 551.61 341.47 39 23 501.76 324.79 22 23
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 91 25 343.8 305.04 45 24
SODIUM HYALURONATE OPHTHALMITIS 20 0.038 529.86 317.91 43 24 476.61 301.07 25 25
CORTISPORIN PAIN EAR 132 0.37 356.64 297.2 81 26 351.69 299.79 43 26
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 94 27 334.42 292.53 47 27
BSS PLUS CORNEAL OPACITY 52 0.129 402.19 293.91 65 28 389.08 290.55 33 28
LOTRISONE SKIN STRIAE 17 0.032 526.76 278.87 44 32 469.59 284.78 27 29
DINOPROSTONE UTER SPASM 56 0.147 381.61 286.21 72 30 368.36 282.62 37 30
EMBOLEX VASOSPASM 19 0.038 505.85 292.86 45 29 455.23 275.07 28 31
MIVACURIUM CHLORIDE CHOLINESTERASE DEC 16 0.032 502.05 282.4 46 31 446.01 261.32 29 32
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.329 315.65 257.98 108 34 310.16 257.62 49 33
MYSTECLIN F ANOMALY TOOTH 28 0.07 401.12 257.86 66 35 374.86 257.4 35 34
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Table E.2b: Top hundred drug and adverse event pairs selected by C-IG model based on the lower bound (φ025) of the 95% credible interval
estimate of φ using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
DOXACURIUM CHLORIDE PARALYSIS FLACCID 16 0.033 484.79 272.69 49 33 429.05 257.09 30 35
DOXYLAMINE HANGOVER 44 0.125 351.27 247.48 88 37 335.38 248.7 46 36
BENZOCAINE METHEMOGLOBIN 29 0.077 376.93 246.96 74 38 354.55 245.26 41 37
MYSTECLIN F DISCOLOR TOOTH 134 0.458 292.78 244.72 130 39 288.33 244.31 62 38
PHENIRAMINE MYDRIASIS 26 0.067 387.95 253.66 70 36 359.88 243.81 39 39
OXYTOCIN HEM POSTPARTUM 103 0.346 297.96 242.99 124 40 292.55 241.33 58 40
CALCIPOTRIENE PSORIASIS 47 0.142 331 239.45 99 41 318.19 238.29 48 41
METHYSERGIDE FIBRO RETROPERIT 87 0.29 300.36 238.21 122 43 292.93 238.18 56 42
DESOXIMETASONE SKIN STRIAE 10 0.017 590.6 236.24 36 45 483.42 237.74 24 43
BSS KERATITIS 74 0.243 305.12 239.15 118 42 297.29 236.07 53 44
CHOLINE CORNEAL OPACITY 77 0.26 295.96 230.62 128 46 288.26 229.95 63 45
NONOXYNOL BALANITIS 51 0.166 306.82 228.61 116 47 297.65 229.07 52 46
PANCRELIPASE STENO INTEST 16 0.038 423.38 238.15 61 44 374.44 216.86 36 47
SODIUM HYALURONATE CORNEAL OPACITY 30 0.094 319.8 213.2 103 49 300.87 209.61 50 48
APROTININ BOVINE THROM CORONARY 13 0.029 452.15 208.68 57 50 387.27 209.08 34 49
GEMCITABINE HYDROCHLORIDE CARCINOMA GI 225 0.952 236.39 205.92 200 51 233.96 206.42 80 50
OXYTOCIN UTER ATONY 32 0.105 306.03 200.83 117 52 289.16 201.76 61 51
BUDESONIDE NASAL SEPTUM DIS 28 0.091 309.31 198.84 113 53 289.59 197.76 60 52
ISOSORBIDE MONONITRATE HEADACHE VASC 40 0.141 283.71 198.59 140 54 269.48 197.7 68 53
SODIUM HYALURONATE KERATITIS 70 0.274 255.2 196.87 167 55 248.36 195.52 76 54
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 234 56 212.94 193.03 96 55
HEMOFIL HIV SYND 22 0.069 318.09 187.96 106 60 291.53 192.07 59 56
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 224 58 217.74 191.28 93 57
BOTULINUM TOXIN A PTOSIS 60 0.238 252.56 189.42 173 59 245.44 190.67 78 58
HEPARIN SODIUM IN DEXTROSE ANTICOAG DEC 29 0.105 275.05 180.21 147 62 257.23 180.52 73 59
PYRIDOSTIGMINE CHOLINERG SYND 10 0.023 439.56 175.82 58 65 360.24 179.2 38 60
CHYMOTRYPSIN KERATITIS 22 0.072 304.72 180.06 119 63 280.06 178.41 66 61
HEMOFIL M HIV SYND 10 0.023 431.67 172.67 60 68 353.62 177.5 42 62
TICE BCG GRANULOMA 55 0.23 239.15 178.27 192 64 230.42 176.37 82 63
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 252 67 203.98 174.39 99 64
DELADUMONE OB HIRSUTISM 21 0.071 295.96 183.21 129 61 269.81 172.08 67 65
NORGESTREL CARCINOMA CERVIX SIT 6 0.009 677.3 225.77 27 48 471.96 169.3 26 66
RIFABUTIN UVEITIS 134 0.665 201.45 168.37 265 70 198.75 167.35 100 67
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Table E.2c: Top hundred drug and adverse event pairs selected by C-IG model based on the lower bound (φ025) of the 95% credible interval
estimate of φ using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
CARBOPROST HEM POSTPARTUM 14 0.041 339.82 169.91 93 69 297.68 167.22 51 68
HYALURONIDASE STRABISMUS 32 0.13 246.93 162.05 180 72 232.42 164.4 81 69
CREON STENO INTEST COLON 6 0.01 576.05 192.02 37 57 408.72 156.41 31 70
BSS CORNEAL OPACITY 21 0.077 271.35 167.98 150 71 248.2 155.79 77 71
BSS PLUS UVEITIS 17 0.059 287.91 152.43 134 80 255.38 153.69 74 72
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 378 77 162.64 153.4 129 73
DIETHYLSTILBESTROL ANOMALY CONGEN 2811 17.749 158.37 152.57 398 79 158.32 153.02 139 74
MIVACURIUM CHLORIDE INCREASED EFFECT 319 1.865 171.02 152.26 356 81 170.15 152.56 120 75
BUSULFAN VENOOCCLUS LIVER SYN 21 0.081 260.1 161.01 160 73 237 152.23 79 76
FLUCLOXACILLIN STENO INTEST COLON 8 0.017 468.79 175.8 51 66 357.85 151.89 40 77
LOTRISONE ATROPHY SKIN 26 0.109 237.95 155.58 197 76 220.58 147.76 92 78
METIPRANOLOL UVEITIS 25 0.105 238.78 152.82 193 78 221.14 147.7 91 79
HETASTARCH HEMOTHORAX 21 0.083 253.02 156.63 170 75 229.02 145.26 83 80
LOTRISONE DERM FUNG 15 0.053 285.44 152.24 138 82 250.9 144.71 75 81
DORNASE ALFA HEMOPTYSIS 64 0.336 190.37 145.75 301 83 184.6 143.3 110 82
BSS PLUS IRITIS 13 0.042 308.04 142.17 115 86 266.1 143.02 69 83
SOMATREM NEOPL CNS 52 0.273 190.7 139.36 299 88 184.28 141.56 111 84
FLUNISOLIDE NASAL SEPTUM DIS 75 0.431 174.04 136.91 344 90 170.16 136.79 119 85
PROTIRELIN URIN URGENCY 9 0.025 357.13 158.72 80 74 283.38 136.12 65 86
CHOLINE KERATITIS 116 0.703 164.99 135.12 372 91 162.61 136.01 130 87
CHYMOTRYPSIN CORNEAL OPACITY 11 0.035 311.16 141.44 112 87 261.72 135.37 72 88
PRILOCAINE HYPALGESIA 21 0.09 234.17 144.96 201 85 214.75 134.49 95 89
NORGESTREL NEOPL CERVIX 5 0.008 636.53 127.31 32 99 400.76 133.84 32 90
METFORMIN ACIDOSIS LACTIC 309 2.074 149.02 132.62 437 94 148.03 133.03 154 91
TETRACYCLINE DISCOLOR TOOTH 1437 10.485 137.05 130 510 95 136.88 130.13 167 92
CHOLINE IRITIS 22 0.101 217.17 128.33 227 96 198.23 127.74 101 93
BENDECTIN ECTROMELIA 111 0.721 154.02 126.27 415 100 151.51 126.51 147 94
CARBACHOL CORNEAL OPACITY 22 0.104 211.66 125.07 239 101 194.22 125.31 105 95
NONOXYNOL CERVIX DIS 1074 8.161 131.61 123.77 552 104 131.36 124.07 177 96
PANALBA K.M. ANOMALY TOOTH 8 0.022 369.52 138.57 76 89 284.03 123.34 64 97
CHYMOTRYPSIN IRITIS 7 0.018 399.26 114.08 67 114 294.92 122.91 55 98
MAXITROL HEALING ABNORM 14 0.056 248.73 124.36 176 102 216.86 120.96 94 99
BETHANECHOL CHLORIDE CHOLINERG SYND 12 0.045 269.03 134.52 152 92 228.4 120.92 84 100
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Figure E.7: Acf plots of ϕ, ψ, ν and the logarithm of the target distribution for C-IG and Data 2.
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Figure E.8: Trace plots of ϕ, ψ, ν and the logarithm of the target distribution for three chains,
for C-IG and Data 2.
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Figure E.9: Bayesian p-value scatter plots for C-IG and Data 2. (a) Plot of logarithm of X2
against logarithm of X1, and (b) Plot of logarithm of SD against logarithm of OD . The red line
is the line of equality.
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Figure E.10: (a) Logarithm of the 95% posterior intervals of φ against the logarithm of the
reporting rate RR for the C-IG model. The plotted values are for 500 drug and adverse event pairs
randomly sampled from Data 2, and (b) Logarithm of posterior medians of φ against the logarithm
of the reporting rate RR for C-IG model. The plotted values are for 1000 drug and adverse event
pairs randomly sampled from Data 2.
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Figure E.11: (a) Scatter plot of logarithm of φ025 against the logarithm of RR025 for C-IG and
Data 2, and (b) Histogram of φs for C-IG and Data 2. The superimposed density curve (in red)
represents the Gamma distribution corresponding to the MCMC estimates of the posterior means
of ϕ and ψ.
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Table E.3: Values of original counts, mean replicate counts, expected counts, RR and φ
for fifty randomly selected drug and side-effect pairs using C-IG a model and Data 2.
Count Mean Rep. Expected RR φ
Count Count
1 0.1 0.000 2816.96 1.15
18 12.7 5.957 3.02 1.87
3 1.4 0.339 8.84 1.18
1 0.2 0.001 694.57 1.14
175 168.7 43.911 3.99 3.80
64 58.8 42.377 1.51 1.36
527 519.3 79.506 6.63 6.52
2 4.2 4.698 0.43 0.55
1 1.4 0.471 2.12 0.79
5 5.5 5.663 0.88 0.67
15 11.4 8.162 1.84 1.20
22 16.8 9.189 2.39 1.65
579 573.7 452.946 1.28 1.26
1481 1473.2 54.248 27.30 27.11
3 3.6 3.064 0.98 0.70
22 18.7 17.797 1.24 0.97
58 49.2 0.098 594.08 492.22
12 19.0 53.081 0.23 0.33
803 794.9 142.740 5.63 5.55
7 4.4 2.600 2.69 1.13
6 0.6 0.010 576.05 8.14
1 1.8 0.880 1.14 0.73
1 0.2 0.002 559.28 1.17
1 0.9 0.160 6.25 0.89
10 2.1 0.017 590.60 61.75
1 1.5 0.616 1.62 0.78
150 141.6 0.228 658.94 617.70
13 11.0 10.760 1.21 0.88
1 1.5 0.570 1.75 0.81
1 3.1 2.780 0.36 0.57
7 2.4 0.418 16.76 2.74
46 37.7 0.073 628.21 496.75
1 2.3 1.519 0.66 0.66
1 2.1 1.298 0.77 0.68
604 598.4 532.731 1.13 1.12
1 2.4 1.708 0.59 0.65
8 6.3 5.231 1.53 0.91
1 1.6 0.597 1.67 0.78
1006 999.8 749.688 1.34 1.33
1196 1195.5 2962.320 0.40 0.40
1094 1087.5 202.805 5.39 5.35
642 638.1 775.209 0.83 0.82
773 764.6 62.563 12.36 12.19
1 1.4 0.431 2.32 0.79
1 3.2 3.125 0.32 0.56
37 28.7 0.041 895.62 656.98
1 2.9 2.429 0.41 0.60
1 2.4 1.623 0.62 0.65
3 3.8 3.550 0.85 0.66
18 18.3 30.366 0.59 0.56
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Table E.4a: Top hundred drug and adverse event pairs selected by C-IG model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 2. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
PERDIEM STENO ESOPH 65 0.024 2694.87 2072.98 3 1 2209.21 1263.23 1 1
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 1526.45 1202.43 2 2
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 9 3 1488.24 1181.98 3 3
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 692.25 567.73 4 4
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 26 9 653.88 517.17 7 5
DIANEAL PERITONITIS 150 0.228 658.94 553.51 28 11 609.31 433.17 9 6
ETIDOCAINE TRISMUS 82 0.105 780.57 618.74 17 7 670.42 396.29 5 7
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 665.22 391.01 6 8
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 473.51 382.77 14 9
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.093 647.58 485.69 30 14 520.5 282.58 10 10
CHOLINE OPHTHALMITIS 58 0.098 594.08 450.68 35 18 473.31 259.61 15 11
HYDROCORTISONE-NEOMYCIN-POLYMYXIN B PAIN EAR 37 0.041 895.62 629.35 13 6 610.71 256.65 8 12
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 91 25 329.98 252.26 20 13
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 94 27 319.86 242.12 22 14
DURANEST W/EPINEPHRINE TRISMUS 46 0.073 628.21 450.67 33 19 469.94 228.61 16 15
CORTISPORIN PAIN EAR 132 0.37 356.64 297.2 81 26 324.94 223.41 21 16
COLFOSCERIL PALMITATE HEM LUNG 41 0.06 681.25 481.86 25 15 487.53 219.13 12 17
PANCRELIPASE STENO INTEST COLON 34 0.047 727.21 491.94 18 13 477.99 194.9 13 18
MYSTECLIN F DISCOLOR TOOTH 134 0.458 292.78 244.72 130 39 268.19 186.37 27 19
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.329 315.65 257.98 108 34 280.13 183.25 26 20
BSS OPHTHALMITIS 28 0.031 889.14 571.59 14 10 516.13 173.51 11 21
OXYTOCIN HEM POSTPARTUM 103 0.346 297.96 242.99 124 40 262.41 171.23 28 22
GEMCITABINE HYDROCHLORIDE CARCINOMA GI 225 0.952 236.39 205.92 200 51 224.5 169.18 37 23
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 234 56 207.55 168.98 43 24
DINOPROSTONE UTER SPASM 56 0.147 381.61 286.21 72 30 303.04 167.59 24 25
BSS PLUS OPHTHALMITIS 32 0.047 685.52 449.87 24 20 434.12 166.14 17 26
BSS PLUS CORNEAL OPACITY 52 0.129 402.19 293.91 65 28 312.59 165.81 23 27
METHYSERGIDE FIBRO RETROPERIT 87 0.29 300.36 238.21 122 43 260.64 162.5 29 28
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 224 58 208.1 157.54 42 29
CHOLINE CORNEAL OPACITY 77 0.26 295.96 230.62 128 46 251.46 151.62 32 30
BSS KERATITIS 74 0.243 305.12 239.15 118 42 255.01 149.65 31 31
DIETHYLSTILBESTROL ANOMALY CONGEN 2811 17.749 158.37 152.57 398 79 157.77 147.12 58 32
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 378 77 161.1 143.45 56 33
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 252 67 192.24 139.33 49 34
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Table E.4b: Top hundred drug and adverse event pairs selected by C-IG model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 2. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
MIVACURIUM CHLORIDE INCREASED EFFECT 319 1.865 171.02 152.26 356 81 165.07 131.08 55 35
DOXYLAMINE HANGOVER 44 0.125 351.27 247.48 88 37 257.63 127.91 30 36
RIFABUTIN UVEITIS 134 0.665 201.45 168.37 265 70 183.4 126.25 51 37
SODIUM HYALURONATE KERATITIS 70 0.274 255.2 196.87 167 55 213.07 125.13 41 38
CHLOROXINE HAIR DISCOLOR 26 0.037 707.23 462.42 21 16 385.28 124.2 18 39
NONOXYNOL BALANITIS 51 0.166 306.82 228.61 116 47 236.67 123.41 35 40
TETRACYCLINE DISCOLOR TOOTH 1437 10.485 137.05 130 510 95 136.05 122.3 68 41
CALCIPOTRIENE PSORIASIS 47 0.142 331 239.45 99 41 246.34 119.29 33 42
BOTULINUM TOXIN A PTOSIS 60 0.238 252.56 189.42 173 59 203.91 117.04 44 43
NONOXYNOL CERVIX DIS 1074 8.161 131.61 123.77 552 104 130.3 115.88 71 44
METFORMIN ACIDOSIS LACTIC 309 2.074 149.02 132.62 437 94 143.47 113.55 65 45
SELENIUM SULFIDE HAIR DISCOLOR 301 2.236 134.64 119.43 526 107 129.52 102.82 74 46
TICE BCG GRANULOMA 55 0.23 239.15 178.27 192 64 187.8 100.59 50 47
OPCON A PAIN EYE 267 2.015 132.49 116.61 547 109 126.67 99.23 77 48
CHOLINE KERATITIS 116 0.703 164.99 135.12 372 91 146.76 98.62 63 49
PHENFORMIN ACIDOSIS LACTIC 390 3.302 118.11 106.61 681 124 114.82 94.08 87 50
BENDECTIN ECTROMELIA 111 0.721 154.02 126.27 415 100 137.99 91.63 66 51
POLIOVIRUS VACCINE, LIVE, ORAL SIDS 146 1.038 140.6 118.45 484 108 128.86 91.31 75 52
ISOSORBIDE MONONITRATE HEADACHE VASC 40 0.141 283.71 198.59 140 54 200.35 90.61 45 53
COPPER UTER DIS 4457 46.398 96.06 93.26 975 151 95.9 90.42 105 54
TETRAHYDROZOLINE PAIN EYE 187 1.43 130.77 112.59 557 117 122.51 89.88 79 55
DORNASE ALFA HEMOPTYSIS 64 0.336 190.37 145.75 301 83 155.66 89.08 59 56
FLUNISOLIDE NASAL SEPTUM DIS 75 0.431 174.04 136.91 344 90 146.77 87.84 62 57
CEFOXITIN ENTEROCOL PSEUDOMEM 138 1.016 135.79 113.16 517 116 124.08 87.31 78 58
DTP VACCINE SCREAMING SYND 966 9.643 100.18 93.95 897 147 99.1 87.28 103 59
MENOTROPINS OVAR DIS 151 1.175 128.48 108.06 583 122 118.76 85.15 84 60
GONADOTROPIN, CHORIONIC OVAR DIS 86 0.567 151.69 119.94 423 106 129.83 82.41 73 61
POLIOVIRUS VACCINE, LIVE, ORAL SCREAMING SYND 344 3.28 104.89 93.91 831 148 101.51 81.8 98 62
MYSTECLIN F ANOMALY TOOTH 28 0.07 401.12 257.86 66 35 229.43 79.83 36 63
MITOMYCIN UREMIA 218 1.995 109.29 95.26 785 142 103.35 78.93 96 64
BENZOCAINE METHEMOGLOBIN 29 0.077 376.93 246.96 74 38 224.38 78.64 38 65
DIPHTHERIA-TETANUS TOXOID-PERTUSSIS VA SCREAMING SYND 147 1.22 120.47 101.62 654 130 110.78 78.53 91 66
SOMATREM NEOPL CNS 52 0.273 190.7 139.36 299 88 148.11 76.92 60 67
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Table E.4c: Top hundred drug and adverse event pairs selected by C-IG model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 2. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
LOMEFLOXACIN HYDROCHLORIDE PHOTOSENSITIVITY 481 5.137 93.64 85.27 1023 166 91.48 76.41 108 68
OXYTOCIN UTER ATONY 32 0.105 306.03 200.83 117 52 195.33 76.39 48 69
METIPRANOLOL IRITIS 22 0.035 623.42 368.39 34 22 290.01 75.46 25 70
PILOCARPINE MIOSIS 103 0.812 126.83 103.44 601 128 112.58 73.68 89 71
SODIUM HYALURONATE CORNEAL OPACITY 30 0.094 319.8 213.2 103 49 195.47 73.36 47 72
OXYTOCIN FETAL DIS 95 0.759 125.14 100.11 616 133 109.78 72.36 92 73
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM INTRACRAN 476 5.426 87.73 79.99 1150 184 85.33 71.07 120 74
TICE BCG CYSTITIS 69 0.475 145.35 111.64 457 119 120.82 70.84 80 75
HAEMOPHILUS B POLYSACCHARIDE VACCINE MENINGITIS 176 1.711 102.86 87.66 851 164 95.67 69.67 106 76
TETRAHYDROZOLINE CONJUNCTIVITIS 230 2.454 93.73 81.91 1021 174 89.05 68.73 115 77
PHENIRAMINE MYDRIASIS 26 0.067 387.95 253.66 70 36 213.36 67.65 40 78
UROKINASE CHILLS 831 10.942 75.95 70.83 1426 220 74.81 65.87 142 79
INFLUENZA VIRUS VACCINE GUILLAIN BARRE SYND 62 0.451 137.47 104.21 507 127 111.21 62.54 90 80
COPPER SALPINGITIS 1484 21.323 69.6 66.08 1635 238 69 62.39 153 81
BUDESONIDE NASAL SEPTUM DIS 28 0.091 309.31 198.84 113 53 178.83 62.25 52 82
OXYTETRACYCLINE DISCOLOR TOOTH 74 0.599 123.49 96.79 633 138 103.92 61.76 95 83
HEPARIN SODIUM IN DEXTROSE ANTICOAG DEC 29 0.105 275.05 180.21 147 62 166.91 61.63 54 84
SUPROFEN PAIN BACK 399 5.188 76.91 69.39 1404 227 74.67 61.14 143 85
RUBELLA VIRUS VACCINE, LIVE LYMPHADENO 115 1.162 98.97 80.9 925 179 88.62 60.71 116 86
NONOXYNOL LEUKORRHEA 603 8.344 72.27 66.51 1516 235 70.91 60.24 147 87
MICONAZOLE VAGINITIS 2262 34.851 64.9 62.24 1818 271 64.59 59.65 175 88
INTRAUTERINE DEVICE UTER DIS 251 3.127 80.26 70.35 1328 224 76.64 59.6 138 89
HYALURONIDASE STRABISMUS 32 0.13 246.93 162.05 180 72 157.88 59.14 57 90
OXYTOCIN LABOR ABNORM 105 1.043 100.68 81.5 887 176 89.69 59.12 112 91
FLOSEQUINAN SUDDEN DEATH 49 0.315 155.79 114.46 404 111 118.51 59.03 85 92
COPPER DEVICE MIGRATION 1490 22.868 65.16 61.88 1811 272 64.69 58.17 174 93
COPPER PAIN PELVIC 1962 30.696 63.92 61.12 1861 278 63.51 58.17 182 94
UROFOLLITROPIN OVAR DIS 46 0.289 159.3 114.28 394 112 119.27 57.16 82 95
ALCOHOL ALCOHOL INTOLER 169 2.006 84.26 71.8 1233 215 78.18 56.96 133 96
THIMEROSAL DERM CONTACT 62 0.501 123.84 93.88 631 149 100.59 56.72 101 97
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM CEREBR 695 10.419 66.71 61.81 1744 274 65.57 56.49 169 98
SODIUM HYALURONATE IRITIS 21 0.038 551.61 341.47 39 23 246.33 56.47 34 99
TIOCONAZOLE VAGINITIS 268 3.558 75.32 66.33 1442 236 71.82 56.17 146 100
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Figure E.12: Acf plots of ϕ, ψ, ν and the logarithm of the target distribution for C-IG and Data
3.
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Figure E.13: Trace plots of ϕ, ψ, ν and the logarithm of the target distribution for three chains,
for C-IG and Data 3.
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Figure E.14: Bayesian p-value scatter plots for C-IG and Data 3. (a) Plot of logarithm of X2
against logarithm of X1, and (b) Plot of logarithm of SD against logarithm of OD . The red line
is the line of equality.
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Figure E.15: (a) Logarithm of the 95% posterior intervals of φ against the logarithm of the
reporting rate RR for the C-IG model. The plotted values are for 500 drug and adverse event pairs
randomly sampled from Data 3, and (b) Logarithm of posterior medians of φ against the logarithm
of the reporting rate RR for C-IG model. The plotted values are for 1000 drug and adverse event
pairs randomly sampled from Data 3.
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Figure E.16: (a) Scatter plot of logarithm of φ025 against the logarithm of RR025 for C-IG and
Data 3, and (b) Histogram of φs for C-IG and Data 3. The superimposed density curve (in red)
represents the Gamma distribution corresponding to the MCMC estimates of the posterior means
of ϕ and ψ.
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Table E.5: Values of original counts, mean replicate counts, expected counts, RR and φ
for fifty randomly selected drug and side-effect pairs using C-IG model and Data 3.
Count Mean Rep. Expected RR φ
Count Count
10 8.7 3.771 2.65 0.94
684 661.6 141.379 4.84 4.62
23 21.6 19.812 1.16 0.80
527 513 477.337 1.10 1.06
89 82.5 88.794 1.00 0.87
527 500.6 79.506 6.63 6.22
28 4.0 0.031 889.14 26.41
1109 1082.5 162.189 6.84 6.64
5 8.9 5.020 1.00 0.74
3164 3133.4 69.702 45.39 44.88
6 9.8 6.055 0.99 0.73
10 12.7 9.937 1.01 0.74
53 33.4 11.698 4.53 2.36
26 3.7 0.037 707.23 16.89
9 12.5 9.014 1.00 0.72
58 28.4 0.098 594.08 231.22
896 877.5 533.355 1.68 1.63
107 99.7 106.067 1.01 0.88
151 141.6 142.483 1.06 0.95
9 12.1 8.989 1.00 0.73
6 6.8 2.228 2.69 0.88
11 13.5 11.050 1.00 0.73
199 170.9 20.056 9.92 8.26
26 37.5 65.969 0.39 0.48
1062 1049.7 904.794 1.17 1.15
126 107.9 58.529 2.15 1.74
20 27.6 38.710 0.52 0.57
695 681.5 684.336 1.02 0.99
5 8.4 4.241 1.18 0.75
8 9.9 5.329 1.50 0.80
17 14.5 9.548 1.78 0.92
7 10.7 7.001 1.00 0.73
10 7.8 2.704 3.70 1.01
1404 1379.2 455.788 3.08 3.02
544 557.4 1218.600 0.45 0.45
557 558.3 917.305 0.61 0.60
1400 1375.5 472.530 2.96 2.91
843 827.9 756.036 1.12 1.09
26 32.9 46.838 0.56 0.58
579 562.2 198.300 2.92 2.78
580 567.4 505.762 1.15 1.11
9 12.1 9.005 1.00 0.73
306 275.9 0.198 1543.39 1365.45
6 1.3 0.004 1577.25 1.29
14 12.0 6.678 2.10 0.94
55 65.5 119.829 0.46 0.50
387 356.4 0.542 714.05 648.96
293 261.8 0.185 1583.73 1387.17
11 13.8 11.036 1.00 0.72
10 12.6 9.043 1.11 0.76
A
P
P
E
N
D
IX
E
.
C
-IG
M
O
D
E
L
R
E
S
U
L
T
S
147
Table E.6a: Top hundred drug and adverse event pairs selected by C-IG model based on the lower bound (φ025) of the 95% credible interval
estimate estimate of φ, using Data 3. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated
RK1, RK11, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 3 2 1356.75 871.02 1 1
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 6 3 1333.86 853.83 2 2
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 12 5 638.13 438.99 4 3
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 16 9 581.32 371.57 5 4
OPCON A MYDRIASIS 351 0.717 489.53 439.33 31 21 431.71 288.62 7 5
DIANEAL PERITONITIS 150 0.228 658.94 553.51 18 11 477.72 234.56 6 6
PERDIEM STENO ESOPH 65 0.024 2694.87 2072.98 1 1 998.79 201.74 3 7
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 52 25 291.08 179.18 10 8
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 54 27 271.75 156.86 11 9
DIETHYLSTILBESTROL ANOMALY CONGEN 2811 17.749 158.37 152.57 165 79 156.05 137.07 23 10
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 111 56 191.89 131.51 16 11
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 158 77 157.32 128.63 22 12
ETIDOCAINE TRISMUS 82 0.105 780.57 618.74 10 7 390.71 124.08 8 13
CORTISPORIN PAIN EAR 132 0.37 356.64 297.2 49 26 246.26 112.45 12 14
GEMCITABINE HYDROCHLORIDE CARCINOMA GI 225 0.952 236.39 205.92 99 51 193.85 111.88 15 15
TETRACYCLINE DISCOLOR TOOTH 1437 10.485 137.05 130 198 94 133.12 110.23 29 16
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 106 58 181.3 105.67 18 17
NONOXYNOL CERVIX DIS 1074 8.161 131.61 123.77 212 103 126.34 102.11 31 18
MIVACURIUM CHLORIDE INCREASED EFFECT 319 1.865 171.02 152.26 148 81 149.07 97.07 25 19
MYSTECLIN F DISCOLOR TOOTH 134 0.458 292.78 244.72 73 39 202.06 96.26 14 20
COPPER UTER DIS 4457 46.398 96.06 93.26 321 150 95.16 85.86 43 21
METFORMIN ACIDOSIS LACTIC 309 2.074 149.02 132.62 174 93 129.9 83.73 30 22
BERACTANT HEM LUNG 71 0.089 797.58 617.84 9 8 338.02 82.78 9 23
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 118 67 154.75 81.19 24 24
DTP VACCINE SCREAMING SYND 966 9.643 100.18 93.95 303 146 95.66 76.1 42 25
SELENIUM SULFIDE HAIR DISCOLOR 301 2.236 134.64 119.43 203 106 116.54 75.44 32 26
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.329 315.65 257.98 59 34 191.45 72.61 17 27
PHENFORMIN ACIDOSIS LACTIC 390 3.302 118.11 106.61 247 123 105.65 72.17 37 28
OXYTOCIN HEM POSTPARTUM 103 0.346 297.96 242.99 70 40 178.46 72.02 19 29
OPCON A PAIN EYE 267 2.015 132.49 116.61 210 108 112.86 70.38 33 30
RIFABUTIN UVEITIS 134 0.665 201.45 168.37 123 70 140.69 63.91 26 31
POLIOVIRUS VACCINE, LIVE, ORAL SCREAMING SYND 344 3.28 104.89 93.91 285 147 92.37 60.68 46 32
LOMEFLOXACIN HYDROCHLORIDE PHOTOSENSITIVITY 481 5.137 93.64 85.27 335 164 85.35 60.59 50 33
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM INTRACRAN 476 5.426 87.73 79.99 364 182 79.78 56.98 53 34
A
P
P
E
N
D
IX
E
.
C
-IG
M
O
D
E
L
R
E
S
U
L
T
S
148
Table E.6b: Top hundred drug and adverse event pairs selected by C-IG model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 3. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
TETRAHYDROZOLINE PAIN EYE 187 1.43 130.77 112.59 214 116 101.88 56.7 38 35
UROKINASE CHILLS 831 10.942 75.95 70.83 426 216 72.02 56.37 58 36
COPPER SALPINGITIS 1484 21.323 69.6 66.08 487 233 67.63 56.35 62 37
MICONAZOLE VAGINITIS 2262 34.851 64.9 62.24 532 265 63.67 54.89 70 38
METHYSERGIDE FIBRO RETROPERIT 87 0.29 300.36 238.21 69 43 160.72 54.48 21 39
COPPER PAIN PELVIC 1962 30.696 63.92 61.12 543 272 62.58 53.61 74 40
COPPER DEVICE MIGRATION 1490 22.868 65.16 61.88 530 266 63.28 52.65 71 41
MITOMYCIN UREMIA 218 1.995 109.29 95.26 275 141 88.46 50.96 48 42
NONOXYNOL LEUKORRHEA 603 8.344 72.27 66.51 457 231 67.49 49.96 63 43
POLIOVIRUS VACCINE, LIVE, ORAL SIDS 146 1.038 140.6 118.45 189 107 101.54 49.77 39 44
TISSUE PLASMINOGEN ACTIVATOR, RECOMBIN HEM CEREBR 695 10.419 66.71 61.81 514 268 63.05 48.14 72 45
SUPROFEN PAIN BACK 399 5.188 76.91 69.39 421 223 69.02 46.89 61 46
MENOTROPINS OVAR DIS 151 1.175 128.48 108.06 221 121 93.37 46.63 45 47
CEFOXITIN ENTEROCOL PSEUDOMEM 138 1.016 135.79 113.16 200 115 96.23 46.06 41 48
COPPER FERTIL DEC FEM 695 10.997 63.2 58.56 553 287 59.62 45.87 80 49
CHOLINE KERATITIS 116 0.703 164.99 135.12 156 91 106.26 45.52 35 50
TETRAHYDROZOLINE CONJUNCTIVITIS 230 2.454 93.73 81.91 334 172 77.35 45.18 57 51
NONOXYNOL DEVICE MIGRATION 800 13.275 60.27 56.12 590 304 57.32 44.16 82 52
TRIAMCINOLONE ATROPHY INJECT SITE 439 6.303 69.65 63.14 483 254 62.81 44.04 73 53
DIPHTHERIA-TETANUS TOXOID-PERTUSSIS VA SCREAMING SYND 147 1.22 120.47 101.62 236 129 86.71 42.74 49 54
HAEMOPHILUS B POLYSACCHARIDE VACCINE MENINGITIS 176 1.711 102.86 87.66 291 162 78.74 41.73 55 55
INTRAUTERINE DEVICE UTER DIS 251 3.127 80.26 70.35 403 220 67.38 41.17 64 56
BENDECTIN ECTROMELIA 111 0.721 154.02 126.27 168 99 98.46 40.39 40 57
TRAZODONE PRIAPISM 347 5.117 67.81 60.77 502 276 59.98 40.24 78 58
TIOCONAZOLE VAGINITIS 268 3.558 75.32 66.33 431 232 63.79 39.65 67 59
CEFACLOR SERUM SICK 3164 69.702 45.39 43.81 845 426 44.79 39.51 108 60
CHOLINE CORNEAL OPACITY 77 0.26 295.96 230.62 71 46 139.96 39.01 27 61
BSS KERATITIS 74 0.243 305.12 239.15 67 42 137.5 38.56 28 62
NAFARELIN ACETATE HEM VAGINAL 506 9.008 56.17 51.29 636 341 51.7 37.64 88 63
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.093 647.58 485.69 19 14 207.29 36.82 13 64
BUTOCONAZOLE NITRATE VAGINITIS 1072 22.835 46.94 44.14 806 422 44.94 36.42 105 65
BUTORPHANOL DRUG DEPEND 457 8.165 55.97 50.95 639 344 50.95 36.37 90 66
MICONAZOLE VULVOVAGINITIS 234 3.168 73.87 64.71 442 243 60.55 36.28 76 67
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Table E.6c: Top hundred drug and adverse event pairs selected by C-IG model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 3. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
CEFUROXIME COLITIS PSEUDOMEM 1063 22.881 46.46 43.7 817 428 44.67 36.07 109 68
PROCAINAMIDE LE SYND 471 8.679 54.27 49.43 666 357 49.63 35.34 92 69
INSULIN NOVOLIN 70/30 HYPERGLYCEM 484 8.959 54.02 49.22 674 360 49.46 35.2 94 70
PRED-G PAIN EYE 644 13.125 49.07 45.33 765 405 46.02 34.76 103 71
ALCOHOL ALCOHOL INTOLER 169 2.006 84.26 71.8 381 211 63.74 33.25 69 72
ISOTRETINOIN CHEILITIS 380 6.983 54.42 48.97 664 364 48.52 33.17 98 73
INSULIN HUMAN HYPERGLYCEM 6200 170.45 36.37 35.47 1123 545 36.12 33.13 139 74
TRETINOIN DERM EXFOL 1213 29.963 40.48 38.21 982 494 39.07 31.96 127 75
COPPER UTER RUPT 270 4.665 57.88 51.02 614 343 48.96 31.34 97 76
PILOCARPINE MIOSIS 103 0.812 126.83 103.44 226 127 77.47 31.12 56 77
CLONIDINE DERM CONTACT 964 23.784 40.53 38.01 980 499 38.93 30.58 128 78
CEFIXIME COLITIS PSEUDOMEM 421 8.596 48.98 44.32 768 420 44.32 30.53 111 79
MINOXIDIL HIRSUTISM 1035 26.322 39.32 36.93 1006 518 37.91 30.44 133 80
PRILOCAINE PARESTH CIRCUMORAL 200 2.995 66.77 57.75 513 297 53.04 30.06 86 81
TIMOPTIC PAIN EYE 695 16.875 41.19 38.16 958 495 38.67 29.48 131 82
RITONAVIR PARESTH CIRCUMORAL 217 3.566 60.84 52.99 579 325 49.44 28.94 95 83
MINOXIDIL HAIR DIS 928 24.654 37.64 35.25 1073 548 35.93 28.12 140 84
ENOXAPARIN SODIUM HEM 342 7.257 47.13 42.17 800 441 41.86 28.04 118 85
RUBELLA VIRUS VACCINE, LIVE LYMPHADENO 115 1.162 98.97 80.9 307 177 63.78 27.91 68 86
SCOPOLAMINE MYDRIASIS 269 5.256 51.18 45.09 725 410 43.42 27.87 114 87
DTP VACCINE SIDS 207 3.495 59.23 51.21 601 342 47.66 27.15 100 88
RISPERIDONE PROLACTIN INC 360 7.978 45.12 40.49 853 462 39.9 27.05 124 89
TUBERCULIN, PURIFIED PROTEIN DERIVATIV INJECT SITE REACT 411 9.536 43.1 39.01 899 486 38.88 27.04 129 90
CHOLINE OPHTHALMITIS 58 0.098 594.08 450.68 23 18 174.03 26.98 20 91
GONADOTROPIN, CHORIONIC OVAR DIS 86 0.567 151.69 119.94 169 105 80.36 26.87 52 92
SODIUM HYALURONATE KERATITIS 70 0.274 255.2 196.87 86 55 105.85 26.66 36 93
BENOXAPROFEN NAIL DIS 382 8.665 44.09 39.7 879 476 39.32 26.57 125 94
CEFACLOR ARTHROSIS 1010 30.298 33.34 31.29 1261 653 32.05 25.61 163 95
PHOTOPLEX PHOTOSENSITIVITY 156 2.359 66.13 55.96 518 307 49.04 25.26 96 96
TRETINOIN SKIN DRY 750 21.028 35.67 33.15 1154 602 33.62 25.26 151 97
ISOTRETINOIN BLIND NIGHT 140 1.94 72.15 60.3 458 279 51.33 24.83 89 98
OXYTOCIN FETAL DIS 95 0.759 125.14 100.11 230 132 71.4 24.62 59 99
NONOXYNOL VAGINITIS 1141 36.497 31.26 29.45 1352 699 30.13 24.51 179 100
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Figure F.1: Histogram of φs for P-IG and Data 1. The superimposed density curve (in red)
represents the Inverse Gamma distribution corresponding to the MCMC estimates of the posterior
means of ϕ and ψ.
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Figure F.2: Acf plots of ϕ, ψ and the logarithm of the target distribution for P-IG and Data 1.
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Figure F.3: Trace plots of ϕ, ψ and the logarithm of the target distribution for three chains, for
P-IG and Data 1.
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Figure F.4: Bayesian p-value scatter plots for P-IG and Data 1. (a) Plot of logarithm of X2
against logarithm of X1, and (b) Plot of logarithm of SD against logarithm of OD . The red line
is the line of equality.
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Figure F.5: (a) Logarithm of the 95% posterior intervals of φ against the logarithm of the reporting
rate RR for the P-IG model. The plotted values are for 500 drug and adverse event pairs randomly
sampled from Data 1, and (b) Logarithm of posterior medians of φ against the logarithm of the
reporting rate RR for P-IG model. The plotted values are for 1000 drug and adverse event pairs
randomly sampled from Data 1.
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Figure F.6: Scatter plot of logarithm of φ025 against the logarithm of RR025 for P-IG and
Data 1.
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Table F.1: Values of original counts, mean replicate counts, expected counts, RR and φ
for fifty randomly selected drug and side-effect pairs using P-IG model and Data 1.
Count Mean Rep. Expected RR φ
Count Count
7 6.7 11.218 0.62 0.59
6 5.3 5.973 1.00 0.89
0 0.0 0.004 0.00 1.01
666 664.9 695.539 0.96 0.96
0 0.4 0.915 0.00 0.48
44 42.6 6.070 7.25 7.01
0 0.0 0.039 0.00 0.86
111 109.4 0.721 154.02 151.43
0 0.0 0.030 0.00 0.93
28 26.5 0.031 889.14 840.13
32 30.5 0.047 685.52 653.33
7 6.2 6.866 1.02 0.90
1 0.8 1.245 0.80 0.68
1 0.8 0.997 1.00 0.76
1 0.7 0.765 1.31 0.89
1 0.5 0.369 2.71 1.21
1 0.7 0.820 1.22 0.83
0 0.2 0.339 0.00 0.61
26 24.4 0.037 707.23 665.93
7 5.5 0.018 399.26 310.91
6 5.1 4.814 1.25 1.06
2022 2019.3 132.310 15.28 15.27
6 4.4 0.010 576.05 428.74
1021 1018.9 1701.710 0.60 0.60
637 636.1 606.791 1.05 1.05
1211 1210.2 739.652 1.64 1.64
933 932.0 854.123 1.09 1.09
1039 1039.0 380.965 2.73 2.72
56 54.4 0.147 381.61 370.99
1 0.5 0.409 2.44 1.19
46 44.3 0.073 628.21 605.84
2 1.5 1.625 1.23 0.89
3664 3662.6 325.306 11.26 11.26
1608 1609.1 1421.430 1.13 1.13
82 80.5 0.105 780.57 767.41
1 0.3 0.206 4.85 1.64
1032 1030.7 519.620 1.99 1.98
594 591.3 392.751 1.51 1.51
3 2.3 2.468 1.22 0.93
2 1.2 0.845 2.37 1.38
66 64.9 55.168 1.20 1.18
0 0.8 2.436 0.00 0.34
19 20.3 93.931 0.20 0.22
306 304.6 0.198 1543.39 1535.14
306 304.6 0.198 1543.39 1535.14
6 4.4 0.004 1577.25 1159.17
10 8.6 0.023 431.67 368.76
1 0.3 0.198 5.05 1.63
3 2.1 1.432 2.09 1.44
5 4.3 4.914 1.02 0.88
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Table F.2a: Top hundred drug and adverse event pairs selected by P-IG model based on the lower bound (φ025) of the 95% credible interval
estimate of φ, using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
PERDIEM STENO ESOPH 65 0.024 2694.87 2072.98 3 1 2610.25 2028.38 1 1
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 1571.77 1395.81 3 2
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 9 3 1532.51 1357.95 4 3
TROLAMINE OTITIS EXT 14 0.007 1895.68 947.84 4 4 1622.86 899.6 2 4
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 710.74 642.88 11 5
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 776.94 607.99 9 6
ETIDOCAINE TRISMUS 82 0.105 780.57 618.74 17 7 762.71 606.3 10 7
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 26 9 675.26 602.72 13 8
HYDROCORTISONE-NEOMYCIN-POLYMYXIN B PAIN EAR 37 0.041 895.62 629.35 13 6 840.21 593.15 7 9
BSS OPHTHALMITIS 28 0.031 889.14 571.59 14 10 823.87 552.5 8 10
DIANEAL PERITONITIS 150 0.228 658.94 553.51 28 11 648.96 551.16 15 11
PANCRELIPASE STENO INTEST COLON 34 0.047 727.21 491.94 18 13 685.58 476.5 12 12
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.093 647.58 485.69 30 14 621.95 476.42 18 13
COLFOSCERIL PALMITATE HEM LUNG 41 0.06 681.25 481.86 25 15 648.52 469.94 16 14
DURANEST W/EPINEPHRINE TRISMUS 46 0.073 628.21 450.67 33 19 599.25 442.55 19 15
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 486.7 440.07 23 16
BSS PLUS OPHTHALMITIS 32 0.047 685.52 449.87 24 20 642.34 437.67 17 17
CHOLINE OPHTHALMITIS 58 0.098 594.08 450.68 35 18 572.17 432.46 20 18
KOATE HIV SYND 7 0.004 1578.59 451.03 7 17 1101.95 428.79 5 19
CHLOROXINE HAIR DISCOLOR 26 0.037 707.23 462.42 21 16 652.62 425.5 14 20
METIPRANOLOL IRITIS 22 0.035 623.42 368.39 34 22 563.3 351 21 21
HEMOFIL M HEPATITIS HBSAG 6 0.004 1577.25 525.75 8 12 1032.36 332.92 6 22
SODIUM HYALURONATE IRITIS 21 0.038 551.61 341.47 39 23 497.35 304.9 22 23
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 91 25 342.91 301.29 44 24
SODIUM HYALURONATE OPHTHALMITIS 20 0.038 529.86 317.91 43 24 476.15 295.4 24 25
CORTISPORIN PAIN EAR 132 0.37 356.64 297.2 81 26 350.82 292.94 39 26
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 94 27 334.84 292.82 45 27
BSS PLUS CORNEAL OPACITY 52 0.129 402.19 293.91 65 28 386.09 288.58 31 28
DINOPROSTONE UTER SPASM 56 0.147 381.61 286.21 72 30 367.63 278.42 36 29
EMBOLEX VASOSPASM 19 0.038 505.85 292.86 45 29 452.9 275.52 27 30
LOTRISONE SKIN STRIAE 17 0.032 526.76 278.87 44 32 464.82 264.53 25 31
MIVACURIUM CHLORIDE CHOLINESTERASE DEC 16 0.032 502.05 282.4 46 31 442.76 260.44 29 32
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.329 315.65 257.98 108 34 309.25 251.45 48 33
MYSTECLIN F ANOMALY TOOTH 28 0.07 401.12 257.86 66 35 370.15 248.78 34 34
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Table F.2b: Top hundred drug and adverse event pairs selected by P-IG model based on the lower bound (φ025) of the 95% credible interval
estimate of φ using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
DOXACURIUM CHLORIDE PARALYSIS FLACCID 16 0.033 484.79 272.69 49 33 424.33 245.93 30 35
DOXYLAMINE HANGOVER 44 0.125 351.27 247.48 88 37 334.55 243.9 46 36
MYSTECLIN F DISCOLOR TOOTH 134 0.458 292.78 244.72 130 39 288.46 241.59 55 37
OXYTOCIN HEM POSTPARTUM 103 0.346 297.96 242.99 124 40 292.42 239.16 53 38
METHYSERGIDE FIBRO RETROPERIT 87 0.29 300.36 238.21 122 43 292.97 237.57 52 39
PHENIRAMINE MYDRIASIS 26 0.067 387.95 253.66 70 36 357.44 236.95 38 40
BSS KERATITIS 74 0.243 305.12 239.15 118 42 295.9 235.04 50 41
BENZOCAINE METHEMOGLOBIN 29 0.077 376.93 246.96 74 38 348.7 234.31 40 42
CALCIPOTRIENE PSORIASIS 47 0.142 331 239.45 99 41 316.95 231.23 47 43
CHOLINE CORNEAL OPACITY 77 0.26 295.96 230.62 128 46 287.99 229.11 56 44
DESOXIMETASONE SKIN STRIAE 10 0.017 590.6 236.24 36 45 464.79 221.25 26 45
NONOXYNOL BALANITIS 51 0.166 306.82 228.61 116 47 293.96 219.97 51 46
PANCRELIPASE STENO INTEST 16 0.038 423.38 238.15 61 44 367.4 211.05 37 47
SODIUM HYALURONATE CORNEAL OPACITY 30 0.094 319.8 213.2 103 49 298.1 204.35 49 48
GEMCITABINE HYDROCHLORIDE CARCINOMA GI 225 0.952 236.39 205.92 200 51 233.6 204.25 80 49
APROTININ BOVINE THROM CORONARY 13 0.029 452.15 208.68 57 50 378.65 201.12 33 50
OXYTOCIN UTER ATONY 32 0.105 306.03 200.83 117 52 285.89 196.29 57 51
SODIUM HYALURONATE KERATITIS 70 0.274 255.2 196.87 167 55 247.75 195.7 74 52
ISOSORBIDE MONONITRATE HEADACHE VASC 40 0.141 283.71 198.59 140 54 269.95 193.04 66 53
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 234 56 212.55 191.74 92 54
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 224 58 217.65 191.13 89 55
BOTULINUM TOXIN A PTOSIS 60 0.238 252.56 189.42 173 59 244.2 188.46 78 56
BUDESONIDE NASAL SEPTUM DIS 28 0.091 309.31 198.84 113 53 284.81 188.38 59 57
HEMOFIL HIV SYND 22 0.069 318.09 187.96 106 60 285.78 180.33 58 58
TICE BCG GRANULOMA 55 0.23 239.15 178.27 192 64 229.5 174.72 82 59
HEPARIN SODIUM IN DEXTROSE ANTICOAG DEC 29 0.105 275.05 180.21 147 62 255.58 173.52 70 60
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 252 67 203.3 173.28 97 61
CHYMOTRYPSIN KERATITIS 22 0.072 304.72 180.06 119 63 275.24 170.74 62 62
DELADUMONE OB HIRSUTISM 21 0.071 295.96 183.21 129 61 266.67 170.02 67 63
RIFABUTIN UVEITIS 134 0.665 201.45 168.37 265 70 198.5 167.32 99 64
PYRIDOSTIGMINE CHOLINERG SYND 10 0.023 439.56 175.82 58 65 348.25 165.75 41 65
HEMOFIL M HIV SYND 10 0.023 431.67 172.67 60 68 346.71 160.79 43 66
HYALURONIDASE STRABISMUS 32 0.13 246.93 162.05 180 72 231.32 160.67 81 67
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Table F.2c: Top hundred drug and adverse event pairs selected by P-IG model based on the lower bound (φ025) of the 95% credible interval
estimate of φ using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, φ and φ025 are designated RK1,
RK11, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 φ φ025 RK3 RK33
CARBOPROST HEM POSTPARTUM 14 0.041 339.82 169.91 93 69 288.75 158.93 54 68
NORGESTREL CARCINOMA CERVIX SIT 6 0.009 677.3 225.77 27 48 448.56 158.76 28 69
BSS CORNEAL OPACITY 21 0.077 271.35 167.98 150 71 245.3 153.79 76 70
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 378 77 162.68 152.96 122 71
MIVACURIUM CHLORIDE INCREASED EFFECT 319 1.865 171.02 152.26 356 81 169.92 152.56 113 72
DIETHYLSTILBESTROL ANOMALY CONGEN 2811 17.749 158.37 152.57 398 79 158.29 152.44 131 73
BUSULFAN VENOOCCLUS LIVER SYN 21 0.081 260.1 161.01 160 73 234.76 147.26 79 74
BSS PLUS UVEITIS 17 0.059 287.91 152.43 134 80 250.05 147.17 73 75
FLUCLOXACILLIN STENO INTEST COLON 8 0.017 468.79 175.8 51 66 347.82 145.89 42 76
DORNASE ALFA HEMOPTYSIS 64 0.336 190.37 145.75 301 83 184.47 143.63 108 77
HETASTARCH HEMOTHORAX 21 0.083 253.02 156.63 170 75 227.72 143.29 83 78
LOTRISONE ATROPHY SKIN 26 0.109 237.95 155.58 197 76 218.63 141.33 87 79
METIPRANOLOL UVEITIS 25 0.105 238.78 152.82 193 78 217.63 141.1 90 80
SOMATREM NEOPL CNS 52 0.273 190.7 139.36 299 88 183.25 138.43 109 81
LOTRISONE DERM FUNG 15 0.053 285.44 152.24 138 82 244.74 134.52 77 82
FLUNISOLIDE NASAL SEPTUM DIS 75 0.431 174.04 136.91 344 90 169.3 134.11 116 83
BSS PLUS IRITIS 13 0.042 308.04 142.17 115 86 258.89 133.77 69 84
CHOLINE KERATITIS 116 0.703 164.99 135.12 372 91 161.99 133.4 125 85
METFORMIN ACIDOSIS LACTIC 309 2.074 149.02 132.62 437 94 147.98 132.5 145 86
PRILOCAINE HYPALGESIA 21 0.09 234.17 144.96 201 85 210.88 130.56 94 87
TETRACYCLINE DISCOLOR TOOTH 1437 10.485 137.05 130 510 95 136.92 130.13 161 88
CREON STENO INTEST COLON 6 0.01 576.05 192.02 37 57 383.06 128.18 32 89
CHYMOTRYPSIN CORNEAL OPACITY 11 0.035 311.16 141.44 112 87 253.13 127.25 71 90
BENDECTIN ECTROMELIA 111 0.721 154.02 126.27 415 100 150.77 125.08 140 91
CHOLINE IRITIS 22 0.101 217.17 128.33 227 96 196.13 123.95 101 92
NONOXYNOL CERVIX DIS 1074 8.161 131.61 123.77 552 104 131.31 123.6 171 93
CARBACHOL CORNEAL OPACITY 22 0.104 211.66 125.07 239 101 192.87 122.65 103 94
PROTIRELIN URIN URGENCY 9 0.025 357.13 158.72 80 74 274.12 121.15 63 95
SELENIUM SULFIDE HAIR DISCOLOR 301 2.236 134.64 119.43 526 107 133.78 119.65 167 96
GONADOTROPIN, CHORIONIC OVAR DIS 86 0.567 151.69 119.94 423 106 148.02 119.13 144 97
OPHTHAINE HCL CORNEAL LESION 21 0.101 207.17 128.25 249 97 187.48 118.28 106 98
PANALBA K.M. ANOMALY TOOTH 8 0.022 369.52 138.57 76 89 273.5 117.57 64 99
POLIOVIRUS VACCINE, LIVE, ORAL SIDS 146 1.038 140.6 118.45 484 108 138.9 117.14 159 100
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Table G.1a: First 100 of Drug and adverse event pairs common to the top 1000 pairs selected by RR, GPS and C-G based on the point
estimates of RR, λ (EBGM) and φ respectively, using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, λ
(EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
PERDIEM STENO ESOPH 65 0.024 2694.87 2072.98 3 1 791.17 615.57 3 3 95.5 74.3 29 35
TROLAMINE OTITIS EXT 14 0.007 1895.68 947.84 4 4 210.56 119.84 38 62 21.32 12.13 642 1004
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 1206.22 1073.85 1 1 349.02 311.32 2 2
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 9 3 1194.52 1065.95 2 2 358.53 320.87 1 1
HYDROCOR’NE-NEOM-POLY B PAIN EAR 37 0.041 895.62 629.35 13 6 370.77 264.93 12 14 53.2 37.52 94 131
BSS OPHTHALMITIS 28 0.031 889.14 571.59 14 10 310.66 237.21 17 18 41.27 28.45 164 224
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 481.99 379.26 8 9 95.73 75.47 28 33
ETIDOCAINE TRISMUS 82 0.105 780.57 618.74 17 7 502.1 401.82 7 8 108.42 87.88 21 26
PANCRELIPASE STENO INTEST COLON 34 0.047 727.21 491.94 18 13 322.71 226.92 15 19 48.51 34.27 117 156
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 644.88 582.98 4 4 323.51 293.66 3 3
CHLOROXINE HAIR DISCOLOR 26 0.037 707.23 462.42 21 16 272.13 181.59 23 32 37.77 25.45 203 277
BSS PLUS OPHTHALMITIS 32 0.047 685.52 449.87 24 20 303.77 211.3 20 22 45.6 31.44 129 183
COLFOSCERIL PALMITATE HEM LUNG 41 0.06 681.25 481.86 25 15 345.34 251.08 14 17 57.63 42.28 84 106
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 26 9 598.72 532.64 5 5 267.66 238.76 4 4
DIANEAL PERITONITIS 150 0.228 658.94 553.51 28 11 524.7 445.7 6 6 170.1 144.86 7 9
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.093 647.58 485.69 30 14 397.15 305.72 10 10 80.63 62.31 44 50
DURANEST W/EPINEPHRINE TRISMUS 46 0.073 628.21 450.67 33 19 349.13 258.63 13 15 63.54 47.75 66 81
METIPRANOLOL IRITIS 22 0.035 623.42 368.39 34 22 233.41 150.03 32 42 32.09 20.9 284 401
CHOLINE OPHTHALMITIS 58 0.098 594.08 450.68 35 18 371.54 284.7 11 11 77 58.9 47 57
SODIUM HYALURONATE IRITIS 21 0.038 551.61 341.47 39 23 216.18 137.36 36 49 30.56 19.68 312 441
SODIUM HYALURONATE OPHTHALMITIS 20 0.038 529.86 317.91 43 24 206.43 129.74 42 52 28.84 18.12 345 517
LOTRISONE SKIN STRIAE 17 0.032 526.76 278.87 44 32 185.63 111.66 52 69 25.05 15.4 474 692
EMBOLEX VASOSPASM 19 0.038 505.85 292.86 45 29 196.33 121.75 46 59 27.63 17.47 375 543
MIVACURIUM CHLORIDE CHOLINESTERASE DEC 16 0.032 502.05 282.4 46 31 175.3 103.72 55 77 23.76 14.59 529 753
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 452.71 407.21 9 7 256.19 230.43 5 5
DOXACURIUM CHLORIDE PARALYSIS FLACCID 16 0.033 484.79 272.69 49 33 173.11 102.42 56 79 23.48 14.13 539 792
APROTININ BOVINE THROM CORONARY 13 0.029 452.15 208.68 57 50 146.91 81.71 74 110 19.19 10.76 785 1243
PANCRELIPASE STENO INTEST 16 0.038 423.38 238.15 61 44 164.43 97.32 61 86 23.26 13.97 547 805
BSS PLUS CORNEAL OPACITY 52 0.129 402.19 293.91 65 28 276.51 208.57 21 24 66.71 50.1 61 75
MYSTECLIN F ANOMALY TOOTH 28 0.07 401.12 257.86 66 35 217.27 147.29 35 44 38.89 27.02 185 252
PHENIRAMINE MYDRIASIS 26 0.067 387.95 253.66 70 36 206.08 137.48 43 48 36.26 24.73 218 295
DINOPROSTONE UTER SPASM 56 0.147 381.61 286.21 72 30 272.47 207.8 22 25 70.17 53.31 54 71
BENZOCAINE METHEMOGLOBIN 29 0.077 376.93 246.96 74 38 213.19 145.49 37 45 40.05 27.79 174 239
CORTISPORIN PAIN EAR 132 0.37 356.64 297.2 81 26 307.86 258.55 19 16 128.91 109.11 15 17
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Table G.1b: First 100 of Drug and adverse event pairs common to the top 1000 pairs selected by RR, GPS and C-G based on the point
estimates of RR, λ (EBGM) and φ respectively, using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, λ
(EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
DOXYLAMINE HANGOVER 44 0.125 351.27 247.48 88 37 238.87 175.58 30 33 56.39 41.71 86 108
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 91 25 320.84 283.33 16 12 184.3 163.13 6 6
CARBOPROST HEM POSTPARTUM 14 0.041 339.82 169.91 93 69 138.53 78.83 79 114 20.47 12.14 695 1002
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 94 27 309.61 270.47 18 13 167.41 147.07 8 8
CALCIPOTRIENE PSORIASIS 47 0.142 331 239.45 99 41 233.87 173.75 31 34 59.21 44.52 80 95
SODIUM HYALURONATE CORNEAL OPACITY 30 0.094 319.8 213.2 103 49 196.04 134.65 47 51 40.4 27.89 171 236
HEMOFIL HIV SYND 22 0.069 318.09 187.96 106 60 171.06 109.87 57 71 30.63 20.12 309 428
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.329 315.65 257.98 108 34 267.85 219.9 24 20 105.76 87.46 22 27
BUDESONIDE NASAL SEPTUM DIS 28 0.091 309.31 198.84 113 53 186.89 126.65 51 55 37.9 25.96 199 268
BSS PLUS IRITIS 13 0.042 308.04 142.17 115 86 127.12 70.71 97 134 19 10.8 798 1234
NONOXYNOL BALANITIS 51 0.166 306.82 228.61 116 47 226.43 170.41 33 35 62.6 47.67 72 82
OXYTOCIN UTER ATONY 32 0.105 306.03 200.83 117 52 195.37 135.86 48 50 42.48 30.06 150 199
BSS KERATITIS 74 0.243 305.12 239.15 118 42 245.5 194.18 28 28 82.7 65.74 40 46
CHYMOTRYPSIN KERATITIS 22 0.072 304.72 180.06 119 63 167.06 107.38 59 74 30.6 19.77 311 435
METHYSERGIDE FIBRO RETROPERIT 87 0.29 300.36 238.21 122 43 249.61 201.14 27 26 92.35 75.08 32 34
OXYTOCIN HEM POSTPARTUM 103 0.346 297.96 242.99 124 40 254.6 208.79 26 23 103.26 85.04 24 29
CHOLINE CORNEAL OPACITY 77 0.26 295.96 230.62 128 46 241.31 191.75 29 29 84.46 67.31 37 42
DELADUMONE OB HIRSUTISM 21 0.071 295.96 183.21 129 61 160.9 102.29 64 80 29 18.51 341 493
MYSTECLIN F DISCOLOR TOOTH 134 0.458 292.78 244.72 130 39 259.43 218.26 25 21 120.37 102.14 18 18
BSS PLUS UVEITIS 17 0.059 287.91 152.43 134 80 143.04 86.09 76 104 24.14 14.97 507 730
LOTRISONE DERM FUNG 15 0.053 285.44 152.24 138 82 133.33 77.51 84 118 21.42 12.45 638 963
ISOSORBIDE MONONITRATE HEADACHE VASC 40 0.141 283.71 198.59 140 54 199.82 144.69 45 46 50.34 36.71 110 138
HEPARIN SODIUM IN DEXTROSE ANTICOAG DEC 29 0.105 275.05 180.21 147 62 175.93 120.01 54 61 38.32 26.63 192 257
BSS CORNEAL OPACITY 21 0.077 271.35 167.98 150 71 153.23 97.36 68 85 28.88 17.99 344 523
BETHANECHOL CHLORIDE CHOLINERG SYND 12 0.045 269.03 134.52 152 92 114.36 61.91 114 169 17.51 9.67 913 1489
BUSULFAN VENOOCCLUS LIVER SYN 21 0.081 260.1 161.01 160 73 149.52 95.01 72 89 28.76 18.13 349 516
SODIUM HYALURONATE KERATITIS 70 0.274 255.2 196.87 167 55 209.95 164.94 39 36 75.42 59.2 48 56
HETASTARCH HEMOTHORAX 21 0.083 253.02 156.63 170 75 147.12 93.45 73 92 28.5 18.18 357 513
BOTULINUM TOXIN A PTOSIS 60 0.238 252.56 189.42 173 59 202.19 155.66 44 38 67.7 52.33 57 73
MAXITROL HEALING ABNORM 14 0.056 248.73 124.36 176 102 120.18 68.42 103 146 19.92 11.53 731 1104
HYALURONIDASE STRABISMUS 32 0.13 246.93 162.05 180 72 169.25 117.74 58 64 40.97 29.06 167 212
TICE BCG GRANULOMA 55 0.23 239.15 178.27 192 64 190.14 144.6 50 47 62.3 47.23 74 85
METIPRANOLOL UVEITIS 25 0.105 238.78 152.82 193 78 152.09 100.54 70 82 33.32 22.25 264 361
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Table G.1c: First 100 of Drug and adverse event pairs common to the top 1000 pairs selected by RR, GPS and C-G based on the point
estimates of RR, λ (EBGM) and φ respectively, using Data 1. The ranks assigned to the drug and event combinations based on RR, RR025, λ
(EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
LOTRISONE ATROPHY SKIN 26 0.109 237.95 155.58 197 76 153.92 102.66 67 78 34.22 23.04 249 339
GEMCITABINE HYDROCHLORIDE CARCINOMA GI 225 0.952 236.39 205.92 200 51 222.58 194.84 34 27 139.78 122.77 12 12
PRILOCAINE HYPALGESIA 21 0.09 234.17 144.96 201 85 140.45 89.24 78 98 28.67 18.5 352 495
FLOXURIDINE ENTERITIS 13 0.057 229 105.69 207 125 110.94 61.7 119 171 18.5 10.57 837 1271
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 224 58 207.82 182.29 40 31 135.44 118.88 13 14
CHOLINE IRITIS 22 0.101 217.17 128.33 227 96 136.47 87.64 81 101 29.28 18.92 337 470
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 234 56 207.07 187.02 41 30 156.35 141.35 9 10
CARBACHOL CORNEAL OPACITY 22 0.104 211.66 125.07 239 101 134.24 86.29 83 103 29.15 18.78 339 481
DEMECLOCYCLINE ANOMALY TOOTH 17 0.08 211.34 111.89 240 118 120.88 72.81 101 128 23.34 14.07 543 795
OPHTHAINE HCL CORNEAL LESION 21 0.101 207.17 128.25 249 97 130.12 82.65 90 109 28.08 17.68 369 538
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 252 67 192.06 164.53 49 37 114.11 97.77 19 20
POTASSIUM IODIDE SALIV GLAND ENLARGE 12 0.059 204.26 102.13 259 129 100.46 54.44 143 220 17.02 9.37 958 1575
RIFABUTIN UVEITIS 134 0.665 201.45 168.37 265 70 184.95 155.6 53 39 101.96 85.48 25 28
MOMETASONE FUROATE LEUKODERMA 18 0.093 194.46 108.03 283 123 117.78 72.03 106 130 24.32 14.9 502 732
SOMATREM NEOPL CNS 52 0.273 190.7 139.36 299 88 156.48 118.05 66 63 56.25 42.52 88 105
DORNASE ALFA HEMOPTYSIS 64 0.336 190.37 145.75 301 83 161.72 125.57 62 57 64.67 50.08 63 76
DINOPROSTONE UTER ATONY 16 0.086 186.95 105.16 311 126 109.56 64.81 123 160 22.04 13.14 606 881
PAMIDRONATE DISODIUM HYPOPHOSPHATEM 14 0.076 184.06 92.03 320 153 102.41 58.28 139 195 19.51 11.22 760 1160
ISOVUE-M MENINGISM 15 0.082 182.77 97.47 321 137 105.16 61.13 131 175 20.73 12.44 678 964
BSS PLUS CORNEAL LESION 27 0.149 181.26 114.13 326 113 129.19 86.86 93 102 33.87 22.64 255 353
INDIUM, IN-111 MENINGITIS 17 0.095 179.59 95.08 333 144 109.59 66 122 154 22.93 14 559 802
CHOLINE UVEITIS 21 0.119 176.9 109.51 337 121 117.33 74.57 107 125 27.34 17.53 381 541
FLUNISOLIDE NASAL SEPTUM DIS 75 0.431 174.04 136.91 344 90 152.87 121.09 69 60 69.25 55.41 55 64
MIVACURIUM CHLORIDE INCREASED EFFECT 319 1.865 171.02 152.26 356 81 165.73 148.27 60 43 126.83 113.36 16 16
PANALBA K.M. TOOTH DIS 33 0.194 170.07 113.38 359 115 129.89 90.87 92 97 38.89 27.87 184 237
ABCIXIMAB HEM RETROPERIT 14 0.083 168.75 84.38 361 168 97.38 55.43 150 215 19.34 11.45 773 1119
TICE BCG PYURIA 17 0.101 168.22 89.06 365 159 105.18 63.34 130 165 22.78 13.98 564 804
NAPHCON-A MYDRIASIS 18 0.109 165.34 91.86 370 154 106.25 64.95 128 159 23.81 14.78 523 738
ETODOLAC BILIRUBINURIA 23 0.139 165.02 100.45 371 132 115.17 74.79 111 124 29.32 19.49 334 451
CHOLINE KERATITIS 116 0.703 164.99 135.12 372 91 152.08 126.25 71 56 85.71 71.27 36 39
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 378 77 161.58 152.26 63 40 148.51 139.79 11 11
IFOSFAMIDE FANCONI SYND 13 0.081 161.42 74.5 385 201 91.86 51.11 173 239 17.86 9.93 882 1425
UROFOLLITROPIN OVAR DIS 46 0.289 159.3 114.28 394 112 131.89 97.69 86 84 48.9 35.97 116 144
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Table G.2a: First 100 of drug and adverse event pairs common to the top 1000 pairs selected by RR, GPS and C-G based on the lower bounds
RR025, λ025 and φ025 of the 95% confidence/credible interval estimates of RR, λ and φ respectively, using Data 1. The ranks assigned to the
drug and event combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33
respectively.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
PERDIEM STENO ESOPH 65 0.024 2694.87 2072.98 3 1 791.17 615.57 3 3 95.5 74.3 29 35
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 1206.22 1073.85 1 1 349.02 311.32 2 2
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 9 3 1194.52 1065.95 2 2 358.53 320.87 1 1
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 644.88 582.98 4 4 323.51 293.66 3 3
HYDROCOR’NE-NEOM-POLY B PAIN EAR 37 0.041 895.62 629.35 13 6 370.77 264.93 12 14 53.2 37.52 94 131
ETIDOCAINE TRISMUS 82 0.105 780.57 618.74 17 7 502.1 401.82 7 8 108.42 87.88 21 26
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 481.99 379.26 8 9 95.73 75.47 28 33
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 26 9 598.72 532.64 5 5 267.66 238.76 4 4
BSS OPHTHALMITIS 28 0.031 889.14 571.59 14 10 310.66 237.21 17 18 41.27 28.45 164 224
DIANEAL PERITONITIS 150 0.228 658.94 553.51 28 11 524.7 445.7 6 6 170.1 144.86 7 9
PANCRELIPASE STENO INTEST COLON 34 0.047 727.21 491.94 18 13 322.71 226.92 15 19 48.51 34.27 117 156
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.093 647.58 485.69 30 14 397.15 305.72 10 10 80.63 62.31 44 50
COLFOSCERIL PALMITATE HEM LUNG 41 0.06 681.25 481.86 25 15 345.34 251.08 14 17 57.63 42.28 84 106
CHLOROXINE HAIR DISCOLOR 26 0.037 707.23 462.42 21 16 272.13 181.59 23 32 37.77 25.45 203 277
CHOLINE OPHTHALMITIS 58 0.098 594.08 450.68 35 18 371.54 284.7 11 11 77 58.9 47 57
DURANEST W/EPINEPHRINE TRISMUS 46 0.073 628.21 450.67 33 19 349.13 258.63 13 15 63.54 47.75 66 81
BSS PLUS OPHTHALMITIS 32 0.047 685.52 449.87 24 20 303.77 211.3 20 22 45.6 31.44 129 183
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 452.71 407.21 9 7 256.19 230.43 5 5
METIPRANOLOL IRITIS 22 0.035 623.42 368.39 34 22 233.41 150.03 32 42 32.09 20.9 284 401
SODIUM HYALURONATE IRITIS 21 0.038 551.61 341.47 39 23 216.18 137.36 36 49 30.56 19.68 312 441
SODIUM HYALURONATE OPHTHALMITIS 20 0.038 529.86 317.91 43 24 206.43 129.74 42 52 28.84 18.12 345 517
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 91 25 320.84 283.33 16 12 184.3 163.13 6 6
CORTISPORIN PAIN EAR 132 0.37 356.64 297.2 81 26 307.86 258.55 19 16 128.91 109.11 15 17
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 94 27 309.61 270.47 18 13 167.41 147.07 8 8
BSS PLUS CORNEAL OPACITY 52 0.129 402.19 293.91 65 28 276.51 208.57 21 24 66.71 50.1 61 75
EMBOLEX VASOSPASM 19 0.038 505.85 292.86 45 29 196.33 121.75 46 59 27.63 17.47 375 543
DINOPROSTONE UTER SPASM 56 0.147 381.61 286.21 72 30 272.47 207.8 22 25 70.17 53.31 54 71
MIVACURIUM CHLORIDE CHOLINESTERASE DEC 16 0.032 502.05 282.4 46 31 175.3 103.72 55 77 23.76 14.59 529 753
LOTRISONE SKIN STRIAE 17 0.032 526.76 278.87 44 32 185.63 111.66 52 69 25.05 15.4 474 692
DOXACURIUM CHLORIDE PARALYSIS FLACCID 16 0.033 484.79 272.69 49 33 173.11 102.42 56 79 23.48 14.13 539 792
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.329 315.65 257.98 108 34 267.85 219.9 24 20 105.76 87.46 22 27
MYSTECLIN F ANOMALY TOOTH 28 0.07 401.12 257.86 66 35 217.27 147.29 35 44 38.89 27.02 185 252
PHENIRAMINE MYDRIASIS 26 0.067 387.95 253.66 70 36 206.08 137.48 43 48 36.26 24.73 218 295
DOXYLAMINE HANGOVER 44 0.125 351.27 247.48 88 37 238.87 175.58 30 33 56.39 41.71 86 108
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Table G.2b: First 100 of drug and adverse event pairs common to the top 1000 pairs selected by RR, GPS and C-G based on the lower bounds
RR025, λ025 and φ025 of the 95% confidence/credible interval estimates of RR, λ and φ respectively, using Data 1. The ranks assigned to the
drug and event combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33
respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
BENZOCAINE METHEMOGLOBIN 29 0.077 376.93 246.96 74 38 213.19 145.49 37 45 40.05 27.79 174 239
MYSTECLIN F DISCOLOR TOOTH 134 0.458 292.78 244.72 130 39 259.43 218.26 25 21 120.37 102.14 18 18
OXYTOCIN HEM POSTPARTUM 103 0.346 297.96 242.99 124 40 254.6 208.79 26 23 103.26 85.04 24 29
CALCIPOTRIENE PSORIASIS 47 0.142 331 239.45 99 41 233.87 173.75 31 34 59.21 44.52 80 95
BSS KERATITIS 74 0.243 305.12 239.15 118 42 245.5 194.18 28 28 82.7 65.74 40 46
METHYSERGIDE FIBRO RETROPERIT 87 0.29 300.36 238.21 122 43 249.61 201.14 27 26 92.35 75.08 32 34
PANCRELIPASE STENO INTEST 16 0.038 423.38 238.15 61 44 164.43 97.32 61 86 23.26 13.97 547 805
CHOLINE CORNEAL OPACITY 77 0.26 295.96 230.62 128 46 241.31 191.75 29 29 84.46 67.31 37 42
NONOXYNOL BALANITIS 51 0.166 306.82 228.61 116 47 226.43 170.41 33 35 62.6 47.67 72 82
SODIUM HYALURONATE CORNEAL OPACITY 30 0.094 319.8 213.2 103 49 196.04 134.65 47 51 40.4 27.89 171 236
GEMCITABINE HYDROCHLO’DE CARCINOMA GI 225 0.952 236.39 205.92 200 51 222.58 194.84 34 27 139.78 122.77 12 12
OXYTOCIN UTER ATONY 32 0.105 306.03 200.83 117 52 195.37 135.86 48 50 42.48 30.06 150 199
BUDESONIDE NASAL SEPTUM DIS 28 0.091 309.31 198.84 113 53 186.89 126.65 51 55 37.9 25.96 199 268
ISOSORBIDE MONONITRATE HEADACHE VASC 40 0.141 283.71 198.59 140 54 199.82 144.69 45 46 50.34 36.71 110 138
SODIUM HYALURONATE KERATITIS 70 0.274 255.2 196.87 167 55 209.95 164.94 39 36 75.42 59.2 48 56
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 234 56 207.07 187.02 41 30 156.35 141.35 9 10
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 224 58 207.82 182.29 40 31 135.44 118.88 13 14
BOTULINUM TOXIN A PTOSIS 60 0.238 252.56 189.42 173 59 202.19 155.66 44 38 67.7 52.33 57 73
HEMOFIL HIV SYND 22 0.069 318.09 187.96 106 60 171.06 109.87 57 71 30.63 20.12 309 428
DELADUMONE OB HIRSUTISM 21 0.071 295.96 183.21 129 61 160.9 102.29 64 80 29 18.51 341 493
HEPARIN SODIUM IN DEXTROS ANTICOAG DEC 29 0.105 275.05 180.21 147 62 175.93 120.01 54 61 38.32 26.63 192 257
CHYMOTRYPSIN KERATITIS 22 0.072 304.72 180.06 119 63 167.06 107.38 59 74 30.6 19.77 311 435
TICE BCG GRANULOMA 55 0.23 239.15 178.27 192 64 190.14 144.6 50 47 62.3 47.23 74 85
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 252 67 192.06 164.53 49 37 114.11 97.77 19 20
RIFABUTIN UVEITIS 134 0.665 201.45 168.37 265 70 184.95 155.6 53 39 101.96 85.48 25 28
BSS CORNEAL OPACITY 21 0.077 271.35 167.98 150 71 153.23 97.36 68 85 28.88 17.99 344 523
HYALURONIDASE STRABISMUS 32 0.13 246.93 162.05 180 72 169.25 117.74 58 64 40.97 29.06 167 212
BUSULFAN VENOOCCLUS LIVER SYN 21 0.081 260.1 161.01 160 73 149.52 95.01 72 89 28.76 18.13 349 516
HETASTARCH HEMOTHORAX 21 0.083 253.02 156.63 170 75 147.12 93.45 73 92 28.5 18.18 357 513
LOTRISONE ATROPHY SKIN 26 0.109 237.95 155.58 197 76 153.92 102.66 67 78 34.22 23.04 249 339
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 378 77 161.58 152.26 63 40 148.51 139.79 11 11
METIPRANOLOL UVEITIS 25 0.105 238.78 152.82 193 78 152.09 100.54 70 82 33.32 22.25 264 361
DIETHYLSTILBESTROL ANOMALY CONGEN 2811 17.749 158.37 152.57 398 79 157.84 152.09 65 41 152.79 147.32 10 7
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Table G.2c: First 100 of drug and adverse event pairs common to the top 1000 pairs selected by RR, GPS and C-G based on the lower bounds
RR025, λ025 and φ025 of the 95% confidence/credible interval estimates of RR, λ and φ respectively, using Data 1. The ranks assigned to the
drug and event combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33
respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
BSS PLUS UVEITIS 17 0.059 287.91 152.43 134 80 143.04 86.09 76 104 24.14 14.97 507 730
MIVACURIUM CHLORIDE INCREASED EFFECT 319 1.865 171.02 152.26 356 81 165.73 148.27 60 43 126.83 113.36 16 16
LOTRISONE DERM FUNG 15 0.053 285.44 152.24 138 82 133.33 77.51 84 118 21.42 12.45 638 963
DORNASE ALFA HEMOPTYSIS 64 0.336 190.37 145.75 301 83 161.72 125.57 62 57 64.67 50.08 63 76
PRILOCAINE HYPALGESIA 21 0.09 234.17 144.96 201 85 140.45 89.24 78 98 28.67 18.5 352 495
SOMATREM NEOPL CNS 52 0.273 190.7 139.36 299 88 156.48 118.05 66 63 56.25 42.52 88 105
FLUNISOLIDE NASAL SEPTUM DIS 75 0.431 174.04 136.91 344 90 152.87 121.09 69 60 69.25 55.41 55 64
CHOLINE KERATITIS 116 0.703 164.99 135.12 372 91 152.08 126.25 71 56 85.71 71.27 36 39
METFORMIN ACIDOSIS LACTIC 309 2.074 149.02 132.62 437 94 144.84 129.37 75 53 113.33 101.49 20 19
TETRACYCLINE DISCOLOR TOOTH 1437 10.485 137.05 130 510 95 136.28 129.37 82 54 129.01 122.5 14 13
CHOLINE IRITIS 22 0.101 217.17 128.33 227 96 136.47 87.64 81 101 29.28 18.92 337 470
OPHTHAINE HCL CORNEAL LESION 21 0.101 207.17 128.25 249 97 130.12 82.65 90 109 28.08 17.68 369 538
BENDECTIN ECTROMELIA 111 0.721 154.02 126.27 415 100 142.21 117.53 77 65 80.76 67.11 43 43
CARBACHOL CORNEAL OPACITY 22 0.104 211.66 125.07 239 101 134.24 86.29 83 103 29.15 18.78 339 481
NONOXYNOL CERVIX DIS 1074 8.161 131.61 123.77 552 104 130.65 123 89 58 121.83 114.78 17 15
GONADOTROPIN, CHORIONIC OVAR DIS 86 0.567 151.69 119.94 423 106 137.2 110.41 80 70 70.3 56.8 52 62
SELENIUM SULFIDE HAIR DISCOLOR 301 2.236 134.64 119.43 526 107 131.12 116.94 87 66 104.37 93.05 23 21
POLIOVIRUS VACCINE, LIVE SIDS 146 1.038 140.6 118.45 484 108 132.92 112.61 85 68 86.33 73.53 35 36
OPCON A PAIN EYE 267 2.015 132.49 116.61 547 109 128.66 113.91 95 67 100.08 88.99 26 24
FLOSEQUINAN SUDDEN DEATH 49 0.315 155.79 114.46 404 111 130.83 97.82 88 83 50.9 38.54 101 123
UROFOLLITROPIN OVAR DIS 46 0.289 159.3 114.28 394 112 131.89 97.69 86 84 48.9 35.97 116 144
BSS PLUS CORNEAL LESION 27 0.149 181.26 114.13 326 113 129.19 86.86 93 102 33.87 22.64 255 353
PANALBA K.M. TOOTH DIS 33 0.194 170.07 113.38 359 115 129.89 90.87 92 97 38.89 27.87 184 237
CEFOXITIN ENTEROCOL PSEUDOMEM 138 1.016 135.79 113.16 517 116 128.21 108.11 96 73 82.86 69.82 39 41
TETRAHYDROZOLINE PAIN EYE 187 1.43 130.77 112.59 557 117 125.49 108.46 98 72 89.85 77.83 33 31
DEMECLOCYCLINE ANOMALY TOOTH 17 0.08 211.34 111.89 240 118 120.88 72.81 101 128 23.34 14.07 543 795
TICE BCG CYSTITIS 69 0.475 145.35 111.64 457 119 129.03 101.11 94 81 61.19 48.18 77 78
CHOLINE UVEITIS 21 0.119 176.9 109.51 337 121 117.33 74.57 107 125 27.34 17.53 381 541
MENOTROPINS OVAR DIS 151 1.175 128.48 108.06 583 122 122.22 103.87 99 76 82.37 70 41 40
MOMETASONE FUROATE LEUKODERMA 18 0.093 194.46 108.03 283 123 117.78 72.03 106 130 24.32 14.9 502 732
PHENFORMIN ACIDOSIS LACTIC 390 3.302 118.11 106.61 681 124 115.99 104.91 109 75 98.53 89.48 27 23
DINOPROSTONE UTER ATONY 16 0.086 186.95 105.16 311 126 109.56 64.81 123 160 22.04 13.14 606 881
INFLUENZA VIRUS VACCINE GUILLAIN BARRE SYND 62 0.451 137.47 104.21 507 127 121.28 93.84 100 91 56.07 43.85 89 97
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Table G.3: Top ten drug and adverse event pairs uniquely selected by RR, GPS, C-G and LogP in their top 1000 pairs based on the point
estimates of RR, λ (EBGM), φ and the values of LogP respectively, using Data 1.
Method Drug Event Rank Count Expected RR RR025 EBGM λ025 φ φ025 LogP
RR NISOLDIPINE HEPATITIS NONSPECIFI 1 1 0.0003 3561.94 0.00 2.4 0.95 1.83 0.25 3.55
ACARBOSE HEPATITIS NONSPECIFI 2 1 0.0004 2816.96 0.00 2.4 0.95 1.76 0.2 3.45
ORTHO-NOVUM 1/80 CARCINOMA LIVER 5 1 0.0005 1840 0.00 2.39 0.95 1.84 0.27 3.26
PLATELET CONCENTRATE, HUMAN LIVER DAMAGE AGGRAV 10 1 0.0008 1320.94 0.00 2.38 0.94 1.8 0.22 3.12
URSODIOL LIVER DAMAGE AGGRAV 11 1 0.0008 1187.47 0.00 2.38 0.94 1.81 0.23 3.07
EMLA HYPALGESIA 12 1 0.0009 1114.14 0.00 2.37 0.94 1.8 0.23 3.05
ORTHO-NOVUM SQ CARCINOMA LARYNX 19 1 0.0014 720.74 0.00 2.35 0.94 1.78 0.2 2.86
COLFOSCERIL PALMITATE INTEST SMALL PER 22 2 0.0029 699.11 0.00 19.81 4.63 3.28 0.75 5.39
AVC BALANITIS 23 1 0.0014 694.57 0.00 2.35 0.93 1.8 0.22 2.84
HYDROCORTIS’NE-NEOMYCIN-POLYMYXIN B OTITIS EXT 29 2 0.0031 648.98 0 19.7 4.62 3.21 0.75 5.32
GPS (EBGM) DACTINOMYCIN SARCOMA 355 12 0.1268 94.63 47.31 63.39 34.35 15.55 8.68 19.49
SODIUM HYALURONATE CORNEAL LESION 378 12 0.1322 90.79 45.4 61.6 33.38 15.52 8.73 19.28
OXYMETAZOLINE NASAL SEPTUM DIS 390 11 0.1201 91.58 41.63 60.16 31.6 14.38 7.93 17.77
ARA-C ATAXIA CEREBELL 409 11 0.1258 87.42 39.74 58.28 30.64 14.39 7.66 17.55
METHOXYFLURANE POLYURIA 418 10 0.1115 89.65 35.86 57.3 29.14 13.2 7.07 16.13
BENDECTIN VENT SEPT DEF 421 10 0.1118 89.47 35.79 57.22 29.07 13.28 6.82 16.12
RIFABUTIN OPHTHALMITIS 429 11 0.1308 84.07 38.22 56.73 29.85 14.25 7.59 17.37
PHENYLEPHRINE IRITIS 437 10 0.1147 87.21 34.88 56.26 28.59 13.19 7.04 16.01
BETAMETHASONE SPERM ARREST 447 9 0.0982 91.66 40.74 55.79 27.21 12.18 6.33 14.67
SULFISOXAZOLE SIDS 450 11 0.1344 81.86 37.21 55.69 29.27 14.22 7.63 17.24
C-G (Phi) NITRODUR II APPLICAT SITE REACT 397 82 2.3929 34.27 27.16 33.34 26.68 26.96 21.58 92.63
PILOCARPINE GLAUCOMA 419 79 2.3374 33.8 26.52 32.85 26.18 26.56 21.26 88.82
PROCHLORPERAZINE TORTICOLLIS 443 66 1.8801 35.1 27.13 33.9 26.43 26.08 20.17 75.44
MINOCYCLINE INTRACRAN HYPERTENS 451 88 2.7479 32.02 25.47 31.26 25.22 25.99 21.09 96.82
EPOGEN THROM 454 79 2.4007 32.91 25.83 32.01 25.51 25.96 20.79 87.93
METHYLPREDNISOLONE NECRO BONE 462 91 2.8903 31.48 25.26 30.76 24.91 25.75 21.07 99.43
LEUCOVORIN MUCOUS MEM DIS 466 59 1.6682 35.37 26.38 34.01 26.11 25.46 19.78 67.74
MASOPROCOL EDEMA 471 61 1.7668 34.53 26.04 33.27 25.67 25.25 19.51 69.38
ISOFLURANE INCREASED EFFECT 501 87 2.9108 29.89 23.71 29.2 23.53 24.39 19.68 93.2
EPINEPHRINE KERATITIS 510 57 1.7256 33.03 24.92 31.79 24.3 24.1 18.45 63.84
LogP LEVONORGESTREL METRORRHAGIA 3 7530 524.2800 14.36 14.04 14.36 14.04 14.35 14.05 5673.72
NICOTINE APPLICAT SITE REACT 8 5085 358.5990 14.18 13.79 14.18 13.79 14.15 13.76 3805.87
DIATRIZOIC ACID URTICARIA 9 5404 442.6480 12.21 11.88 12.21 11.88 12.19 11.88 3719.83
PERMETHRIN NO DRUG EFFECT 11 4029 249.0420 16.18 15.68 16.17 15.68 16.12 15.64 3231.32
INSULIN HUMAN NO DRUG EFFECT 14 6194 1003.6500 6.17 6.02 6.17 6.02 6.17 6.03 2643.75
ESTRADIOL APPLICAT SITE REACT 16 3664 325.3060 11.26 10.9 11.26 10.9 11.24 10.89 2405.46
IOTHALAMIC ACID URTICARIA 20 2924 248.9040 11.75 11.32 11.74 11.32 11.72 11.3 1968.83
INSULIN HYPERGLYCEM 21 2429 148.4330 16.36 15.72 16.36 15.72 16.28 15.69 1960.18
DTP VACCINE FEVER 23 2494 192.1860 12.98 12.47 12.97 12.47 12.93 12.42 1778.66
ESTRADIOL RASH 24 4852 952.2200 5.1 4.95 5.09 4.97 5.09 4.95 1739.75
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Table G.4: Top ten drug and adverse event pairs uniquely selected by RR, GPS and C-G in their top 1000 pairs based on the lower bounds
RR025, λ025 and φ025 of the 95% confidence/credible interval estimates of RR, λ and φ respectively, using Data 1.
Method Drug Event Rank Count Expected RR RR025 EBGM λ025 φ φ025
RR CREON STENO INTEST 41 4 0.0074 538.02 134.5 56.79 18.23 6.40 2.26
SALICYLIC ACID SALICYLISM 85 4 0.0113 355.05 88.76 53.61 17.19 6.27 2.22
PANCREATIN STENO INTEST COLON 104 4 0.0125 318.95 79.74 52.63 16.92 6.21 2.09
ENOXACIN TENDON RUPT 131 4 0.0137 292.03 73.01 51.77 16.61 6.28 2.29
IOCARMATE MEGLUMINE PARAPLEGIA 155 4 0.0151 264.64 66.16 50.76 16.31 6.20 2.21
PHENACETIN NECRO KIDNEY PAPILL 172 4 0.0158 252.83 63.21 50.27 16.15 6.22 2.12
CEPHAPIRIN RESPIRAT DISTRES SYN 186 4 0.0165 242.36 60.59 49.80 15.99 6.28 2.23
HYALURONIDASE NEURITIS RETROBULBAR 244 4 0.0191 209.48 52.37 48.10 15.45 6.28 2.20
ECHOTHIOPHATE IODIDE CHOLINERG SYND 258 4 0.0195 204.64 51.16 47.82 15.35 6.28 2.24
NORMOSOL-R ALKALOSIS 272 4 0.0201 198.93 49.73 47.47 15.27 6.25 2.31
GPS (EBGM) CLOBETASOL PROPIONATE LEUKODERMA 703 7 0.1002 69.84 19.95 42.41 27.45 9.55 4.54
PENICILLAMINE GLOMERULITIS 1022 22 0.5865 37.51 22.17 33.67 21.65 17.84 11.70
FLUOROMETHOLONE KERATITIS 923 17 0.4103 41.44 21.94 35.67 21.47 16.04 10.03
MOTIVAL DRUG DEPEND 820 13 0.2746 47.34 21.85 38.20 21.26 14.29 8.09
METHOXYFLURANE KIDNEY FAIL ACUTE 974 18 0.4540 39.65 22.03 34.58 21.12 16.47 10.14
HAEMOPHILUS B POLYSACCHARIDE VACCINE LARYNGITIS 890 14 0.3171 44.15 22.08 36.54 20.80 14.61 8.53
NORINYL THROM CEREBR 863 13 0.2848 45.65 21.07 37.06 20.61 14.08 8.19
MEGESTROL ADREN INSUFFIC 906 14 0.3215 43.54 21.77 36.11 20.55 14.59 8.63
NORFLOXACIN ENTEROCOL PSEUDOMEM 1122 22 0.6231 35.31 20.86 31.87 20.48 17.40 11.33
CYCLOPENTOLATE HEM EYE 760 10 0.1830 54.64 21.85 40.28 20.48 12.12 6.29
C-G (Phi) INSULIN HUMAN HYPOGLYCEM 682 1810 87.0265 20.8 19.84 20.78 19.84 20.65 19.7
MINOXIDIL SKIN DRY 714 1038 50.7291 20.46 19.22 20.43 19.22 20.20 19.00
PILOCARPINE CONJUNCTIVITIS 635 244 10.7042 22.79 19.99 22.64 19.94 21.49 18.96
SELENIUM SULFIDE NO DRUG EFFECT 697 722 34.7374 20.78 19.29 20.74 19.27 20.40 18.92
PROTAMINE HEM 659 355 16.2651 21.83 19.61 21.73 19.56 21.01 18.88
LEVONORGESTREL REACT UNEVAL 770 5043 259.501 19.43 18.9 19.43 18.90 19.38 18.84
FINASTERIDE DEATH 711 544 26.2034 20.76 19.04 20.70 19.02 20.23 18.63
FLUOROURACIL MUCOUS MEM DIS 622 157 6.5840 23.85 20.20 23.59 20.11 21.71 18.63
PIROXICAM ULCER PEPTIC 621 134 5.5321 24.22 20.25 23.92 20.12 21.72 18.41
FINASTERIDE GYNECOMASTIA 735 511 25.0667 20.39 18.63 20.33 18.62 19.86 18.27
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G.1 Formula for Computing LogP
LogPij = − log10 [Pr(X ≥ Nij)] where X ∼ Poisson(Eij)
= − log10

 ∑
n≥Nij
e−Eij (Eij)
n
n!


= − log10

1− (Nij−1)∑
n=0
e−Eij (Eij)
n
n!


which is approximated by (G.1) to avoid computational problems when Nij >> Eij
and LogPij is large (LogPij > 12) [19].
− log10

(Nij+3)∑
n=Nij
e−Eij (Eij)
n
n!

 (G.1)
=
Eij
log(10)
−Nij log10 (Eij) + log10(Nij !)
− log10
[
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Nij + 1
+
(Eij)
2
(Nij + 1)(Nij + 2)
+
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3
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]
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Table G.5: Drug and adverse event pairs with various combinations of observed and expected counts. The ranks assigned to the drug and
event combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11, RK2, RK22, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
EMLA HYPALGESIA 1 0.0009 1114.14 0.00 12 154785 2.37 0.94 29826 55171 1.80 0.23 63130 186757
COPPER UTER DIS 4457 46.3981 96.06 93.26 975 151 95.93 93.15 155 94 94.76 91.97 30 22
VINCRISTINE PURPURA THROMBOPEN 2 11.4792 0.17 0.00 373725 375525 0.21 0.07 374503 372101 0.18 0.04 373694 360887
DILTIAZEM RASH 1697 1374.8900 1.23 1.18 189850 33326 1.23 1.18 99124 41473 1.23 1.18 140633 34513
NICOTINE RASH 3827 1187.1800 3.22 3.12 78434 10609 3.22 3.14 20191 12293 3.22 3.12 20403 8143
IBUPROFEN NO DRUG EFFECT 1547 1161.5000 1.33 1.27 178655 30505 1.33 1.27 85474 37764 1.33 1.27 124225 30832
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Table G.6a: Top fifty drug and adverse event pairs selected by C-G using the point estimate of φ. The ranks assigned to the drug and event
combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 9 3 1194.52 1065.95 2 2 358.53 320.87 1 1
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 1206.22 1073.85 1 1 349.02 311.32 2 2
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 644.88 582.98 4 4 323.51 293.66 3 3
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 26 9 598.72 532.64 5 5 267.66 238.76 4 4
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 452.71 407.21 9 7 256.19 230.43 5 5
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 91 25 320.84 283.33 16 12 184.3 163.13 6 6
DIANEAL PERITONITIS 150 0.228 658.94 553.51 28 11 524.7 445.7 6 6 170.1 144.86 7 9
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 94 27 309.61 270.47 18 13 167.41 147.07 8 8
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 234 56 207.07 187.02 41 30 156.35 141.35 9 10
DIETHYLSTILBESTROL ANOMALY CONGEN 2811 17.749 158.37 152.57 398 79 157.84 152.09 65 41 152.79 147.32 10 7
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 378 77 161.58 152.26 63 40 148.51 139.79 11 11
GEMCITABINE HYDROCHLORIDE CARCINOMA GI 225 0.952 236.39 205.92 200 51 222.58 194.84 34 27 139.78 122.77 12 12
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 224 58 207.82 182.29 40 31 135.44 118.88 13 14
TETRACYCLINE DISCOLOR TOOTH 1437 10.485 137.05 130 510 95 136.28 129.37 82 54 129.01 122.5 14 13
CORTISPORIN PAIN EAR 132 0.37 356.64 297.2 81 26 307.86 258.55 19 16 128.91 109.11 15 17
MIVACURIUM CHLORIDE INCREASED EFFECT 319 1.865 171.02 152.26 356 81 165.73 148.27 60 43 126.83 113.36 16 16
NONOXYNOL CERVIX DIS 1074 8.161 131.61 123.77 552 104 130.65 123 89 58 121.83 114.78 17 15
MYSTECLIN F DISCOLOR TOOTH 134 0.458 292.78 244.72 130 39 259.43 218.26 25 21 120.37 102.14 18 18
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 252 67 192.06 164.53 49 37 114.11 97.77 19 20
METFORMIN ACIDOSIS LACTIC 309 2.074 149.02 132.62 437 94 144.84 129.37 75 53 113.33 101.49 20 19
ETIDOCAINE TRISMUS 82 0.105 780.57 618.74 17 7 502.1 401.82 7 8 108.42 87.88 21 26
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.329 315.65 257.98 108 34 267.85 219.9 24 20 105.76 87.46 22 27
SELENIUM SULFIDE HAIR DISCOLOR 301 2.236 134.64 119.43 526 107 131.12 116.94 87 66 104.37 93.05 23 21
OXYTOCIN HEM POSTPARTUM 103 0.346 297.96 242.99 124 40 254.6 208.79 26 23 103.26 85.04 24 29
RIFABUTIN UVEITIS 134 0.665 201.45 168.37 265 70 184.95 155.6 53 39 101.96 85.48 25 28
OPCON A PAIN EYE 267 2.015 132.49 116.61 547 109 128.66 113.91 95 67 100.08 88.99 26 24
PHENFORMIN ACIDOSIS LACTIC 390 3.302 118.11 106.61 681 124 115.99 104.91 109 75 98.53 89.48 27 23
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 481.99 379.26 8 9 95.73 75.47 28 33
PERDIEM STENO ESOPH 65 0.024 2694.87 2072.98 3 1 791.17 615.57 3 3 95.5 74.3 29 35
COPPER UTER DIS 4457 46.398 96.06 93.26 975 151 95.93 93.15 155 94 94.76 91.97 30 22
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Table G.6b: Top fifty drug and adverse event pairs selected by C-G using the point estimate of φ. The ranks assigned to the drug and
event combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33 respectively –
continued.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
DTP VACCINE SCREAMING SYND 966 9.643 100.18 93.95 897 147 99.55 93.41 146 93 93.9 88.19 31 25
METHYSERGIDE FIBRO RETROPERIT 87 0.29 300.36 238.21 122 43 249.61 201.14 27 26 92.35 75.08 32 34
TETRAHYDROZOLINE PAIN EYE 187 1.43 130.77 112.59 557 117 125.49 108.46 98 72 89.85 77.83 33 31
POLIOVIRUS VACCINE, LIVE SCREAMING SYND 344 3.28 104.89 93.91 831 148 102.99 92.52 138 96 87.35 78.75 34 30
POLIOVIRUS VACCINE, LIVE SIDS 146 1.038 140.6 118.45 484 108 132.92 112.61 85 68 86.33 73.53 35 36
CHOLINE KERATITIS 116 0.703 164.99 135.12 372 91 152.08 126.25 71 56 85.71 71.27 36 39
CHOLINE CORNEAL OPACITY 77 0.26 295.96 230.62 128 46 241.31 191.75 29 29 84.46 67.31 37 42
LOMEFLOXACIN HYDRO’DE PHOTOSENSITIVITY 481 5.137 93.64 85.27 1023 166 92.54 84.54 169 107 83.08 76.13 38 32
CEFOXITIN ENTEROCOL PSEUDOMEM 138 1.016 135.79 113.16 517 116 128.21 108.11 96 73 82.86 69.82 39 41
BSS KERATITIS 74 0.243 305.12 239.15 118 42 245.5 194.18 28 28 82.7 65.74 40 46
MENOTROPINS OVAR DIS 151 1.175 128.48 108.06 583 122 122.22 103.87 99 76 82.37 70 41 40
MITOMYCIN UREMIA 218 1.995 109.29 95.26 785 142 106.07 92.67 129 95 82.28 71.86 42 37
BENDECTIN ECTROMELIA 111 0.721 154.02 126.27 415 100 142.21 117.53 77 65 80.76 67.11 43 43
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.093 647.58 485.69 30 14 397.15 305.72 10 10 80.63 62.31 44 50
DIPHTHERIA-TET TOX-PERT VA SCREAMING SYND 147 1.22 120.47 101.62 654 130 114.79 97.31 113 87 78.45 66.58 45 45
TISSUE PLAS’GEN ACT, REC HEM INTRACRAN 476 5.426 87.73 79.99 1150 184 86.75 79.22 191 113 78.28 71.37 46 38
CHOLINE OPHTHALMITIS 58 0.098 594.08 450.68 35 18 371.54 284.7 11 11 77 58.9 47 57
SODIUM HYALURONATE KERATITIS 70 0.274 255.2 196.87 167 55 209.95 164.94 39 36 75.42 59.2 48 56
HAEMOPHILUS B POLY’DE VAC MENINGITIS 176 1.711 102.86 87.66 851 164 99.33 85.44 147 106 74.45 64.4 49 48
TETRAHYDROZOLINE CONJUNCTIVITIS 230 2.454 93.73 81.91 1021 174 91.45 80.2 175 112 74.12 65.21 50 47
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Table G.7a: Top fifty drug and adverse event pairs selected by GPS using the point estimate (EBGM) of λ. The ranks assigned to the drug and
event combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 1206.22 1073.85 1 1 349.02 311.32 2 2
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 9 3 1194.52 1065.95 2 2 358.53 320.87 1 1
PERDIEM STENO ESOPH 65 0.024 2694.87 2072.98 3 1 791.17 615.57 3 3 95.5 74.3 29 35
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 644.88 582.98 4 4 323.51 293.66 3 3
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 26 9 598.72 532.64 5 5 267.66 238.76 4 4
DIANEAL PERITONITIS 150 0.228 658.94 553.51 28 11 524.7 445.7 6 6 170.1 144.86 7 9
ETIDOCAINE TRISMUS 82 0.105 780.57 618.74 17 7 502.1 401.82 7 8 108.42 87.88 21 26
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 481.99 379.26 8 9 95.73 75.47 28 33
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 452.71 407.21 9 7 256.19 230.43 5 5
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.093 647.58 485.69 30 14 397.15 305.72 10 10 80.63 62.31 44 50
CHOLINE OPHTHALMITIS 58 0.098 594.08 450.68 35 18 371.54 284.7 11 11 77 58.9 47 57
HYDROCOR’NE-NEOM-POLY B PAIN EAR 37 0.041 895.62 629.35 13 6 370.77 264.93 12 14 53.2 37.52 94 131
DURANEST W/EPINEPHRINE TRISMUS 46 0.073 628.21 450.67 33 19 349.13 258.63 13 15 63.54 47.75 66 81
COLFOSCERIL PALMITATE HEM LUNG 41 0.06 681.25 481.86 25 15 345.34 251.08 14 17 57.63 42.28 84 106
PANCRELIPASE STENO INTEST COLON 34 0.047 727.21 491.94 18 13 322.71 226.92 15 19 48.51 34.27 117 156
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 91 25 320.84 283.33 16 12 184.3 163.13 6 6
BSS OPHTHALMITIS 28 0.031 889.14 571.59 14 10 310.66 237.21 17 18 41.27 28.45 164 224
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 94 27 309.61 270.47 18 13 167.41 147.07 8 8
CORTISPORIN PAIN EAR 132 0.37 356.64 297.2 81 26 307.86 258.55 19 16 128.91 109.11 15 17
BSS PLUS OPHTHALMITIS 32 0.047 685.52 449.87 24 20 303.77 211.3 20 22 45.6 31.44 129 183
BSS PLUS CORNEAL OPACITY 52 0.129 402.19 293.91 65 28 276.51 208.57 21 24 66.71 50.1 61 75
DINOPROSTONE UTER SPASM 56 0.147 381.61 286.21 72 30 272.47 207.8 22 25 70.17 53.31 54 71
CHLOROXINE HAIR DISCOLOR 26 0.037 707.23 462.42 21 16 272.13 181.59 23 32 37.77 25.45 203 277
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.329 315.65 257.98 108 34 267.85 219.9 24 20 105.76 87.46 22 27
MYSTECLIN F DISCOLOR TOOTH 134 0.458 292.78 244.72 130 39 259.43 218.26 25 21 120.37 102.14 18 18
OXYTOCIN HEM POSTPARTUM 103 0.346 297.96 242.99 124 40 254.6 208.79 26 23 103.26 85.04 24 29
METHYSERGIDE FIBRO RETROPERIT 87 0.29 300.36 238.21 122 43 249.61 201.14 27 26 92.35 75.08 32 34
BSS KERATITIS 74 0.243 305.12 239.15 118 42 245.5 194.18 28 28 82.7 65.74 40 46
CHOLINE CORNEAL OPACITY 77 0.26 295.96 230.62 128 46 241.31 191.75 29 29 84.46 67.31 37 42
DOXYLAMINE HANGOVER 44 0.125 351.27 247.48 88 37 238.87 175.58 30 33 56.39 41.71 86 108
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Table G.7b: Top fifty drug and adverse event pairs selected by GPS using the point estimate (EBGM) of λ. The ranks assigned to the drug and
event combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33 respectively –
continued.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
CALCIPOTRIENE PSORIASIS 47 0.142 331 239.45 99 41 233.87 173.75 31 34 59.21 44.52 80 95
METIPRANOLOL IRITIS 22 0.035 623.42 368.39 34 22 233.41 150.03 32 42 32.09 20.9 284 401
NONOXYNOL BALANITIS 51 0.166 306.82 228.61 116 47 226.43 170.41 33 35 62.6 47.67 72 82
GEMCITABINE HYDROCHLORIDE CARCINOMA GI 225 0.952 236.39 205.92 200 51 222.58 194.84 34 27 139.78 122.77 12 12
MYSTECLIN F ANOMALY TOOTH 28 0.07 401.12 257.86 66 35 217.27 147.29 35 44 38.89 27.02 185 252
SODIUM HYALURONATE IRITIS 21 0.038 551.61 341.47 39 23 216.18 137.36 36 49 30.56 19.68 312 441
BENZOCAINE METHEMOGLOBIN 29 0.077 376.93 246.96 74 38 213.19 145.49 37 45 40.05 27.79 174 239
TROLAMINE OTITIS EXT 14 0.007 1895.68 947.84 4 4 210.56 119.84 38 62 21.32 12.13 642 1004
SODIUM HYALURONATE KERATITIS 70 0.274 255.2 196.87 167 55 209.95 164.94 39 36 75.42 59.2 48 56
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 224 58 207.82 182.29 40 31 135.44 118.88 13 14
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 234 56 207.07 187.02 41 30 156.35 141.35 9 10
SODIUM HYALURONATE OPHTHALMITIS 20 0.038 529.86 317.91 43 24 206.43 129.74 42 52 28.84 18.12 345 517
PHENIRAMINE MYDRIASIS 26 0.067 387.95 253.66 70 36 206.08 137.48 43 48 36.26 24.73 218 295
BOTULINUM TOXIN A PTOSIS 60 0.238 252.56 189.42 173 59 202.19 155.66 44 38 67.7 52.33 57 73
ISOSORBIDE MONONITRATE HEADACHE VASC 40 0.141 283.71 198.59 140 54 199.82 144.69 45 46 50.34 36.71 110 138
EMBOLEX VASOSPASM 19 0.038 505.85 292.86 45 29 196.33 121.75 46 59 27.63 17.47 375 543
SODIUM HYALURONATE CORNEAL OPACITY 30 0.094 319.8 213.2 103 49 196.04 134.65 47 51 40.4 27.89 171 236
OXYTOCIN UTER ATONY 32 0.105 306.03 200.83 117 52 195.37 135.86 48 50 42.48 30.06 150 199
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 252 67 192.06 164.53 49 37 114.11 97.77 19 20
TICE BCG GRANULOMA 55 0.23 239.15 178.27 192 64 190.14 144.60 50 47 62.3 47.23 74 85
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Table G.8a: Top fifty drug and adverse event pairs selected by GPS using the lower bound (λ025) of the 95% credible interval estimate of λ.
The ranks assigned to the drug and event combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2,
RK22, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 1206.22 1073.85 1 1 349.02 311.32 2 2
HEMOFIL HIV TEST POS 306 0.198 1543.39 1371.9 9 3 1194.52 1065.95 2 2 358.53 320.87 1 1
PERDIEM STENO ESOPH 65 0.024 2694.87 2072.98 3 1 791.17 615.57 3 3 95.5 74.3 29 35
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 644.88 582.98 4 4 323.51 293.66 3 3
PANALBA K.M. DISCOLOR TOOTH 289 0.425 680.75 603.02 26 9 598.72 532.64 5 5 267.66 238.76 4 4
DIANEAL PERITONITIS 150 0.228 658.94 553.51 28 11 524.7 445.7 6 6 170.1 144.86 7 9
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 452.71 407.21 9 7 256.19 230.43 5 5
ETIDOCAINE TRISMUS 82 0.105 780.57 618.74 17 7 502.1 401.82 7 8 108.42 87.88 21 26
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 481.99 379.26 8 9 95.73 75.47 28 33
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.093 647.58 485.69 30 14 397.15 305.72 10 10 80.63 62.31 44 50
CHOLINE OPHTHALMITIS 58 0.098 594.08 450.68 35 18 371.54 284.7 11 11 77 58.9 47 57
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.742 346.17 304.41 91 25 320.84 283.33 16 12 184.3 163.13 6 6
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.645 337.74 294.36 94 27 309.61 270.47 18 13 167.41 147.07 8 8
HYDROCOR’NE-NEOM-POLY B PAIN EAR 37 0.041 895.62 629.35 13 6 370.77 264.93 12 14 53.2 37.52 94 131
DURANEST W/EPINEPHRINE TRISMUS 46 0.073 628.21 450.67 33 19 349.13 258.63 13 15 63.54 47.75 66 81
CORTISPORIN PAIN EAR 132 0.37 356.64 297.2 81 26 307.86 258.55 19 16 128.91 109.11 15 17
COLFOSCERIL PALMITATE HEM LUNG 41 0.06 681.25 481.86 25 15 345.34 251.08 14 17 57.63 42.28 84 106
BSS OPHTHALMITIS 28 0.031 889.14 571.59 14 10 310.66 237.21 17 18 41.27 28.45 164 224
PANCRELIPASE STENO INTEST COLON 34 0.047 727.21 491.94 18 13 322.71 226.92 15 19 48.51 34.27 117 156
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.329 315.65 257.98 108 34 267.85 219.9 24 20 105.76 87.46 22 27
MYSTECLIN F DISCOLOR TOOTH 134 0.458 292.78 244.72 130 39 259.43 218.26 25 21 120.37 102.14 18 18
BSS PLUS OPHTHALMITIS 32 0.047 685.52 449.87 24 20 303.77 211.3 20 22 45.6 31.44 129 183
OXYTOCIN HEM POSTPARTUM 103 0.346 297.96 242.99 124 40 254.6 208.79 26 23 103.26 85.04 24 29
BSS PLUS CORNEAL OPACITY 52 0.129 402.19 293.91 65 28 276.51 208.57 21 24 66.71 50.1 61 75
DINOPROSTONE UTER SPASM 56 0.147 381.61 286.21 72 30 272.47 207.8 22 25 70.17 53.31 54 71
METHYSERGIDE FIBRO RETROPERIT 87 0.29 300.36 238.21 122 43 249.61 201.14 27 26 92.35 75.08 32 34
GEMCITABINE HYDROCHL’DE CARCINOMA GI 225 0.952 236.39 205.92 200 51 222.58 194.84 34 27 139.78 122.77 12 12
BSS KERATITIS 74 0.243 305.12 239.15 118 42 245.5 194.18 28 28 82.7 65.74 40 46
CHOLINE CORNEAL OPACITY 77 0.26 295.96 230.62 128 46 241.31 191.75 29 29 84.46 67.31 37 42
TETRACYCLINE ANOMALY TOOTH 380 1.776 213.96 192.57 234 56 207.07 187.02 41 30 156.35 141.35 9 10
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Table G.8b: Top fifty drug and adverse event pairs selected by GPS using the lower bound (λ025) of the 95% credible interval estimate of λ.
The ranks assigned to the drug and event combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2,
RK22, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
DINOPROSTONE LABOR ABNORM 231 1.052 219.5 191.94 224 58 207.82 182.29 40 31 135.44 118.88 13 14
CHLOROXINE HAIR DISCOLOR 26 0.037 707.23 462.42 21 16 272.13 181.59 23 32 37.77 25.45 203 277
DOXYLAMINE HANGOVER 44 0.125 351.27 247.48 88 37 238.87 175.58 30 33 56.39 41.71 86 108
CALCIPOTRIENE PSORIASIS 47 0.142 331 239.45 99 41 233.87 173.75 31 34 59.21 44.52 80 95
NONOXYNOL BALANITIS 51 0.166 306.82 228.61 116 47 226.43 170.41 33 35 62.6 47.67 72 82
SODIUM HYALURONATE KERATITIS 70 0.274 255.2 196.87 167 55 209.95 164.94 39 36 75.42 59.2 48 56
DINOPROSTONE FETAL DIS 167 0.81 206.1 175.25 252 67 192.06 164.53 49 37 114.11 97.77 19 20
BOTULINUM TOXIN A PTOSIS 60 0.238 252.56 189.42 173 59 202.19 155.66 44 38 67.7 52.33 57 73
RIFABUTIN UVEITIS 134 0.665 201.45 168.37 265 70 184.95 155.6 53 39 101.96 85.48 25 28
BENDECTIN ANOMALY CONGEN 1106 6.785 163 153.42 378 77 161.58 152.26 63 40 148.51 139.79 11 11
DIETHYLSTILBESTROL ANOMALY CONGEN 2811 17.749 158.37 152.57 398 79 157.84 152.09 65 41 152.79 147.32 10 7
METIPRANOLOL IRITIS 22 0.035 623.42 368.39 34 22 233.41 150.03 32 42 32.09 20.9 284 401
MIVACURIUM CHLORIDE INCREASED EFFECT 319 1.865 171.02 152.26 356 81 165.73 148.27 60 43 126.83 113.36 16 16
MYSTECLIN F ANOMALY TOOTH 28 0.07 401.12 257.86 66 35 217.27 147.29 35 44 38.89 27.02 185 252
BENZOCAINE METHEMOGLOBIN 29 0.077 376.93 246.96 74 38 213.19 145.49 37 45 40.05 27.79 174 239
ISOSORBIDE MONONITRATE HEADACHE VASC 40 0.141 283.71 198.59 140 54 199.82 144.69 45 46 50.34 36.71 110 138
TICE BCG GRANULOMA 55 0.23 239.15 178.27 192 64 190.14 144.6 50 47 62.3 47.23 74 85
PHENIRAMINE MYDRIASIS 26 0.067 387.95 253.66 70 36 206.08 137.48 43 48 36.26 24.73 218 295
SODIUM HYALURONATE IRITIS 21 0.038 551.61 341.47 39 23 216.18 137.36 36 49 30.56 19.68 312 441
OXYTOCIN UTER ATONY 32 0.105 306.03 200.83 117 52 195.37 135.86 48 50 42.48 30.06 150 199
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Table G.9a: Top fifty drug and adverse event pairs selected by the point estimate of RR. The ranks assigned to the drug and event combinations
based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
NISOLDIPINE HEPATITIS NONSPECIFI 1 0.0003 3561.94 0 1 154780 2.4 0.95 29410 54652 1.83 0.25 61020 176165
ACARBOSE HEPATITIS NONSPECIFI 1 0.0004 2816.96 0 2 154781 2.4 0.95 29473 54836 1.76 0.2 66479 209700
PERDIEM STENO ESOPH 65 0.0241 2694.87 2072.98 3 1 791.17 615.57 3 3 95.5 74.3 29 35
TROLAMINE OTITIS EXT 14 0.0074 1895.68 947.84 4 4 210.56 119.84 38 62 21.32 12.13 642 1004
ORTHO-NOVUM 1/80 CARCINOMA LIVER 1 0.0005 1840 0 5 154782 2.39 0.95 29583 54731 1.84 0.27 60769 171588
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 1206.22 1073.85 1 1 349.02 311.32 2 2
KOATE HIV SYND 7 0.0044 1578.59 451.03 7 17 107.86 47.23 125 277 10.77 4.83 2231 4217
HEMOFIL M HEPATITIS HBSAG 6 0.0038 1577.25 525.75 8 12 92.71 37.64 168 404 9.37 3.93 2826 5759
HEMOFIL HIV TEST POS 306 0.1983 1543.39 1371.9 9 3 1194.52 1065.95 2 2 358.53 320.87 1 1
PLATELET CON, HUMAN LIVER DAMAGE AGGRAV 1 0.0008 1320.94 0 10 154783 2.38 0.94 29728 55175 1.8 0.22 63086 195535
URSODIOL LIVER DAMAGE AGGR 1 0.0008 1187.47 0 11 154784 2.38 0.94 29782 55065 1.81 0.23 62640 188914
EMLA HYPALGESIA 1 0.0009 1114.14 0 12 154785 2.37 0.94 29826 55171 1.8 0.23 63130 186757
HYDRO’NE-NEOM-POLY B PAIN EAR 37 0.0413 895.62 629.35 13 6 370.77 264.93 12 14 53.2 37.52 94 131
BSS OPHTHALMITIS 28 0.0315 889.14 571.59 14 10 310.66 237.21 17 18 41.27 28.45 164 224
BC POWDER SALICYLISM 3 0.0034 885.18 0 15 154786 43.33 11.44 675 2181 4.75 1.39 9818 27036
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 481.99 379.26 8 9 95.73 75.47 28 33
ETIDOCAINE TRISMUS 82 0.1051 780.57 618.74 17 7 502.1 401.82 7 8 108.42 87.88 21 26
PANCRELIPASE STENO INTEST COLON 34 0.0468 727.21 491.94 18 13 322.71 226.92 15 19 48.51 34.27 117 156
ORTHO-NOVUM SQ CARCINOMA LARYNX 1 0.0014 720.74 0 19 154787 2.35 0.94 30164 55426 1.78 0.2 65355 210519
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 644.88 582.98 4 4 323.51 293.66 3 3
CHLOROXINE HAIR DISCOLOR 26 0.0368 707.23 462.42 21 16 272.13 181.59 23 32 37.77 25.45 203 277
COLFOSCERIL PALMITATE INTEST SMALL PER 2 0.0029 699.11 0 22 154788 19.81 4.63 2282 7285 3.28 0.75 19648 65118
AVC BALANITIS 1 0.0014 694.57 0 23 154789 2.35 0.93 30201 55765 1.8 0.22 63388 195229
BSS PLUS OPHTHALMITIS 32 0.0467 685.52 449.87 24 20 303.77 211.3 20 22 45.6 31.44 129 183
COLFOSCERIL PALMITATE HEM LUNG 41 0.0602 681.25 481.86 25 15 345.34 251.08 14 17 57.63 42.28 84 106
PANALBA K.M. DISCOLOR TOOTH 289 0.4245 680.75 603.02 26 9 598.72 532.64 5 5 267.66 238.76 4 4
NORGESTREL CARCINOMA CERVIX SIT 6 0.0089 677.3 225.77 27 48 85.66 34.83 197 457 9.37 4.09 2828 5415
DIANEAL PERITONITIS 150 0.2276 658.94 553.51 28 11 524.7 445.7 6 6 170.1 144.86 7 9
HYDRO’NE-NEOM-POLY B OTITIS EXT 2 0.0031 648.98 0 29 154790 19.7 4.62 2305 7295 3.21 0.75 20600 64747
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.0927 647.58 485.69 30 14 397.15 305.72 10 10 80.63 62.31 44 50
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Table G.9b: Top fifty drug and adverse event pairs selected by the point estimate of RR. The ranks assigned to the drug and event combinations
based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11 RK2, RK22, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
OCTREOTIDE ACETATE LIVER DAMAGE AGGR 1 0.0015 646.31 0 31 154791 2.35 0.93 30276 55642 1.82 0.23 61642 186034
NORGESTREL NEOPL CERVIX 5 0.0079 636.53 127.31 32 99 71.72 26.42 282 693 7.8 3.09 3931 8249
DURANEST W/EPINEPHRINE TRISMUS 46 0.0732 628.21 450.67 33 19 349.13 258.63 13 15 63.54 47.75 66 81
METIPRANOLOL IRITIS 22 0.0353 623.42 368.39 34 22 233.41 150.03 32 42 32.09 20.9 284 401
CHOLINE OPHTHALMITIS 58 0.0976 594.08 450.68 35 18 371.54 284.7 11 11 77 58.9 47 57
DESOXIMETASONE SKIN STRIAE 10 0.0169 590.6 236.24 36 45 129.98 66.08 91 153 15.18 8.12 1189 1944
CREON STENO INTEST COLON 6 0.0104 576.05 192.02 37 57 83.7 34.01 200 478 9.47 4.13 2782 5330
DELADUMONE OB UTER ATONY 1 0.0018 559.28 0 38 154792 2.34 0.93 30463 55725 1.84 0.22 60495 189568
SODIUM HYALURONATE IRITIS 21 0.0381 551.61 341.47 39 23 216.18 137.36 36 49 30.56 19.68 312 441
PHENAPHEN W/CODEIN NO. 3 MYELOID MAT ARREST 1 0.0018 549.33 0 40 154793 2.34 0.93 30493 55650 1.8 0.22 63472 195022
CREON STENO INTEST 4 0.0074 538.02 134.5 41 93 56.79 18.23 428 1135 6.4 2.26 5654 13169
NORLESTRIN NEOPL BONE 1 0.0019 530.33 0 42 154794 2.34 0.93 30533 55733 1.8 0.22 63237 192170
SODIUM HYALURONATE OPHTHALMITIS 20 0.0377 529.86 317.91 43 24 206.43 129.74 42 52 28.84 18.12 345 517
LOTRISONE SKIN STRIAE 17 0.0323 526.76 278.87 44 32 185.63 111.66 52 69 25.05 15.4 474 692
EMBOLEX VASOSPASM 19 0.0376 505.85 292.86 45 29 196.33 121.75 46 59 27.63 17.47 375 543
MIVACURIUM CHLORIDE CHOLINESTERASE DEC 16 0.0319 502.05 282.4 46 31 175.3 103.72 55 77 23.76 14.59 529 753
PENBUTOLOL SULFATE ADAMS STOKES SYND 1 0.002 500.08 0 47 154795 2.33 0.93 30638 55766 1.81 0.23 62560 187489
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 452.71 407.21 9 7 256.19 230.43 5 5
DOXACURIUM CHLORIDE PARALYSIS FLACCID 16 0.033 484.79 272.69 49 33 173.11 102.42 56 79 23.48 14.13 539 792
PHYSOSTIGMINE CHOLINESTERASE DEC 1 0.0021 482.23 0 50 154796 2.33 0.93 30681 56029 1.81 0.21 62662 197242
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Table G.10a: Top fifty drug and adverse event pairs selected by RR using the lower bound (RR025) of the 95% confidence interval estimate of
RR. The ranks assigned to the drug and event combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11
RK2, RK22, RK3 and RK33 respectively.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
PERDIEM STENO ESOPH 65 0.0241 2694.87 2072.98 3 1 791.17 615.57 3 3 95.5 74.3 29 35
IOPHENDYLATE ARACHNOIDITIS 293 0.185 1583.73 1405.36 6 2 1206.22 1073.85 1 1 349.02 311.32 2 2
HEMOFIL HIV TEST POS 306 0.1983 1543.39 1371.9 9 3 1194.52 1065.95 2 2 358.53 320.87 1 1
TROLAMINE OTITIS EXT 14 0.0074 1895.68 947.84 4 4 210.56 119.84 38 62 21.32 12.13 642 1004
INPERSOL W/DEXTROSE PERITONITIS 387 0.542 714.05 643.93 20 5 644.88 582.98 4 4 323.51 293.66 3 3
HYDROCOR’NE-NEOM-POLY B PAIN EAR 37 0.0413 895.62 629.35 13 6 370.77 264.93 12 14 53.2 37.52 94 131
ETIDOCAINE TRISMUS 82 0.1051 780.57 618.74 17 7 502.1 401.82 7 8 108.42 87.88 21 26
BERACTANT HEM LUNG 71 0.089 797.58 617.84 16 8 481.99 379.26 8 9 95.73 75.47 28 33
PANALBA K.M. DISCOLOR TOOTH 289 0.4245 680.75 603.02 26 9 598.72 532.64 5 5 267.66 238.76 4 4
BSS OPHTHALMITIS 28 0.0315 889.14 571.59 14 10 310.66 237.21 17 18 41.27 28.45 164 224
DIANEAL PERITONITIS 150 0.2276 658.94 553.51 28 11 524.7 445.7 6 6 170.1 144.86 7 9
HEMOFIL M HEPATITIS HBSAG 6 0.0038 1577.25 525.75 8 12 92.71 37.64 168 404 9.37 3.93 2826 5759
PANCRELIPASE STENO INTEST COLON 34 0.0468 727.21 491.94 18 13 322.71 226.92 15 19 48.51 34.27 117 156
DIETHYLSTILBESTROL ANOMALY CONGEN UG 60 0.0927 647.58 485.69 30 14 397.15 305.72 10 10 80.63 62.31 44 50
COLFOSCERIL PALMITATE HEM LUNG 41 0.0602 681.25 481.86 25 15 345.34 251.08 14 17 57.63 42.28 84 106
CHLOROXINE HAIR DISCOLOR 26 0.0368 707.23 462.42 21 16 272.13 181.59 23 32 37.77 25.45 203 277
KOATE HIV SYND 7 0.0044 1578.59 451.03 7 17 107.86 47.23 125 277 10.77 4.83 2231 4217
CHOLINE OPHTHALMITIS 58 0.0976 594.08 450.68 35 18 371.54 284.7 11 11 77 58.9 47 57
DURANEST W/EPINEPHRINE TRISMUS 46 0.0732 628.21 450.67 33 19 349.13 258.63 13 15 63.54 47.75 66 81
BSS PLUS OPHTHALMITIS 32 0.0467 685.52 449.87 24 20 303.77 211.3 20 22 45.6 31.44 129 183
OPCON A MYDRIASIS 351 0.717 489.53 439.33 48 21 452.71 407.21 9 7 256.19 230.43 5 5
METIPRANOLOL IRITIS 22 0.0353 623.42 368.39 34 22 233.41 150.03 32 42 32.09 20.9 284 401
SODIUM HYALURONATE IRITIS 21 0.0381 551.61 341.47 39 23 216.18 137.36 36 49 30.56 19.68 312 441
SODIUM HYALURONATE OPHTHALMITIS 20 0.0377 529.86 317.91 43 24 206.43 129.74 42 52 28.84 18.12 345 517
DEMECLOCYCLINE DISCOLOR TOOTH 257 0.7424 346.17 304.41 91 25 320.84 283.33 16 12 184.3 163.13 6 6
CORTISPORIN PAIN EAR 132 0.3701 356.64 297.2 81 26 307.86 258.55 19 16 128.91 109.11 15 17
IMMUNE GLOBULIN, HUMAN HEPATITIS C 218 0.6455 337.74 294.36 94 27 309.61 270.47 18 13 167.41 147.07 8 8
BSS PLUS CORNEAL OPACITY 52 0.1293 402.19 293.91 65 28 276.51 208.57 21 24 66.71 50.1 61 75
EMBOLEX VASOSPASM 19 0.0376 505.85 292.86 45 29 196.33 121.75 46 59 27.63 17.47 375 543
DINOPROSTONE UTER SPASM 56 0.1467 381.61 286.21 72 30 272.47 207.8 22 25 70.17 53.31 54 71
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Table G.10b: Top fifty drug and adverse event pairs selected by RR using the lower bound (RR025) of the 95% confidence interval estimate of
RR. The ranks assigned to the drug and event combinations based on RR, RR025, λ (EBGM), λ025, φ and φ025 are designated RK1, RK11
RK2, RK22, RK3 and RK33 respectively – continued.
Drug Event Count Expected RR RR025 RK1 RK11 EBGM λ025 RK2 RK22 φ φ025 RK3 RK33
MIVACURIUM CHLORIDE CHOLINESTERASE DEC 16 0.0319 502.05 282.4 46 31 175.3 103.72 55 77 23.76 14.59 529 753
LOTRISONE SKIN STRIAE 17 0.0323 526.76 278.87 44 32 185.63 111.66 52 69 25.05 15.4 474 692
DOXACURIUM CHLORIDE PARALYSIS FLACCID 16 0.033 484.79 272.69 49 33 173.11 102.42 56 79 23.48 14.13 539 792
MIVACURIUM CHLORIDE PARALYSIS FLACCID 104 0.3295 315.65 257.98 108 34 267.85 219.9 24 20 105.76 87.46 22 27
MYSTECLIN F ANOMALY TOOTH 28 0.0698 401.12 257.86 66 35 217.27 147.29 35 44 38.89 27.02 185 252
PHENIRAMINE MYDRIASIS 26 0.067 387.95 253.66 70 36 206.08 137.48 43 48 36.26 24.73 218 295
DOXYLAMINE HANGOVER 44 0.1253 351.27 247.48 88 37 238.87 175.58 30 33 56.39 41.71 86 108
BENZOCAINE METHEMOGLOBIN 29 0.0769 376.93 246.96 74 38 213.19 145.49 37 45 40.05 27.79 174 239
MYSTECLIN F DISCOLOR TOOTH 134 0.4577 292.78 244.72 130 39 259.43 218.26 25 21 120.37 102.14 18 18
OXYTOCIN HEM POSTPARTUM 103 0.3457 297.96 242.99 124 40 254.6 208.79 26 23 103.26 85.04 24 29
CALCIPOTRIENE PSORIASIS 47 0.142 331 239.45 99 41 233.87 173.75 31 34 59.21 44.52 80 95
BSS KERATITIS 74 0.2425 305.12 239.15 118 42 245.5 194.18 28 28 82.7 65.74 40 46
METHYSERGIDE FIBRO RETROPERIT 87 0.2897 300.36 238.21 122 43 249.61 201.14 27 26 92.35 75.08 32 34
PANCRELIPASE STENO INTEST 16 0.0378 423.38 238.15 61 44 164.43 97.32 61 86 23.26 13.97 547 805
DESOXIMETASONE SKIN STRIAE 10 0.0169 590.6 236.24 36 45 129.98 66.08 91 153 15.18 8.12 1189 1944
CHOLINE CORNEAL OPACITY 77 0.2602 295.96 230.62 128 46 241.31 191.75 29 29 84.46 67.31 37 42
NONOXYNOL BALANITIS 51 0.1662 306.82 228.61 116 47 226.43 170.41 33 35 62.6 47.67 72 82
NORGESTREL CARCINOMA CERVIX SIT 6 0.0089 677.3 225.77 27 48 85.66 34.83 197 457 9.37 4.09 2828 5415
SODIUM HYALURONATE CORNEAL OPACITY 30 0.0938 319.8 213.2 103 49 196.04 134.65 47 51 40.4 27.89 171 236
APROTININ BOVINE THROM CORONARY 13 0.0288 452.15 208.68 57 50 146.91 81.71 74 110 19.19 10.76 785 1243
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